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Abstract 
The high rates of cannabis use (CU) among people with psychosis, and its negative 
biological, psychological and social consequences are well established. However, current 
treatment approaches to substance use (SU) in people with psychosis have shown mixed and 
poor long-term results. Further research aimed at increasing clinical understanding of the 
relationship between SU and psychosis is required to guide the development of more 
innovative and effective treatments for this population. A growing number of studies 
examining reasons for CU among psychotic populations have provided insights into the 
development of treatment strategies aimed at boosting motivation. However, treatment 
research is yet to capitalize on how up to a third of people with psychotic disorders 
‘naturally’ reduce their consumption of cannabis after experiencing a psychotic episode.  
This thesis investigates how people with psychosis naturally recover from CU. The first 
study conducts a systematic review of the literature of natural recovery and SU (Chapter 2). 
The systematic search elicited 7 studies which met search criteria. Overall the limited number 
of studies indicated a void in this research field and the need to address this to improve 
current understanding of naturalistic recovery of SU in people with psychosis. The review 
then compared the results with reviews on natural recovery from SU in the general 
population. Limited differences were noted between the groups, with difference in the SU 
group being related to the psychotic illness and subsequent consequences (i.e., functional 
problems).    
Chapters 3 and 4 provide estimates of change in control groups of RCTs of SU 
treatment studies for the general population and psychotic individuals using meta-analysis. 
Both studies found 8 articles that met inclusion criteria. Reduction in days of CU/SU was 
measured by use in the past 30 days. For the general population group average weighted 
mean days of use reduced from 24.5 to 19.9, and a meta-analysis showed an average 
reduction of 0.442 SD across 2-4 months. In the psychosis group weighted mean days of use 
reduced from 13.2 to 10.6 at 6 months, and a mean reduction of 0.3-0.4 SD across 6 to 24 
months was found. The results of Chapter 3 and 4 provide a baseline for assessment of 
required treatment effects and strengthen the concept of natural recovery.   
In Chapters 5 and 6, two existing data sets are then examined, to explore predictors of 
natural recovery from SU in psychosis. Chapter 5 uses data on 786 patients with first episode 
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psychosis (FEP) treated at The Early Psychosis Prevention and Intervention Centre (EPPIC) 
in Australia. The study aimed to identify baseline predictors of reduction or cessation in SU 
in this sample over an 18-month follow-up. Results from multivariate analysis found that 
CUD alone and better premorbid social and occupational functioning were significant 
predictors of SU cessation/reduction. Chapter 6 uses data on 67 consecutively admitted 
patients between the ages of 18 and 40 with early psychosis. Predictors of cannabis cessation 
over a 6-month follow-up were identified, using more detailed and frequent assessments of 
CU than the study in Chapter 5. Multivariate analysis reported that living in private 
accommodation and receiving an income were significant predictors of CU cessation. 
Chapter 7 and 8 provide data on motivators for cessation/reduction, maintenance 
strategies and relapse contexts. Chapter 7 presents a qualitative study that retrospectively 
explores both reasons for ceasing or reducing CU and the strategies used by 10 people with a 
psychotic disorder who had ceased or reduced CU for at least a month in the previous 3 years. 
Increased awareness of the consequences of SU across multiple domains, social supports and 
utilising a combination of coping strategies were important in motivating cessation/reduction. 
Factors which assisted in maintaining control of CU included the ability to manage mental 
health symptoms, while the capacity to address pressure from substance using peers was 
commonly mentioned relapse strategy. 
Chapter 8 addresses the limitations of recall bias in Chapter 7 by prospectively 
examining reasons for cessation/reduction in CU among 22 individuals with psychosis who 
had ceased or reduced their use. Participants were followed-up over a 3-month period to 
identify changes in CU. Reasons for initiating cessation/reduction included worsening mental 
health, relationship, lifestyle difficulties. Maintenance strategies identified psychological, 
relationship, lifestyle and medication themes. Relapse was associated with substance-using 
peers, relationship difficulties and problems with negative emotions. 
Results of this program of research provide a valuable contribution to the literature on 
CU and psychosis and more broadly SU and severe mental illness (SMI). They highlight 
specific factors (i.e., addressing mental health issues) for clinical focus in the initial change of 
CU, maintenance of a reduction/cessation of CU and strategies to assist with relapse. The 
thesis argues that there is an ongoing need for exploration of natural recovery, in order to 
develop ways to further improve treatments. 
    
 Natural Recovery of People with Cannabis Use and Psychosis i
Submitted Manuscripts and Publications from the 
PhD Program 
Paper 1 
Rebgetz, S., Kavanagh, D. J. & Hides, L. (2015). Can exploring natural recovery from 
substance misuse in psychosis assist with treatment? A review of current research. Addictive 
Behaviors, 46, 106-112. doi:10.1016/j.addbeh.2015.03.006 Journal Impact Factor = 2.76. 
Accepted 7 March 2015.  
Paper 2 
Rebgetz, S., Kavanagh, D. J. & Hides, L. (2015). Systematic analysis of changes in 
cannabis use among control conditions of randomised controlled trials. Addictive Behaviors 
Reports, 1, 76-80. doi:10.1016/j.abrep.2015.06.001. Accepted 1 June 2015.  
Paper 3 
Rebgetz, S., Kavanagh, D. J. & Hides, L. (2016). Changes in cannabis use among 
psychotic clients without specialised substance use treatment. Schizophrenia Research. doi: 
10.1016/j.schres.2016.03.030. Journal Impact Factor = 3.92. Accepted 24 March 2016. 
Paper 4 
Rebgetz, S., Conus, P., Hides, L., Kavanagh, D. J., Cotton, S., Schimmelmann, B. G., 
McGorry, P. D. & Lambert, M. (2014). Predictors of substance use reduction in an 
epidemiological first-episode psychosis cohort. Early Intervention in Psychiatry, 8, 358-365. 
doi: 10.111/eip.12067. Journal Impact Factor = 1.95. Accepted 20 May 2013.  
Paper 5 
Rebgetz, S., Hides, L., Kavanagh, D. J., Dawe, S. & Young, R. M. (2014). A 
prospective study of natural recovery from cannabis use in early psychosis. European 
Journal of Psychiatry, 28, 218-229. doi: 10.4321/S0213-61632014000400003. Journal 
Impact Factor = 0.46. Accepted 15 October 2014.  
 
 
 
 ii Natural Recovery of People with Cannabis Use and Psychosis 
Paper 6 
Rebgetz, S., Hides, L., Kavanagh, D. J. & Choudhary, A. (2015). Natural recovery 
from cannabis use in people with psychosis: A qualitative study. Journal of Dual Diagnosis, 
11, 179-183. doi: 10.1080/15504263.2015.1100472. Journal Impact Factor = 0.80. Accepted 
12 October 2015.  
Paper 7 
Rebgetz, S., Hides, L., Kavanagh, D. J. & Choudhary, A. (2016). Prospective recovery 
of cannabis use in a psychotic population: A qualitative analysis. Addictive Behaviors 
Reports. Accepted 16 July 2016.   
 
 
 
 
 
 
 
 
 Natural Recovery of People with Cannabis Use and Psychosis iii
Table of Contents 
Keywords ................................................................................................................................. ii 
Abstract ................................................................................................................................... iii 
Submitted Manuscripts and Publications from the PhD Program ............................................ i 
Table of Contents .................................................................................................................... iii 
List of Figures ......................................................................................................................... vi 
List of Tables ......................................................................................................................... vii 
List of Abbreviations ............................................................................................................ viii 
Statement of Original Authorship ........................................................................................... ix 
Acknowledgements ...................................................................................................................x 
Chapter 1: Overview and Literature Review .....................................................1 
1.1 Overview ........................................................................................................................1 
1.1.1 Overview of the PhD Research Program ..............................................................1 
1.2 Psychosis and Cannabis Misuse .....................................................................................3 
1.3 Impact of Substance Misuse ...........................................................................................4 
1.4 Reasons for Use ..............................................................................................................5 
1.5 Treatment of Substance Use in Psychosis ......................................................................6 
1.6 Relapse of Substance Use ...............................................................................................8 
1.7 Psychosis Relapse ...........................................................................................................9 
1.8 Natural Recovery in Substance Use .............................................................................10 
1.9 Maintenance ..................................................................................................................12 
1.10 Extent of Natural Recovery in Control Groups ............................................................12 
1.11 Qualitative Data on Recovery of Substance Use in Psychosis .....................................13 
1.12 Commentary (Summary and Implications)...................................................................15 
Chapter 2: Paper 1 ..............................................................................................17 
2.1 Notes .............................................................................................................................17 
2.2 Introduction ..................................................................................................................21 
2.3 Methods ........................................................................................................................23 
2.4 Results ..........................................................................................................................23 
2.5 Discussion .....................................................................................................................28 
2.6 Conclusion ....................................................................................................................30 
2.7 Commentary (Summary and Implications)...................................................................31 
Chapter 3: Paper 2 ..............................................................................................37 
3.1 Notes .............................................................................................................................37 
3.2 Introduction ..................................................................................................................41 
3.3 Methods ........................................................................................................................42 
 iv Natural Recovery of People with Cannabis Use and Psychosis 
3.4 Results ..........................................................................................................................43 
3.5 Discussion .....................................................................................................................44 
3.6 Conclusions ..................................................................................................................45 
3.7 Commentary (Summary and Implications)...................................................................46 
Chapter 4: Paper 3 ..............................................................................................51 
4.1 Notes .............................................................................................................................51 
4.2 Introduction ..................................................................................................................55 
4.3 Methods ........................................................................................................................56 
4.4 Results ..........................................................................................................................57 
4.5 Discussion .....................................................................................................................63 
4.6 Commentary (Summary and Implications)...................................................................67 
Chapter 5: Paper 4 ..............................................................................................68 
5.1 Notes .............................................................................................................................68 
5.2 Introduction ..................................................................................................................74 
5.3 Material and Methods ...................................................................................................75 
5.4 Results ..........................................................................................................................78 
5.5 Discussion .....................................................................................................................80 
5.6 Commentary (Summary and Implications)...................................................................84 
Chapter 6: Paper 5 ..............................................................................................88 
6.1 Notes .............................................................................................................................88 
6.2 Introduction ..................................................................................................................93 
6.3 Methods ........................................................................................................................94 
6.4 Results ..........................................................................................................................97 
6.5 Discussion .....................................................................................................................98 
6.6 Commentary (Summary and Implications).................................................................101 
Chapter 7: Paper 6 ............................................................................................108 
7.1 Notes ...........................................................................................................................108 
7.2 Introduction ................................................................................................................113 
7.3 Materials and Methods ...............................................................................................113 
7.4 Results ........................................................................................................................115 
7.5 Discussion ...................................................................................................................115 
7.6 Conclusion ..................................................................................................................117 
7.7 Commentary (Summary and Implications).................................................................118 
Chapter 8: Paper 7 ............................................................................................122 
8.1 Notes ...........................................................................................................................122 
8.2 Introduction ................................................................................................................127 
8.3 Materials and Methods ...............................................................................................128 
 Natural Recovery of People with Cannabis Use and Psychosis v
8.4 Results ........................................................................................................................130 
8.5 Discussion ...................................................................................................................139 
8.6 Commentary (Summary and Implications).................................................................143 
Chapter 9: General Discussion ........................................................................145 
9.1 Overall Discussion ......................................................................................................145 
9.2 Discussion of Papers in Relation to Project Aims ......................................................148 
9.2.1 What triggers the decision to initiate a change and what are the associated reasons 
for reducing/ceasing CU among substance users with psychosis? ...................148 
9.2.2 What maintains cannabis cessation among substance users with psychosis? ..150 
9.2.3 What predicts lapses in control, and what strategies are most commonly used to 
regain control among substance users with psychosis? ....................................150 
9.3 Clinical Implications of Findings ...............................................................................151 
9.3.1 Motivators for reduction/cessation ...................................................................151 
9.3.2 Maintenance factors for continued reduction/cessation ...................................153 
9.3.3 Relapse contexts ...............................................................................................153 
9.3.4 Theoretical implications ...................................................................................153 
9.4 Strengths and Limitations of this Project ....................................................................156 
9.5 Future Directions for this Research ............................................................................158 
9.6 Final Comment ...........................................................................................................159 
References ................................................................................................................161 
Appendices ...............................................................................................................182 
 vi Natural Recovery of People with Cannabis Use and Psychosis 
List of Figures 
Figure 1.1 Overview of the PhD project. ......................................................................3 
Figure 3.1 Control group changes over 2-4 months in non-psychotic groups. ...........50 
Figure 4.1 Flow chart of inclusion criteria..................................................................58 
Figure 4.2 Control group effects over 6 months .........................................................62 
Figure 4.3 Control group effects over 12 months .......................................................62 
Figure 4.4 Control group effects over 24 months .......................................................63 
 
 Natural Recovery of People with Cannabis Use and Psychosis vii
List of Tables 
Table 2.1 Articles exploring natural recovery from substance use in psychosis ........32 
Table 2.2: Comparison of reasons for change/reduction in substance use .................35 
Table 3.1  Studies on treatment of cannabis use in the past 30 days within control 
groups of general populations: Studies reporting mean values. ...................47 
Table 3.2. Mean days of cannabis use in the past 30 days, in control groups of treatment 
trials on people with cannabis use disorders .................................................48 
Table 3.3  Methodological review of control treatments from the included randomised 
controlled trials .............................................................................................49 
Table 4.1. Methodological characteristics of cannabis and other substance use treatment 
trials in psychotic populations: Studies reporting the days of cannabis or other 
substance use in the past 30 days ..................................................................59 
Table 4.2. Methodological review of control treatments from the included randomised 
controlled trials .............................................................................................60 
Table 5.1 Demographics of the 432 FEP patients with SUDs ....................................85 
Table 5.2 Univariate predictors ...................................................................................86 
Table 5.3 Results of a multivariate logistic regression, with simultaneous entry of 
univariate predictors with significance of p < .05. .......................................87 
Table 6.1 Demographic, substance use and clinical characteristics of the patients who 
ceased (N=19) and did not cease (N=48) cannabis use for 6 months .........103 
Table 6.2 Results of univariate logistic regressions predicting cannabis cessation over 
the following 6 months ...............................................................................104 
Table 6.3 Multivariate logistic regression predicting a cessation in cannabis use ...107 
Table 7.1 Reasons for Cannabis Cessation ...............................................................119 
Table 7.2  Strategies for Maintaining Cannabis Cessation .......................................120 
Table 7.3  Relapse to CU ..........................................................................................121 
Table 8.1 Participation and cannabis use ..................................................................134 
Table 8.2 Demographic, substance use and clinical characteristics of the patients who 
ceased/reduced (N=13) and did not cease/reduce (N=9) cannabis use.......135 
Table 8.3  Motivators and effective strategies for reduction or cessation of cannabis use
 ....................................................................................................................138 
Table 8.4 Cannabis use over time .............................................................................144 
 
 viii Natural Recovery of People with Cannabis Use and Psychosis 
List of Abbreviations 
BPRS      Brief Psychiatric Rating Scale 
CBT      Cognitive Behaviour Therapy 
CU      Cannabis Use 
CUD      Cannabis Use Disorder 
EP      Early Psychosis 
FEP      First Episode Psychosis 
MI      Motivational Interviewing 
RCT      Randomised Control Trial 
SMI      Severe Mental Illness 
SU      Substance Use 
SUD      Substance Use Disorder 
UCLA      University of California, Los Angeles 
 Natural Recovery of People with Cannabis Use and Psychosis ix
Statement of Original Authorship 
The work contained in this thesis has not been previously submitted to meet 
requirements for an award at this or any other higher education institution. To the best of my 
knowledge and belief, the thesis contains no material previously published or written by 
another person except where due reference is made. 
 
 
Signature:
 
Date:  09/11/2016 
 
QUT Verified Signature
 x Natural Recovery of People with Cannabis Use and Psychosis 
 
Acknowledgements 
This thesis is dedicated to the loving memory of Evan Arthur Rebgetz (06.12.54-
06.06.13).Without you I would not be where I am today, I miss you every day. 
The quote of “life is a marathon, not a sprint” became my motto throughout my thesis – 
renamed “PhD is a marathon, not a sprint”. In essence the PhD is a journey and with most 
journeys has ups and downs and many challenges along the way. Without the support and 
guidance of my dedicated supervisors, friends, family and research participants my thesis 
marathon would not be over, so I thank you.  
Professor David Kavanagh, for your vision, patience and guidance. Thank you for your 
valuable time and expert knowledge and skills in shaping me into a true scientist-practitioner. 
With your trust and support I was able to complete my PhD marathon.   
Dr Leanne Hides, for her experience and knowledge in the area of psychosis and 
substance use. Your addition to my supervisory team was invaluable. Thank you for being 
down to earth and sharing your real world combination of research and practice. 
Dr Anand Choudhary, for your professional insight and support in navigating the 
systems of Queensland Health and recruitment of participants for the project. A special thank 
you to Monica O’Neill, Hazel Goodenough, and Kylie Garrick who provided operational and 
managerial support. Thank you to Dr Meg Richardson for your support with the editing of the 
final thesis. Without this support I would still be running.  
Corinne, Kiora and Kaeden –the most important people in my life – thank you. Corinne 
thank you for running the marathon with me and your unwavering support and unconditional 
love. Kiora – thank you for your understanding and not being so upset when I could not play 
with you – I promise to always choose you over the computer from now on. 
My parents, Evan and Linda, who gave me the opportunity to study and encouraged me 
to undertake the marathon without your love and continued support I could not have achieved 
all I have. 
Finally, to my colleagues and research participants. Without your assistance I could not 
have completed this fascinating piece of research. I have learnt so much from you all. 
 Chapter 1: Overview and Literature Review 1 
Chapter 1: Overview and Literature Review 
1.1 OVERVIEW 
It is now evident, through research and clinical practice, that cannabis use (CU) is 
widespread among individuals with psychosis and has a negative impact on social, 
occupational, and treatment outcomes in this population (2015). Individuals presenting with 
psychosis and substance use (SU) can be difficult to engage in treatment and have poor 
treatment outcomes compared to those presenting with psychosis alone (Hjorthøj, Fohlmann, 
& Nordentoft, 2009; Lambert et al., 2005). Research over the last two decades has clearly 
shown that integrated treatments for co-occurring disorders have superior impact than non-
integrated approaches, and that motivational components are beneficial. However, it is 
important to note that trials comparing best practice treatments with control conditions have 
not been able to consistently replicate findings of substantially superior differential effects 
across substances and over time (e.g., Hjorthøj, et al., 2009; Kavanagh, Young, et al., 2004; 
Lambert, et al., 2005). A greater understanding of how individuals recover naturally from SU 
and psychosis is expected to aid in the refinement of current treatment protocols and improve 
findings. The aim of this research program is to fill this knowledge gap, by exploring natural 
recovery from CU (and more broadly, SU) among individuals with psychosis.  
1.1.1 Overview of the PhD Research Program 
This thesis by publication used quantitative and qualitative methods to develop an 
understanding of process of natural recovery from CU in individuals with psychosis. This 
chapter provides an overview of the program of research undertaken in this PhD, as well as a 
review of the existent literature on self change in SU among individuals with psychosis. 
This thesis aimed to identify what variables and processes are involved in 
cessation/reduction of CU among individuals with psychosis. Specifically, the research 
sought to identify:  
What triggers the decision to initiate a change and what are the associated reasons for 
reducing/ceasing CU among substance users with psychosis? 
What maintains cannabis cessation among substance users with psychosis? 
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What predicts lapses in control, and what strategies are most commonly used to regain 
control among substance users with psychosis? 
These aims were explored across seven papers. Paper 1 conducted a systematic review 
of the literature on natural recovery from SU, which is presented in Chapter 2. A meta-
analyses (Paper 2) of control conditions of treatment trials receiving no or limited 
intervention in psychotic populations is presented in Chapter 3. Findings from this meta-
analysis included the identification of a baseline for likely changes in CU, which can inform 
future treatment trials. Paper 3 systematically explored the literature on natural recovery from 
CU among individuals in the control conditions of treatment trials receiving no or limited 
intervention in the general (See Chapter 4) population. Papers 4 to 7 comprised a series of 
natural recovery studies, all of which aimed to guide the refinement, and increase the 
effectiveness of interventions for SU in psychosis. Papers 4 and 5 used two existing 
prospective data sets to explore natural recovery from SU among treated and untreated people 
with psychosis. Paper 4 explored factors associated with substance cessation/decline (See 
Chapter 5), and paper 5 identified factors that predicted cessation of CU over 6 months (See 
Chapter 6). Paper 6 utilised qualitative methodology to retrospectively explore the reasons for 
ceasing or reducing CU among a new sample of people with a psychotic disorder (See 
Chapter 7). Results of Paper 6 informed the development of paper 7, which explored natural 
recovery from CU among a sample of people with psychosis over a 3-month period (See 
Chapter 8).  Figure 1.1 shows the sequence of stages involved in the research program. 
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Figure 1.1 Overview of the PhD project. 
 
Overall, the thesis aimed to develop a greater understanding of people’s self-change in 
CU, which in turn can guide design of more effective treatments to support reductions in CU 
and assist in relapse prevention and control strategies.   
1.2 PSYCHOSIS AND CANNABIS MISUSE 
People with psychosis have higher lifetime rates of SU than the general population, 
with rates of 40-50% reported (Degenhardt, Hall, & Lynskey; Hjorthøj, et al., 2009; 
Pourmand, Kavanagh, & Vaughan, 2005). For example, studies in the US and UK have both 
found an incidence of substance use disorders (SUDs) of 47% in people with psychosis, 
compared with 13.5% of the general US population (Barrowclough, Haddock, Fitzsimmons, 
& Johnson, 2006; Korkeila et al., 2005). In the general population, young people have 
particularly high rates of SU, but even in this age group, people with first episode psychosis 
(FEP) have heightened rates of SU (Bendall et al., 2008; Cassidy, Schmitz, & Malla, 2008; 
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Hides, Dawe, Young, & Kavanagh, 2007). Australia has high rates of CU in the general 
population (35% of the general population) and cannabis is the most commonly used illicit 
substance among people suffering from FEP and as a result was chosen as the main substance 
of focus during this project (Australian Institute of Health and Welfare, 2014; Cassidy, 
Schmitz, & Malla, 2008).  
1.3 IMPACT OF SUBSTANCE MISUSE 
SU can trigger the onset of psychosis in at-risk individuals, with those who use 
cannabis before being 1.4 times more likely to develop a psychotic illness (Moore et al., 
2007). Cannabis users with psychosis have been found to have a younger age of onset of 
psychosis than non-substance users, as well as a greater number of positive symptoms and 
more severe depression than non-cannabis users. There is a dose-response effect in the 
increased risk of psychosis with those who use cannabis frequently (2.09, 1.54-2.84), and the 
effect remains (albeit diminished) when the effects of potential confounding variables (e.g., 
having parents who had divorced) are controlled (Andreasson, Allebeck, Engstrom, & 
Rydberg, 1987; Hall & Degenhardt, 2000; Moore, et al., 2007).  
Problems with SU remain after the onset of psychosis. People with psychosis and a 
comorbid SUD have poorer functional outcomes, worse global functioning and increased 
severity of psychotic symptoms than those without comorbidity (Pencer & Addington, 2008; 
Seddon et al., 2015; van der Meer, Velthorst, & Generic Risk and Outcome of Psychosis 
(GROUP) Investigators, 2015). In particular, SU has a substantial negative impact on 
vocational and social learning, and role transitions that occur in adolescence and young 
adulthood (Pencer & Addington, 2008). Additional ill effects include increased rates of 
treatment noncompliance, relapse, distorted perception and cognition, suicidal ideation, social 
exclusion, homelessness, aggression, incarceration, injury, HIV, hepatitis, and cardiovascular, 
liver, and gastrointestinal disease (Cleary, Hunt, Matheson, Siegfried, & Walter, 2008b; 
Drake, Mueser, Brunette, & McHugo, 2004; Horsfall, Cleary, Hunt, & Walter, 2009).  
Individuals with psychosis and comorbid SU have significantly higher hospital readmission 
rates, poor medication compliance and a poorer overall prognosis (Archie et al., 2007; 
Barrowclough, et al., 2006). It is not only people with psychosis who use cannabis heavily 
who run these risks of symptom exacerbation; people who use cannabis irregularly or in 
minimal amounts are also at increased risk of relapse to CU (Lobbana et al., 2010). These 
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results certainly suggest that psychosis may increase a person’s sensitivity to the deleterious 
effects of cannabis. 
SU greatly impacts on mental illness and this leads to a substantial effect on health 
services. For example, SU has been associated with reduced medication effectiveness and 
increase in psychotic symptoms (Thornton et al., 2012; Ziedonis & Nickou, 2001). All the 
above impacts on the cost to health care with individuals with psychosis and SU increasingly 
using psychiatric hospitals, emergency medical care and general practitioner care (Thornton, 
et al., 2012; Ziedonis & Nickou, 2001). It is therefore important that research strives to refine 
and improve intervention and prevention strategies.   
1.4 REASONS FOR USE 
Research on reasons for CU among psychotic populations has provided some insight 
into the factors that maintain SU despite its negative effects. An increased understanding of 
the reasons people use cannabis may also inform the development of more effective 
treatments. To date, it appears people with psychosis choose to use substances to relieve a 
variety of non-psychotic experiences (Kolliakou et al., 2015; Noordsy et al., 1991; Thornton, 
et al., 2012). Alcohol, cannabis and cocaine are used to decrease depression, and cannabis 
and alcohol are used to decrease anxiety (Dixon, Haas, Weiden, Sweeney, & Frances, 1991).  
Individuals with psychosis generally endorse relaxation/social motives, pleasure and coping 
with unpleasant affect (Kolliakou, et al., 2015; Thornton, et al., 2012). Nonetheless, 
expectancies do not always mirror experiences; for example, a study using Q methodology1 
in a group of people with chronic schizophrenia found that patients did not actually gain 
much symptom relief via their SU (Addington & Duchak, 1997). Gregg and colleagues 
(2009) found that the most commonly endorsed reasons for SU in people with schizophrenia 
and other psychotic disorders were: when I want to chill out or relax (94.3%), when I am 
feeling stressed (90.4%), and when I am bored and want something to do to pass the time 
(89.6%).  They also found that 50.9% of participants used substances to cope with or reduce 
auditory hallucinations, and 57.4% to abate feelings of suspiciousness or paranoia (Gregg, et 
al., 2009). Specifically exploring the role of cannabis and psychosis, Thornton (2012) 
concluded cannabis was used for pleasure. Recently, Mane and colleagues (2015) exploring 
the relationship between1 cannabis and psychosis in FEP cannabis users found reasons to use 
                                                 
 
1
 
Q Methodology is a research method used to study people's "subjectivity"—that is, their viewpoint. It is used both in clinical settings for assessing a patient's progress over 
time (intra-rater comparison), as well as in research settings to examine how people think about a topic (inter-rater comparisons).
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were associated with helping arrange thoughts and dealing with hallucinations and 
suspiciousness. 
Reasons for SU in people with early psychosis appear to be slightly different. For 
example, a sample of 18-30 year olds with FEP and comorbid SU endorsed the following 
reasons for use through their responses on the reasons for use scale: to relieve boredom, 
something to do with friends, to help them feel less anxious, and to feel more relaxed (Pencer 
& Addington, 2008). Understanding processes around why individuals with psychosis 
continue to use substances when little relief is in fact received could greatly assist in the 
design of effective treatments.     
Baker and colleagues have consistently suggested that different treatment approaches 
may be required for different substance groups (Baker, Turner, Kay-Lambkin, & Lewin, 
2009) and therefore specifically exploring cannabis alone could assist in improving 
interventions. In addition they have suggested that intervention needs to be tailored to the 
specific psychiatric disorder and taking into account the above differences, consideration 
needs to be taken for interventions at different phases of psychotic illness (i.e., early 
psychosis versus chronic) and different types of psychotic illness (Thornton, et al., 2012).  
1.5 TREATMENT OF SUBSTANCE USE IN PSYCHOSIS 
Clinical experience suggests that people with psychosis are difficult to engage in 
treatment (Addington & Addington, 2007). Clinical trials examining the efficacy of SU 
treatment in people with psychosis have generally inconsistent and limited results (Cleary, et 
al., 2008b; Hjorthøj, et al., 2009; Kavanagh & Mueser, 2007; Lambert, et al., 2005). 
Exploring treatment in previously homeless individuals with dual diagnosis Henwood and 
colleagues (2012) concluded that SU improvements were seldom linked to therapeutic 
interventions. Treatments have typically involved multiple components (e.g., cognitive 
behaviour therapy, motivational interviewing, behavioural interventions, family 
interventions) and studies seeking to identify which strategies contribute to change have not 
yet been attempted. The only treatment component that has demonstrated an independent 
impact is motivational intervention (MI), and even then, the impact has primarily been on 
longer engagement in treatment, rather than treatment outcome (Mueser, Kavanagh, & 
Brunette, 2007). Recently, Hjorthøj and colleagues’ (2014) systematic review and meta-
analysis concluded that MI showed a reduction in the quantity however not the frequency of 
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CU. They suggested that given the nature of MI, it is unlikely to change the frequency and 
other effective treatments are required.  
The limited impact of psychosocial treatments is further highlighted by an RCT of 130 
participants with a diagnosed psychotic disorder and coexisting problems with SU compared 
a MI/cognitive behaviour therapy (CBT) treatment group with treatment as usual (Baker et 
al., 2006). The treatment group received ten 1-hour sessions on a weekly basis, with sessions 
1-4 focusing on MI and sessions 5-10 focusing on CBT. Results suggested only short-term 
benefits (at 15 weeks), and there were no significant differences between the two groups in 
SU or abstinence rates at 12-month follow-up (Baker, et al., 2006). Similar results were 
reported in a RCT examining the effectiveness of CBT for schizophrenia and SU (Haddock et 
al., 2003). This would suggest that MI and CBT techniques provide short term reductions in 
SU, but few long-term treatment gains. The potential long-term efficacy of other therapies 
has also been examined, with similar results. For example, the trial of MI, CBT, and family 
intervention by Barrowclough et al (2006) showed modest but statistically significant results 
at the end of treatment and at 9-12 month follow-up, but these effects lost significance at an 
18-month follow-up. Recently, Barrowclough and colleagues have provided evidence and a 
framework to include families in the treatment of SU and psychosis with potentially 
promising results, however further exploration is required (Lobban & Barrowclough, 2016; 
Smeerdiijk et al., 2014) 
Exploring the wider evidence to gain further insights into the effectiveness of current 
interventions found few differences. A review of 25 RCTs on severe mental illness (SMI) and 
SU suggested that individual (i.e., one on one therapy) MI and CBT was no more effective 
than  standard care in  reducing SU, retaining participants in treatment, or preventing relapse 
(Cleary, Hunt, Matheson, Siegfried, & Walter, 2008a). It was concluded that there was no 
convincing evidence to support the efficacy of one psychosocial treatment (i.e., MI + CBT, 
CBT alone, skills training) over another. The studies included in the review used very 
different methodologies (e.g., choice of measure, inconsistent inclusion and exclusion 
criteria) which hinder interpretation of the meta-analysis.  
The mechanisms of change in MI and CBT treatments are poorly understood.  
Furthermore, there is limited understanding of the interaction between SU and psychosis, and 
how this impacts on individuals’ motivation to make a change in their SU (Barrowclough, et 
al., 2006). For example, Lobanna and colleagues (2010) reported that motivation to change 
increased following a psychiatric inpatient admission, but tends to fluctuate in frequency and 
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intensity over time. It is possible that an increased targeting of the specific mechanisms 
underlying motivation to change may increase the effectiveness of interventions. An 
increased understanding of differences in the patterns of SU at different ages and different 
stages of psychosis, as well as the motivating and maintaining factors of change in SU, may 
also enhance treatment (Lobbana, et al., 2010). 
Integrated dual diagnosis programs which address both the SU and psychosis 
components have been found to be superior to either intervention in isolation (Drake, O'Neal, 
& Wallach, 2008). Despite the above mentioned limited effectiveness to date, integrated 
programs are the standard treatment for individuals with psychosis and SU. The components 
which are important in the recovery of SU are not well understood (Davidson & White, 2007; 
Horsfall, et al., 2009). Current approaches appear to be integrating non-traditional SU 
treatments. For example, the NAVIGATE program is a team-based, multicomponent 
treatment program which can be incorporated into routine mental health services (Mueser et 
al., 2015). The aim of the program is to assist people with FEP (and their families) toward 
psychological and functional health. The multicomponents include family education, 
individual resiliency training, supported employment and education, and individualised 
medication treatment. The philosophy of the program is a shared decision-making approach 
which highlights a recovery model including collaboration with the entire system in treatment 
planning and reviews (Mueser, et al., 2015). Using individuals’ experiences of natural 
recovery may assist in fine tuning such specialised services.    
It has been suggested that the limited results found in the current literature may be due 
to the short nature of the interventions provided and longer interventions required given the 
complexity of SU and psychosis (Baker, Hides, & Lubman, 2010; Barrowclough et al., 
2014). Only one RCT has been conducted on longer term interventions to date. 110 
participants were randomly allocated to short-term MI-CBT, longer-term MI-CBT up to 24 
sessions over 9 months or treatment as usual. The authors concluded that there was no benefit 
in either intervention in relation to frequency or amount of cannabis used (Barrowclough, et 
al., 2014).   
1.6 RELAPSE OF SUBSTANCE USE 
A large number of studies have focused on understanding predictors of a poor clinical 
course and relapse in SU. Current models of relapse for SU focus on the interaction between 
situational risk factors and individual characteristics. From a CBT framework, self-efficacy, 
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coping, and the relapse context interact to determine whether a person will use or resist from 
using. Marlatt and Gordon’s (1980) taxonomy of relapse situations incorporated both 
intrapersonal and interpersonal factors. Initial studies on substance abusing adults found that 
intrapersonal factors, particularly negative emotional states, predicted return to use following 
abstinence. In contrast, studies on adolescents reported the major reason for initial use 
following treatment was direct social pressure in interpersonal settings (Brown, Vik, & 
Creamer, 1989).   
However, a general population study of adolescent and adult relapse, found that adults 
were most likely to relapse in negative intrapersonal states (66.9%) or in other intrapersonal 
states (95%) (Ramo & Brown, 2008). The latter included coping with urges or temptation 
both in the presence (55%) and absence of cues (26%). Adolescent participants had similar 
relapse rates for negative intrapersonal states (64.4%) and other intrapersonal states (86.7%). 
Compared to adults, adolescents were most likely to relapse when experiencing a positive 
emotional state (41%) and when giving into temptations in the presence of cues (37.2%). As 
relapse is likely to involve contextual factors, research needs to be mindful to include 
environmental contexts (Drake, Wallach, & McGovern, 2005).               
It is therefore clear that a further understanding of relapse contexts for those with CU 
and psychosis is needed. There has been limited focus on relapse of SU in people with 
psychosis and SMI. Findings indicate that individuals with SU and psychosis are likely to 
relapse in regards to their SU even once they are in remission (Drake, et al., 2005). Relapse is 
associated with exacerbations of mental illness, social pressures within drug-using networks, 
lack of meaningful activities and social supports for recovery, independent housing in high-
risk neighbourhoods, and lack of substance abuse or dual diagnosis treatments (Drake, et al., 
2005). Understanding the different contexts across stages of illness and in different age 
groups may also be important for optimal treatment design.  
1.7 PSYCHOSIS RELAPSE 
Previous research has identified difficulties with a clear definition of psychosis relapse, 
and numerous recommendations have been made for the appropriate definition of this 
concept (Falloon, Marshall, Boyd, Razani, & Wood-Siverio, 1983). The UCLA criteria for 
psychotic relapse has been widely used over recent years and is considered the most robust 
measure (Hides, Dawe, Kavanagh, & Young, 2006). The definition is clinician-rated using 
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the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) and defined as elevation 
on a BPRS remitted psychotic symptom to ≥ 6 for a 1 week period (Hides, et al., 2006).  
In samples with psychosis, consideration also needs to be given to the context in which 
relapses in psychotic symptoms occur. Relapse contexts are likely to differ between psychotic 
populations with and without a SUD, indicating the two groups may require different relapse 
prevention strategies (Drake, et al., 2005). Those with a SUD have more severe mental health 
problems, as well as pervasive cognitive (i.e., reduced effectiveness of learning new skills) 
and social dysfunction (i.e., isolation and victimisation) that needs to be addressed in 
treatment.   
There is evidence to suggest that psychotic relapse risk increases with increased CU 
(Hides, et al., 2006). It is also considered the strongest predictor of relapse of psychosis. In 
turn, cannabis relapse was also predictive of psychosis relapse which suggests a bidirectional 
relationship (Hides, et al., 2006). Exploring the relationship between CU and psychosis has 
suggested that those who continue to use cannabis compared to those who cease or reduce 
their use have increased episodes of psychotic relapses (van der Meer, et al., 2015). Due to 
this relationship, it is important to consider psychotic symptoms and potentially other mental 
health symptoms in the context of cannabis relapse and maintenance. 
1.8 NATURAL RECOVERY IN SUBSTANCE USE 
‘Natural recovery’ in the literature is defined as a process of initiating and sustaining 
recovery, without professional intervention or involvement in a self-help/12-step group. It is 
defined as reductions or remission of SU over time periods ranging from 3-4 months to over 
18 months. Research on the natural course of recovery from SU among populations suggests 
it has a variable and often fluctuating course. A large proportion of individuals who use 
cannabis cease by their mid-thirties and the most successful cessation occur without treatment 
(Chen & Kandel, 1998; Cunningham, 2000; Price, Risk, & Spitznagel, 2001). Studies on 
natural recovery from alcohol, heroin and cocaine abuse have shown that many individuals 
can change their drug use when the benefits of use are outweighed by the negative impact 
(Toneatto, Sobell, Sobell, & Rubel, 1999). This cognitive re-evaluation of the costs and 
benefits of use is a critical process in natural recovery (Mohatt et al., 2008). A better 
understanding of the natural recovery process from SU in people with psychosis is important, 
as it would allow a better understanding of behaviour change in this specific population.  
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Exploring the research on natural recovery in SU among the general population may 
shed light into recovery efforts for individuals with psychosis. Although a large proportion of 
SU in the general population cease over time, little is known about the prevalence of those 
who cease smoking each year. Toneatto and colleagues (1999), in their study of natural 
recovery from cocaine dependence, found that the most commonly reported negative 
consequences of use were interpersonal problems including the negative impact on one’s self-
concept. The study concluded that cognitive evaluation was the main reason for ceasing use. 
Other reasons for ceasing cocaine use included: external pressures or an ultimatum from 
significant others, financial problems, health problems, tired of using, lifestyle, fear of 
continued use, and observation of effect of use on others. The study reported that the most 
important factors in maintaining change were an improvement in self-concept, change of 
friends, change in social life, avoidance of social situations in which use may occur, support 
from significant others, change in drug use, change of address, and change in job. The study 
did not explore the process by which individuals made the decision to engage in these 
maintaining factors, which would be of interest in treating people with psychosis and 
substance misuse. The most frequent triggers for urges were reported to be substance-related 
stimuli, with the most common being the recall of pleasant effects of the substance, talking 
about the use of substances, and being in the presence of the substance or someone using the 
substance. Negative mood states and boredom were also reported as triggers for urges to use. 
Cognitive coping strategies were the most commonly reported coping behaviours for urges, 
while the most common responses for not resuming use were the awareness of the negative 
consequences of use, lack of desire or need, and having an incompatible lifestyle with SU.   
In conclusion, research on natural recovery from SU has indicated that cognitive re-
evaluation of the costs and benefits of use are a critical process in natural recovery. Increased 
understanding of such natural recovery from SU in psychosis may provide valuable insights 
into potential treatment targets to reduce CU in this vulnerable population. Research in this 
area would potentially impact on designing self-change strategies, improving formal 
treatment, developing effective intervention strategies, and contributing to the knowledge of 
the natural history of cannabis use disorder (CUD) in psychosis (Watson & Sher, 1998). As 
very little is known about long-term recovery, natural recovery studies could be very valuable 
for tracking its stability over time. 
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1.9 MAINTENANCE  
No known research has specifically explored what factors maintain cannabis cessation 
in individuals with psychosis. Research among people with schizophrenia and SU found 7 out 
of 17 participants who were currently abstinent had intentions to continue abstinence (Asher 
& Gask, 2010). Reported reasons for maintaining abstinence were disliking the negative 
effects of cannabis, problems with the law, improved finances, becoming older, physical 
health, insight into the link between use and mental health symptoms, support from others 
and hope for change in personal circumstances (e.g., relationships, employment, 
accommodation). Another study which reported possible reasons for maintenance found that 
the role of protective and supportive friends or family stopped participants from using again. 
It is clear that further research is required in this area to improve longer term 
abstinence/reduction in SU. 
 Research on natural recovery studies from SU have found that similar reasons for 
initial change appear to also serve maintenance factors. In a recent review of natural recovery 
studies from 1999 to 2005, Carballo and colleagues (2007) found that maintenance factors 
were reported by 59.1% of all studies. The two most commonly mentioned maintenance 
factors were social support and family support, as reported in 54.5% and 45.5% of studies, 
respectively. The reviewers highlighted that these two factors were also the most common in 
the first natural recovery review (Sobell, Ellingstad, & Sobell, 2000). Other factors reported 
in the review included avoidance of substance-use situations (36.4%), self-control (31.8%) 
and religion (34.6%).  
1.10 EXTENT OF NATURAL RECOVERY IN CONTROL GROUPS 
Most puzzling is evidence from RCTs suggesting that substance users with psychosis in 
assessment only or minimal treatment conditions achieve similar reductions in SU over time 
to those in more active treatments. ‘Control groups’ could be suggestive of natural recovery 
where no formal treatments are provided. Exploration of these control groups may offer 
further insight into factors that influence recovery. 
Reviewing the literature of RCT’s for SU treatment in people with psychosis has found 
people in the control groups make substantial recovery gains. The First Episode Psychosis 
Outcome Study (FEPOS) study conducted at the Early Psychosis Prevention and Intervention 
Centre (EPPIC) in Melbourne, Australia consisted of 786 FEP patients. Lambert et al. (2005)  
reported that the lifetime prevalence of CU was 74.1% (n = 463), baseline prevalence was 
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61.6% (n = 385) and follow-up (18 months) was 36.9% (n = 91). This supports other research 
which has concluded that some people cease SU without formal treatment (‘natural 
recovery’) and possibly before the onset of psychotic symptoms (Addington & Addington, 
2001; Archie, et al., 2007; Carr, Norman, & Manchanda, 2009; Harrison et al., 2008; Hinton 
et al., 2007).   
There also appears to be no benefit of speciality care programs for those with SU and 
psychosis. In a recent review of nine studies without specialised substance abuse treatment 
and five with specialised substance abuse treatment, all participants across different 
conditions were able to reduce their SU. Specialised substance abuse treatments did not 
obtain better rates of abstinence or reduction (Wisdom, Manuel, & Drake, 2011). These 
findings strongly support a role for natural recovery from SU.   
1.11 QUALITATIVE DATA ON RECOVERY OF SUBSTANCE USE IN PSYCHOSIS 
Qualitative research exploring the processes of natural recovery from SU in people with 
psychosis could potentially lead to improvement in current treatments.  Lobbana et al., (2010) 
conducted the first qualitative study exploring natural recovery from SU in a psychotic 
population. Four overall themes emerged; including, the influence of perceived drug norms, 
attributions for initial and on-going drug taking behaviour, changes in life goals affecting 
drug use, and beliefs about the links between mental health and drug use. Changes in 
personal life goals were often related to an increase in the perceived value of health, 
disposable income and close family relationships. Similarly, Bennett et al (2009) found that 
the ability to remit from cocaine dependence in schizophrenia may be reliant on an individual 
recognising the serious impact of drug use on their life and functioning, limiting problem use 
to only one drug, and having only one substance class to address. Change appeared to be 
associated with the recognition that drug use was causing problems, increased number of 
problems, and making an effort to do things differently.   
The differences between people with psychosis who cease cannabis and those that 
continue to use was explored in a chart review of 206 consecutive inpatients with 
schizophrenia or related disorders (Dekker et al., 2008). Reported reasons for cessation 
included an admission, worsening of mental health symptoms, complaints after CU, New 
Year’s resolution, pressure by others, and health related issues. These results were similar to 
Addington and Duchak’s (1997) observations on cessation of alcohol and cannabis. In their 
study, Addington and Duchak (1997) found that reductions in alcohol use were associated 
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with a fear of health risks, financial cost, doctor’s  disapproval, not liking the way they were 
thinking or acting, parents’ or relatives’ disapproval, a bad experience, becoming confused, 
and being hospitalised. Similar reasons were identified for cannabis; including excessive cost, 
parents’ or relatives’ disapproval, fear of health risks, doctor’s disapproval, becoming 
paranoid, and being unable to keep a job, remain in school or remain in a treatment program.  
Further evidence of themes from natural recovery studies has found a variety of helpful 
factors. Maisto et al (1999) collected qualitative data through focus groups of 21 participants 
with schizophrenia and a SUD. Therapeutic factors that were perceived as helpful included 
individual and group treatments, and self-help or 12-step groups. The main theme across the 
therapeutic factors was emotional and practical support. Extratherapeutic factors that were 
helpful included social support, changes in  social environment, keeping busy, acute negative 
experiences or hitting bottom, weighing the pros and cons of quitting versus using, faith, 
prayer, or meditation, goals, and more effective medication. These results were similar to a 
study that assessed 25 participants with SMI and alcohol disorder (Stasiewicz, Bradizza, & 
Maisto, 1997). Among other findings, 48% reported engaging in a cognitive appraisal of the 
pros and cons of drinking, and 68% reported that a negative life event was associated with the 
initiation of change.   
Research on natural recovery from SU in people with psychosis is in its infancy. 
Learning from the literature on natural recovery from SU alone is vital in progressing this 
important field of study forward. Areas of research have pointed to similarities in SU in 
psychosis and SU alone. These include drugs of choice, patterns of use, and initial reasons for 
use (Bennett, et al., 2009). While it could be surmised that natural recovery from SU is 
similar in the psychosis population, it is known that people with psychosis are difficult to 
treat and have additional and complex illness-related treatment needs (Addington & 
Addington, 2007; Bennett, et al., 2009). Current treatment design for SU in psychosis has not 
been guided by a strong body of research on natural recovery. Natural recovery is arguably an 
important concept for both refining treatments, and increasing their impact (Green, 
Kavanagh, & Young, 2007; Mueser, et al., 2007).   
A series of natural recovery studies could play a vital role in guiding the development 
of new and more effective interventions for SU in psychosis (Green, et al., 2007; Mueser, et 
al., 2007). Undertaking a study of a group of people in the early stages of psychosis with 
comorbid SU is warranted, due to this group potentially having a greater chance of recovery 
and being relatively free from the confounding effect of suffering from a chronic illness on 
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functioning. This approach could be inductive in nature and observe individuals that had 
recovered from SU, exploring the strategies and techniques that aided in this process. 
Knowledge gained from such research would enable the development of conceptual models 
of recovery within a comorbid population, instead of generalising from a study of recovery in 
people with only SU.  
1.12 COMMENTARY (SUMMARY AND IMPLICATIONS) 
The incidence of CU among individuals with psychosis is high, and associated with 
negative biological, psychological and social consequences. It is clear that current treatment 
approaches to SU in individuals with psychosis have yielded mixed, and also less than 
satisfactory long-term results. Importantly, individuals with psychotic disorders have been 
found to naturally reduce their CU after a psychotic episode. Further research is needed to 
learn more about the ‘natural recovery’ from CU among psychotic populations, including the 
mechanisms underlying this process. Such knowledge is critical for improving current 
approaches to treatment. A starting point is to specifically explore the state of the literature on 
natural recovery from CU in individuals with psychosis. 
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Abstract 
Substance misuse in people with psychosis presents significant problems, but trials of 
treatments to address it show little sustained advantage over control conditions. An 
examination of mechanisms underpinning unassisted improvements may assist in the 
refinement of comorbidity treatments. This study reviewed existing research on natural 
recovery from substance misuse in people with psychosis. To address this issue, a systematic 
search identified only 7 articles that fulfilled criteria. Their results suggest that people with 
psychosis report similar reasons to change as do non-psychotic groups, although they did not 
clarify whether the relative frequencies or priority orders were the same. Differences 
involved issues relating to the disorder and the functional problems faced by this group: 
receipt of treatment for mental health difficulties, worsening of mental health difficulties, and 
homelessness. The current research on reasons for change in people with psychosis is sparse 
and has significant limitations, and as yet it offers little inspiration for new treatments. A 
more fertile source may prove to be a detailed investigation of successful substance control 
strategies that are used in self-management by this group.  
 
Keywords: Natural recovery; psychosis; substance use; comorbidity 
 
 
 
 
 
 21 
 
2.2 INTRODUCTION 
Problematic SU is more common in people with psychosis than in the general 
community, having significant detrimental effects on mental and physical health, and on 
social functioning (Hjorthøj, et al., 2009; Kavanagh, Waghorn, et al., 2004). While research 
over the last two decades has shown that integrated treatments for co-occurring disorders 
have superior impact than non-integrated ones and that motivational components are 
beneficial, trials comparing best practice treatments with control conditions have not been 
able to consistently replicate findings of substantially superior differential effects across 
substances and over time (e.g., Hjorthøj, et al., 2009; Kavanagh, Young, et al., 2004; 
Lambert, et al., 2005). This observation does not mean that participants show poor 
improvement rates: rather, studies typically show reductions in SU across conditions. While 
these effects may represent regression to the mean, they suggest that many people with 
psychosis stop or reduce consumption of psychoactive substances by themselves, without 
clinical intervention or treatment. However, this ‘natural recovery’ has received relatively 
little research attention to date. A review of the current literature on natural recovery is timely 
due to growing research in this area. A review would allow a consolidation of the current 
state of the research area and provide future areas of research efforts. ‘Natural recovery’ in 
this article is defined as a process of initiating and sustaining recovery, without professional 
intervention or involvement in a self-help/12-step group.    
Natural Recovery in Substance Abuse 
Natural recovery from substance misuse is common in the general population (e.g. 
Ellingstad, Sobell, Sobell, Eickleberry, & Golden, 2006; Sobell, et al., 2000). Most natural 
recovery research has focused on cigarette smoking (Sobell, et al., 2000) and alcohol misuse 
(mostly exploring alcohol addiction; Ellingstad, et al., 2006; Sobell, et al., 2000), although 
some studies have focused on illegal drugs. While the course to recovery from substance 
misuse is variable and fluctuating, many people can reduce consumption or attain abstinence 
when the perceived benefits of use are outweighed by negative impacts. The number of 
negative consequences is not necessarily greater (Toneatto, et al., 1999), but qualitative 
differences can often be seen.  For example, Toneatto et al. (1999) found that the most 
common reported reason for cessation of cocaine use involved a cognitive evaluation of its 
consequences, not dissimilar to the one evoked by motivational interviewing (Miller & 
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Rollnick, 1991), and the most common prompt was a conscious decisional process. Other 
reasons included external pressures or ultimata from significant others, or financial or health 
problems (Toneatto, et al., 1999). Some were tired of the related lifestyle, expressed a fear of 
future negative consequences or had noticed negative effects on others. Conversely, those 
who continued use typically focused on the immediate effects of intoxication (euphoria and 
escape from problems). A greater understanding of natural recovery in studies such as this 
has informed advances in treatment design and policy making (Klingemann & Sobell, 2001).     
A methodological review of studies reporting natural recovery from alcohol and illicit 
substances by Sobell et al. (2000) found that the most frequently reported reason for self-
change across the studies involved health concerns (17 studies, 43%), followed by negative 
personal effects (30%; e.g. negative feelings about themselves, embarrassment), and financial 
concerns (30%). Close behind were changes in the way they viewed their SU (28%), 
influence from a significant other (25%), or family or social reasons (each 20%). Religious 
reasons were cited in 7 studies (18%), and work, living arrangements or lifestyle changes 
were each mentioned in 15% of studies.  
Importantly, the review also examined factors that supported maintenance of self-
change. The most common were social (support or changes in the social group in 33%, 
significant other or family factors in 28%), followed by competing behaviors (nonsubstance 
interests in 20%, and lifestyle change, avoidance of SU situations, work-related changes were 
each in 18%). Religion, self-control or willpower, and changes in living arrangements were 
each cited in 15% of studies. 
Therefore the first aim of the current review was to identify and explore the current 
studies on natural recovery from SU in people with psychosis. By summarising and exploring 
limitations to these studies, it was hoped to identify ways that future research might drive this 
important area forward. The second aim was to explore whether the reasons for change that 
underpinned natural recovery from substance misuse in people with psychosis differed from 
those in the general population. Consideration of these processes was hoped to assist in 
developing treatments that show more consistent and sustained benefits over controls. 
Accordingly, this study undertook a systematic review of the current research literature on 
natural recovery in people with serious mental disorders. A comparison was made with 
results of studies in the general population. 
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2.3 METHODS 
An electronic literature search was conducted in August 2014, using Medline, 
PsycINFO, Psychology Journals, and Psychology Subject Corner.  Search terms for the 
psychosis group were: (psychosis OR psychoses OR schizophren* OR schizotypal OR 
psychotic OR bipolar OR severe mental OR serious mental); (substance OR cannabis OR 
alcohol OR marijuana OR addiction OR abuse OR cocaine OR dual diagnosis OR comorbid 
OR comorbidity OR marihuana OR co-occurring); (treatment OR reduction OR cessation OR 
predict* OR longitudinal OR natural recovery OR prospective OR cohort OR course OR 
follow-up).  For comparison a general population search was conducted using similar 
inclusion criteria and variables for analysis; (substance OR cannabis OR alcohol OR 
marijuana OR addiction OR abuse OR cocaine OR dual diagnosis OR comorbid OR 
comorbidity OR marihuana OR co-occurring); (reduction OR cessation OR predict* OR 
longitudinal OR natural recovery OR prospective OR cohort OR course OR follow-up). 
Potential studies were evaluated for inclusion in this study by the first author, based on 
whether they: (a) reported natural recovery (including other terms reflecting the same 
phenomenon – self-change, self-quitters, natural resolution, spontaneous recovery); (b) were 
in English; (c) reported original results; (d) had respondents with a past or current drug 
problem; (e) did not comprise case studies or personal accounts; (f) could exclude an 
attribution of recovery to treatment (i.e., no-treatment control groups of randomised 
controlled trials). Studies of people in treatment for psychosis were included, unless they 
specifically reported that they were receiving treatment for substance misuse. For the general 
population search only studies that excluded participants with a SMI were included. 
2.4 RESULTS 
Studies on people with psychosis 
The search elicited 2,510 articles. A review of the title of articles indicated 311 
included words that were consistent with the search criteria (i.e., they met inclusion criteria 
(a) and (b) above). This number was reduced to 109 after reading abstracts, in which 
inclusion criteria (c) to (f) needed to be satisfied. Forward and backward searches on the 
identified papers yielded another 13 potential articles, whose abstracts were also reviewed for 
relevance. A final decision on inclusion of a study involved reading of the full paper. Based 
on reviews no relevant articles appeared to be missed and ambiguous articles were reviewed 
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additionally by the second and third author and a consensus reached. Seven articles 
examining reasons or strategies relating to natural recovery for SU in serious mental 
disorders were identified, and are listed in Table 2.1. Results on reasons for cessation and 
maintenance of change were examined. 
Asher and Gask (2010) qualitatively explored factors that maintained illicit drug use in 
patients with schizophrenia. During this study they found seven of the participants had ceased 
use and aimed for this to continue. For these patients reasons reported were disliking the 
effects and illegality of cannabis, financial, increasing age, health, impact on mental state, 
family support and occupational/accommodation status. As this was not the main aim of the 
study, only minimal information pertaining to these reasons was given and the authors did not 
report the number of participants who endorsed each reason. There was nil confirmation of 
diagnosis, and it was unclear how long participants had ceased use. 
Lobbana and colleagues’ (2010) study appears to be the first to qualitatively explore 
natural recovery from substance misuse in a psychotic population. Young people with a 
psychotic disorder from an early intervention service in England were assessed. Participants 
were currently misusing substances (n=10) or used substances (n=9) during the previous 3 to 
72 months. The study retrospectively assessed substance misuse patterns, reasons for drug 
use, factors influencing decision to abstain from SU, and factors influencing continued use of 
substances through a qualitative interview. Analysis elicited four themes: influence of 
perceived drug norms on behaviour, attributions for initial and on-going drug taking 
behaviour, changes in life goals affecting drug use, and beliefs about the links between 
mental health and drug use. The changes in life goals affecting drug use theme explored the 
concept of natural recovery (cessation/reduction in use reasons) from SU. Changes in 
personal life goals, particularly an increase in the perceived value of health, disposable 
income and close family relationships (largely identified by older participants) appeared to be 
key reasons for reducing or stopping use. Social aspects played a role in the reduction or 
cessation of use including identifying with non-using social groups. For a small number of 
respondents, change occurred after a significant life event.  
Limitations of the study included a lack of distinction between the themes reported by 
participants who were or were not currently using substances. The qualitative focus of the 
study also prevented an assessment of the frequency of each change strategy. The substance 
misuse threshold appears to have been low, using on at least 2 days each week, on half of the 
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weeks in a 3-month period). In addition, the absence of a clear definition of reduction in SU 
also made results difficult to interpret.  
Childs and colleagues (2011) attempted to build on the qualitative methodology of 
Lobbana et al. (2010), examining the experiences of seven cannabis users over time. The 
authors observed progressive experiences that led participants to making a decision to cease 
or continue using. Among those who ceased using cannabis, reasons included consequences 
of continued use on their mental health, and having protective friends and family members 
who shielded them against ongoing use and temptation.   
 Data from a naturalistic 12-month longitudinal study compared motivation to change 
and the process of change in people with cocaine dependence with schizophrenia and 
affective disorders (Bennett, et al., 2009). The current review focused on subgroups of 
participants with schizophrenia and cocaine dependence termed ‘S/D’, who either identified 
reduced use in the past 3 months or did not. The group that said they reduced consumption 
identified a greater number of lifetime consequences, and used more behavioural and 
experiential processes (such as consciousness raising, contingency management). Process of 
change was explored in a subgroup of S/D participants who commenced a drug treatment 
program in the previous three months and those who did not. The two groups did not differ 
on a range of variables. Exploring the differences between cocaine dependence and cocaine 
remission in the schizophrenic group yielded a number of differences in terms of drug use 
and consequence. Bennet et al, (2009) concluded that the ability to remit from cocaine 
dependence in schizophrenia may be reliant on the participant recognising the serious impact 
of drug use on their life and functioning, limiting problem use to only one drug, and having 
only one substance class to address rather than two (cannabis and alcohol). Change was 
associated with the recognition that substance misuse is causing problems and a number of 
problems and taking active steps to change. A methodological weakness of the study as it 
relates to natural recovery was that length of remission was not recorded, which does not 
allow differences between those participants that had reduced use for 3 months and those who 
had reduced use for 6 months to be compared. This study was the first of its kind to use a 
comparison group, however having a control group of non-using participants would have 
improved the methodology of the study. The study did not explore specific reasons for 
cessation/reduction in use, therefore the results are limited.     
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A chart review of young people with schizophrenia or related disorders sort to identify 
differences  between those that ceased or continued CU (Dekker, et al., 2008). No differences 
in patient characteristics (gender, age of first CU, age of first psychiatric care for psychosis, 
age at admission to clinic, drug use defined as cannabis only or cannabis and ‘hard’ drugs – 
ecstasy, cocaine, LSD, amphetamines, opiates, and joints used per week) were found. Of the 
206 patients 45 of the records mentioned reasons for cessation of CU. Reasons for cessation 
included a prior admission (n=23), worsening of psychotic symptoms (n=11), panic/anxiety 
(n=3), complaints after CU (i.e., nausea) (n=3), New-Year’s resolution (n=2), pressure by 
others (n=2), and fear of brain damage (n=1).  However, the conclusions of this study relating 
to natural recovery were limited by the lack of a clear definition and variability in the length 
of abstinence or reduction required and the fact only inpatients with the most severe 
psychiatric difficulties were included in the chart review.  
Stasiewicz, Bradizza, and Maisto, (1997) assessed participants with a SMI and alcohol 
disorder. Resolution of alcohol disorder was defined as abstinence for at least one year. 
Reported reason for resolution included hit rock bottom (n=15), major lifestyle change 
(n=13), weighed pros and cons (n=12), received treatment for mental illness (n=11), and a 
traumatic event (n=11). With regard to reasons for change, 48% of the sample reported 
engaging in a cognitive appraisal of the pros and cons of drinking and 68% reported that a 
negative life event was associated with the initiation of change. A methodological limitation 
of the study was that the stringent resolution criteria adopted (abstinence for one year) may 
not have captured clinically important predictors of change in people that have reduced use or 
people that have ceased use for shorter time periods (e.g. 3 or 6 months). In addition, 
“lumping” all SMI together may lose important predictors for certain diagnostic categories 
(i.e., schizophrenia v major depressive disorder). The results of the study are consistent with 
previous research investigating the resolution of alcohol disorders with people that do not 
have a SMI, however a control group could have provided a direct comparison. Furthermore 
as the authors noted, past or current use of other drugs was not assessed, which could 
confound the results.   
  A study of participants with schizophrenia who met criteria for substance abuse or 
dependence were assessed to identify the reasons for SU, their subjective effects, and the 
reasons for stopping use (Addington & Duchak, 1997). The study did not mention whether 
participants had ceased using and if so for how long. It appears that the cited reasons for 
change were hypothetical (i.e., potential reasons for change as opposed to actual reasons).  
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Possible reasons for cessation of alcohol included, was afraid of what it might do to my 
health (76%), it costs too much (73%), my doctor disapproves (67%), I did not like they way 
I was thinking or acting (67%), my parents/relatives disapproved (67%), I had a bad 
experience with it (67%), I became confused (58%), I was hospitalized (52%).  For cannabis 
it included: it costs too much (86%), my parents/relatives disapproved (86%), I was afraid of 
what it might do to my health (71%), my doctor disapproves (71%), I became paranoid 
(71%), I could not keep a job/remain in school/remain in a treatment program (57%).  
Comparison of studies in psychosis and in the general population 
The general population comparison group included studies exploring naturalistic 
recovery of substance users without SMI. Studies that only provided data on substance 
misuse treatment were excluded. The search was conducted by the first author, and initially 
elicited 4,853 titles. Reviewing article titles to confirm that they met the search criteria left 
57, and this number was reduced to 14 after reviewing abstracts. Two major reviews in the 
area were examined (Carballo, et al., 2007; Sobell, et al., 2000) to identify any additional 
papers, but none were added from that procedure. Forward and backward searches on the 
identified papers yielded another 30 potential articles.  
A final decision on inclusion was determined after reading the full paper, and any that 
raised potential questions on inclusion were reviewed by all authors, with a resolution being 
by consensus. Thirty-seven articles met full criteria for inclusion as part of the comparison 
analysis.  
A comparison of reasons for use in the studies on samples with serious mental disorders 
and in the general population (of substance users) is given in Table 2.2. Based on the current 
research, which is modest in the psychotic populations, the reported reasons for change were 
generally similar across the two groups. One major difference was that psychotic patients 
indicated that treatment for mental health difficulties and worsening of mental health 
difficulties played a significant role in the decision to cease using. Concrete and immediately 
relevant events (i.e., homelessness, unemployment, financial difficulties, criminal justice, 
advice/threats from significant others and support services) may be more important for 
change in people with psychosis.   
No large-scale quantitative study that compared the relative incidence or perceived 
importance of specific reasons in psychotic and control samples was identified. Accordingly, 
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we were unable to assess whether specific reasons were of greater frequency or influence in 
people with and without psychosis. 
2.5 DISCUSSION 
 It is clear that research on natural recovery from substance misuse in people with 
psychosis is in its infancy. Although the above studies are not as convincing as randomised 
control trials or large surveys, the results reflect individuals’ change processes and the 
willingness of people to be forthcoming in reporting their change story (Sobell et al., 2000).  
Limitations of the study included the fact that only one author conducted the literature search, 
although decisions on inclusion that were not clear-cut were referred to all authors for 
collective decision. No papers were identified from the reviews that were not already 
obtained from the search. Another issue was the exploratory nature of several studies, and the 
presence of significant methodological limitations, including limited exploration of specific 
change strategies, inclusion of samples with differing psychiatric diagnoses or substances 
being used, and a lack of control for symptom severity, or for multiple SU. Differences in 
methodology also made comparisons between studies difficult—for example, using different 
definitions of substance misuse and of reduction or cessation of use, reduction versus 
cessation, differing follow-up durations, and different durations of change to meet the study’s 
criteria for change.   
The limited number of studies required that the current review combine data from 
qualitative and quantitative studies. Similarly, the current review combined studies with 
differing diagnoses, and studies using longitudinal and cross-sectional designs. Once more 
studies emerge, systematic reviews should attempt to separate findings that are obtained from 
these very different methodologies.  
Learning from natural recovery from substance misuse in people with psychosis is vital 
in progressing this area of research forward. As there are only 7 studies in this area to date, 
caution needs to be taken when drawing conclusions from the results. From these initial 
results, there appear to be both similarities and differences between the predictors of 
improvements in substance misuse of the general population and of people with psychosis 
research.  
 Few differences between factors supporting natural recovery in psychosis and in the 
general population were identified, although the reviewed data does not exclude the 
possibility that the reasons are differentially weighted or have different frequencies in people 
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with psychosis. For example, the relationship of social acceptance to both reasons for use and 
for cessation (e.g. in Lobbana et al., 2010) may have special importance in people with 
psychosis, whose social networks rapidly constrict during early stages of their disorder (Stain 
et al., 2012). Similarly, social anxiety and coercion (Lobbana et al., 2010) may pose 
particular challenges for resistance to use in populations where social isolation is common. In 
the second Australian National Survey of Psychosis, it was concluded that most adults 
indicated experiencing loneliness (80.1%) and need for more friends (48.1%), which may 
increase the ongoing use of substances if peers are substance users (Stain, et al., 2012).  
 Natural recovery studies generally focus on reasons for self-change, and may 
overlook other characteristics that affect natural recovery, such as being in a relationship or 
having fewer diagnoses. To the authors’ knowledge, there are no current studies specifically 
addressing this question. There is related research which explores predictors of change in SU 
in people with psychosis, but the findings are variable and inconsistent (Rebgetz et al., 2014; 
Rebgetz, Hides, Kavanagh, Dawe, & Young, 2014), and  the nature of current/previous 
treatments for SU are not sufficiently described. Combining these two research approaches 
may provide insights that neither approach can offer alone.    
As having psychotic symptoms stable and having close connections with people seem 
to be two major slight differences in the psychosis population, it might be that these two areas 
need to be addressed in treatment before other strategies identified in both populations and 
found to be significant in the general population research (i.e., decisional balance) can be 
effective. For example, Maisto et al. (1999) study was excluded from the analysis as it was 
clear that participants had received some treatment for SU. The study collected qualitative 
data through focus groups of participants with schizophrenia and a SUD. They rated 
cessation/reduction using the stage-of-change model, with 17 of the participants being 
abstinent for at least one month. Reported themes included therapeutic factors helpful in the 
quitting process, helpful factors that were extratherapeutic, less helpful therapeutic factors, 
hindrances to change, and abstinence versus reduced use. Therapeutic factors that were 
helpful included individual, group and self-help/12-step groups. The main theme across the 
therapeutic factors was emotional and practical support, which was likely learned from 
therapy. The extratherapeutic factors that were helpful included social support (n=14), 
changes in one’s social environment (n=11), keeping busy (n=8), acute negative 
experiences/hitting bottom (n=8), weighing the pros and cons (decisional balance) of quitting 
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versus using (n=9), faith, prayer, or meditation (n=6), goals and additional personal factors 
(n= 3), and greater effectiveness of medication (n=2).   
2.6 CONCLUSION 
It is clear that treatment of substance misuse in people with psychosis, both in the 
research and clinical field, is a difficult area with limited effectiveness. Natural recovery in 
the general substance misuse literature has provided valuable insights into recovery strategies 
that drive current interventions. Adopting a similar research approach to drive future 
interventions for people with psychosis and comorbid substance misuse is a logical avenue. 
At this point, there appear to be few differences between people with and without 
psychosis in their reasons for reducing SU, beyond their symptoms and issues related to their 
social context and functional deficits. However, the current research is very limited and is 
plagued with methodological limitations. Greater clarity could be obtained by studies with 
matched clinical and control groups, improved characterisation of participants in terms of 
symptoms, diagnostic history and degree of SU problems, and a distinguishing of reasons for 
controlling different substances or substance combinations. 
To ensure that future studies are comparing similar constructs, it is important that a 
clear definition of abstinence or reduction of use is used across studies. Natural recovery 
from substance misuse alone has generally used abstinence periods of 12 months or longer, 
whereas studies exploring patterns in substance misuse in psychotic populations have 
generally used 3 months. It might be useful to study both periods, as reasons for change 
initially and in maintenance may differ. As research and treatment within people with 
psychosis remains in infancy, inclusion of qualitative data would seem reasonable. However, 
some consensus on assessment strategies within quantitative studies is required to ensure 
comparability.        
While additional data with improved methodology will increase confidence in 
conclusions about reasons for change, the current data did not offer a basis for substantial 
improvements to current treatments. A more fertile ground for inspiration may be a detailed 
examination of successful self-management strategies for reduction or cessation of SU that 
are applied by people with psychosis. 
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2.7 COMMENTARY (SUMMARY AND IMPLICATIONS) 
The literature review pointed to the potential benefit of exploring natural recovery from 
CU (and more broadly SU) among people with psychosis. The initial step of reviewing the 
literature in this area was conducted by a systematic search. The search identified only 7 
articles that fulfilled criteria. The results suggest that people with psychosis report similar 
reasons to change as do non-psychotic groups, although specifically the frequency or priority 
orders are not known to be the same of different. Differences noted included issues relating to 
psychosis and related functional problems (receipt of treatment for mental health difficulties, 
worsening of mental health difficulties, and homelessness). The review highlighted that 
current research on reasons for change in people with psychosis is sparse and has significant 
limitations. It highlights the need for a detailed investigation of natural recovery from CU 
(and more broadly SU) among people with psychosis. Additionally the literature review 
highlighted treatment studies targeting SU in this population have reported mixed results and 
the need to firstly quantify the amount of recovery from SU within control groups of 
treatment studies containing samples of psychotic and non-psychotic substance users.   
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Table 2.1 Articles exploring natural recovery from substance use in psychosis  
Author 
(Date) 
N Participant Characteristics Natural Recovery Definition Design 
Childs et al., 
2011 
7 Setting: 
Early intervention 
service.  
 
Country: 
England 
 
Age Range: 16-
30 
 
Median: Not 
reported. 
Inclusion Criteria: 
Currently experiencing an 
episode of psychosis or had 
experienced symptoms of 
psychosis in the past 12 months, 
regular user of cannabis 
currently or in the past  
Self-reported regular users of 
cannabis who subsequently 
stopped using by themselves. 
Qualitative 
Interview 
Cross-Sectional 
 
Measures: 
Interview schedule developed based 
on existing Interpretative 
Phenomenological Analysis. Example 
topics covered experiences of using 
cannabis and impact and meaning of 
using cannabis 
Lobbana et 
al., 2010 
19 Setting: 
Early intervention 
service.  
 
Country: 
England 
 
Age Range: 18-
35 
 
Median: 23 
Inclusion Criteria: 
Diagnosis of a psychotic 
disorder, currently misusing or 
recently misusing substances  
Self-reported reduction checked 
against measures of substance 
use. No history of substance use 
treatment noted. 
Qualitative 
Interview 
Cross-Sectional 
 
Measures: 
Substance Use Checklist, Substance 
use modules of the SCID 
Interview schedule exploring decision 
to abstain from drugs 
Asher & 
Gask, 2010 
17 Setting: 
Psychiatric 
services 
 
Country: 
England 
 
Age Range: 16-
<40 
 
Median: Not 
reported. 
Inclusion Criteria: 
Diagnosis of schizophrenia, used 
substances, and known to local 
psychiatric services.  
Self-reported reasons for 
substance abstinence. No formal 
treatment for substance use 
reported.  
Qualitative 
Interview 
Cross-Sectional 
 
Measures: 
Interview of history of drug misuse 
Bennett et 
al., 2009 
240 Setting: 
Outpatient mental 
health clinics. 
 
Country: 
USA 
Age Range:18-55 
 
Median:43.2 
Inclusion Criteria: 
Affective Disorders, 
Schizophrenia/ Schizoaffective 
Disorders & DSM-IV diagnosis 
of current cocaine dependence, 
early full or sustained full 
remission 
DSM-IV criteria for substance 
remission as measured during the 
assessment phases, not reported 
to relate to therapeutic 
interventions. 
Naturalistic 
Longitudinal follow-up of 12 months 
 
Measures: 
SCID, PANSS, The Addiction 
Severity Index, The Inventory of Drug 
Use Consequences, The Substance 
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 Use Event Survey for Severe Mental 
Illness, University of Rhode Island 
Change Assessment-Maryland, The 
Process of Change Questionnaire, drug 
version of the Decisional Balance 
Questionnaire, Temptation to Use 
Drugs Scale, Abstinence Self-Efficacy 
Scale. 
Dekker et al., 
2008 
206 
 
 
Setting: 
Inpatient and day-
care unit of an 
Adolescent Clinic. 
 
Country: Holland/ 
The Netherlands 
 
Age Range: Not 
reported. 
 
Mean: 21.8 (SD 
3) 
Inclusion Criteria: 
Schizophrenia or related disease 
(Schizoaffective disorder, 
schizophreniform disorder, 
psychosis due to cannabis use 
and psychosis NOS). Cessation 
of cannabis prior to admittance 
(up to 15 months) 
 
81% had used cannabis n=167 
Self-reported quantitative data of 
drug use and urinalysis. 
Cessation of cannabis prior to 
hospital admission, no reported 
formal treatment for substance 
use. 
Chart review. 
Retrospective cohort.  
 
Measures: 
Structured clinical interview at time of 
admission. Data collected on previous 
and current substance use and self-
reported reasons for cessation. 
Stasiewicz et 
al., 1997 
25 Setting: 
Outpatient Mental 
Health Clinic 
 
Country: 
USA 
 
Age Range: Not 
reported. 
 
Mean: 45.7 (SD 
7.9) 
 
Inclusion Criteria:  
Severe Mental Illness with a 2 
year minimum psychiatric 
history and more than one 
hospitalization and one 
diagnosed concurrent alcohol 
disorder. 1 Year resolution 
period. 
32% Diagnosis of Schizophrenia 
Self-reported life events and 
other reasons associated with 
resolution. No specific substance 
use treatment reported. 
Quantitative 
Retrospective 
 
Measures: 
The Brief Michigan Alcoholism 
Screening Test. DSM-IV criteria, 16-
item Drinking Consequences 
Checklist, 8-item alcohol treatment 
checklist, Lifetime Drinking History, 
qualitative questions to assess problem 
resolution, brief checklist to assess 
reasons for resolution, checklist to 
assess maintenance factors 
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Addingtion 
& Duchak, 
1997 
41 Setting: 
Outpatient clinic 
and community 
mental health 
clinic. 
 
Country: 
Canada  
 
Age Range: 
19 – 64  
 
Mean: 
35 (SD 9.3) 
Inclusion Criteria: 
Diagnosis of 
Schizophrenia/Schizoaffective 
Disorder who fulfilled the 
criteria for substance abuse of 
dependence 
Self-reported reasons for 
cessation. Nil evidence of formal 
substance use treatment. 
Quantitative 
Cross-Sectional 
 
Measures: 
SCID, PANNS, Reasons for Use 
section of a scale for assessing drug 
and alcohol use in psychotic patients. 
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Table 2.2: Comparison of reasons for change/reduction in substance use 
Psychotic Group General Population Group 
Health-related (Addington & Duchak, 1997; Asher & Gask, 2010; Bennett, et al., 
2009; Dekker, et al., 2008) 
Health-related (Copersino et al., 2006; Ellingstad, et al., 2006; Sobell, et al., 2000; 
Toneatto, et al., 1999) 
Finance-related/work related (Addington & Duchak, 1997; Asher & Gask, 2010; 
Lobbana, et al., 2010) 
Finance-related/work related (Ellingstad, et al., 2006; Sobell, et al., 2000; Toneatto, 
et al., 1999) 
Related to significant other/family (Childs, et al., 2011; Dekker, et al., 2008; 
Lobbana, et al., 2010) 
Related to significant other/family (Ellingstad, et al., 2006; Sobell, et al., 2000; 
Toneatto, et al., 1999) 
Negative personal effects (Addington & Duchak, 1997; Asher & Gask, 2010; 
Bennett, et al., 2009; Lobbana, et al., 2010; Maisto, et al., 1999; Stasiewicz, et al., 
1997)   
Negative personal effects (Ellingstad, et al., 2006; Sobell, et al., 2000; Toneatto, et 
al., 1999) 
Legal issues (Asher & Gask, 2010; Maisto, et al., 1999)  Legal issues (Ellingstad, et al., 2006; Sobell, et al., 2000) 
Changes in living arrangements/social environment (Lobbana, et al., 2010; Maisto, et 
al., 1999) 
Changes in living arrangements/social environment (Boyd et al., 2005; Sobell, et al., 
2000) 
Viewed substance use/self differently (Bennett, et al., 2009; Maisto, et al., 1999) Viewed substance use/self differently (Ellingstad, et al., 2006; Sobell, et al., 2000; 
Toneatto, et al., 1999) 
Religious/spiritual reasons (Dekker, et al., 2008) Religious/spiritual reasons (Ellingstad, et al., 2006; Sobell, et al., 2000) 
Social related (Asher & Gask, 2010; Lobbana, et al., 2010; Maisto, et al., 1999) Social related (Ellingstad, et al., 2006; Sobell, et al., 2000) 
Lifestyle change (Asher & Gask, 2010; Lobbana, et al., 2010; Maisto, et al., 1999; 
Stasiewicz, et al., 1997) 
Lifestyle change (Ellingstad, et al., 2006) 
Treatment for mental illness/Worse symptoms/Paranoid/Confused (Addington & 
Duchak, 1997; Asher & Gask, 2010; Childs, et al., 2011; Dekker, et al., 2008; 
Stasiewicz, et al., 1997) 
-- 
Hospitalisation (Addington & Duchak, 1997; Dekker, et al., 2008) -- 
Doctor disapproves (Addington & Duchak, 1997) -- 
Medication (Dekker, et al., 2008) -- 
New Year’s Resolution (Dekker, et al., 2008) -- 
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3.1 NOTES 
Citation for this paper: 
Rebgetz, S., Kavanagh, D. J. & Hides, L. (2015). Systematic analysis of changes in 
cannabis use among control conditions of randomised controlled trials. Addictive Behaviors 
Reports, 1, 76-80. doi:10.1016/j.abrep.2015.06.001. Accepted 1 June 2015.  
Authors’ contribution to this paper: 
The candidate is the first author and was responsible for conducting the literature search 
and review; summarising the results of the review and completing the data analysis; writing 
the first draft of the manuscript and completing edits based on feedback prior to submission 
and resubmission. The second and third authors reviewed the summarised results, assisted 
with data analysis and provided editorial feedback on the manuscript.      
Overview of this paper: 
The current paper was the first to explore change in control groups of treatment trials of 
CU interventions. This provided a baseline for assessment of required treatment effects as 
well as giving additional support for the contention of natural recovery of CU in individuals.  
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Abstract 
Introduction: Cannabis remains the most used illegal substance across the globe, and 
negative outcomes and disorders are common. A spotlight therefore falls on reductions in CU 
in people with CUD. Current estimates of unassisted cessation or reduction in CU rely on 
community surveys, and few studies focus on individuals with disorder. A key interest of 
services and researchers is to estimate effect size of reductions in consumption among 
treatment seekers who do not obtain treatment. Effects within waiting list or information-only 
control conditions of RCTs offer an opportunity to study this question. Method: This paper 
examines the extent of reductions in days of CU in the control groups of RCTs on treatment 
of CUD. A systematic literature search was performed to identify trials that reported days of 
CU in the previous 30 (or equivalent). Results: Since all but one of the eight identified studies 
had delayed treatment controls, results could only be summarised across 2-4 months. Average 
weighted days of use in the previous 30 fell from 24.5 to 19.9, and a meta-analysis using a 
random effects model showed an average reduction of 0.442 SD. However, every study had 
at least one significant methodological issue. Conclusions: While further high-quality data is 
needed to confirm the observed effects, these results provide a baseline from which 
researchers and practitioners can estimate the extent of change required to detect effects of 
cannabis treatments in services or treatment trials.  
 
Keywords:  Cannabis; self-management; natural recovery; control conditions. 
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3.2 INTRODUCTION 
 Cannabis remains the most used illegal drug across the world, and while rates of use 
are generally falling, the incidence of related harm is rising internationally (United Nations 
Office on Drugs and Crime, 2014). Australia has particularly high rates of use, with 35% of 
adults reporting lifetime consumption, and 10% using it in the previous 12 months 
(Australian Institute of Health and Welfare, 2014). 
 However, 70-80% of cannabis users stop using it by their mid-thirties (Chen & 
Kandel, 1998), and even over 5-6 years, substantial rates of cessation or reduced consumption 
in adolescents or young adults are seen (Kandel & Raveis, 1989; Pollard, Tucker, de-la-Haye, 
Green, & Kennedy, 2014; Sussman & Dent, 2004). In common with other substances, most 
successful cessation occurs without treatment (Cunningham, 2000; Price, et al., 2001). While 
these changes are typically greatest among infrequent or non-problematic users (Chen & 
Kandel, 1998), people with cannabis abuse or dependence also have substantial rates of 
recovery. For example, an analysis of data from Wave 1 of the National Epidemiologic 
Survey on Alcohol and Related Conditions (Agosti & Levin, 2007) found that 81% of people 
with lifetime cannabis dependence did not meet criteria over the previous year.   
 While community samples can provide good estimates of the degree and timing of 
recovery from CUD, sample sizes need to be large to provide accurate estimates of these 
rates. So, a study of 1228 adolescents (Perkonigg et al., 1999) found only 12 with lifetime 
cannabis dependence, and the resultant estimate of full remission (32%) therefore had a 
substantial standard error (26%). Furthermore, treatment trial researchers and services need 
estimates of remission in treatment seekers. 
 A study of control groups in treatment studies provides fertile ground for the 
estimation of changes in treatment seekers who do not receive substantial assistance. These 
studies have several advantages: high-quality trials typically have diagnostic interviews and 
other assessments that are able to characterise the samples well, the nature of treatments is 
standardised or tracked carefully, and substantial effort is put into ensuring that follow-up 
assessments maximise retention rates. While individual studies often have relatively small 
sample sizes in their control group, meta-analytic methods provide an opportunity to obtain 
estimations of effect sizes over multiple studies and substantial samples. 
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 Accordingly, the aim of the current paper was to determine the degree of ‘natural 
recovery’ in the control groups from RCTs on SUDs, which reported changes in the 
frequency of CU.  
3.3 METHODS 
Electronic searches were performed in January 2015, to find studies that included a 
control group that had explored the topic of CU treatment. The search used title, abstract and 
keywords of Medline, PsycINFO, Psychology Journals, and Psychology Subject Corner. The 
search terms were: (cannabis OR marijuana OR marihuana OR addiction OR abuse OR 
substance) AND (treatment OR randomi* control).  
Potential studies were evaluated for inclusion in this study by the first author, based on 
whether they: (a) provided data on CU, which allowed the calculation of pre-post effect sizes 
in a group of participants randomised to receive inactive (e.g. waitlist) or minimal 
interventions (e.g. drug-related information only); (b) were in English; (c) did not comprise 
case studies or personal accounts; (d) did not include participants with severe mental 
disorders. In order to report results on a single measure, we restricted the studies to those 
allowing a calculation of CU in the previous 30 days.  
The formal examination of effect sizes used Comprehensive Meta-Analysis 
(Borenstein, Hedges, Higgins, & Rothstein, 2005), and the primary analysis applied a random 
effects model. This is the appropriate approach to use when samples or treatments are 
potentially different, regardless of whether significant heterogeneity is evidenced 
(Borenstein, Hedges, Higgins, & Rothstein, 2009). We report effects as standardised mean 
differences (Cohen’s d). Analyses of degree of change require estimates of test-retest 
correlations of the measures, or reported analyses of changes within groups. While Timeline 
Followback assessments of CU can have a 7-14 day test-retest reliability of 0.92 (Robinson, 
Sobell, Sobell, & Leo, 2014), we do not know the reliability of the 3-12 month assessments 
of CU in the current trials. We use an estimate of 0.70 for the primary analyses below, but 
also undertake sensitivity analyses with test-retest correlations of .60 and .80. Where means 
and standard deviations were reported on different sample sizes at baseline and follow-up, we 
used the follow-up sample size for the analysis, estimating baseline scores for retained 
participants from reported data using the full sample. We also present sample-weighted mean 
days of use at baseline, post and follow-up assessments.  
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3.4 RESULTS 
 The search of cannabis treatment in general population samples elicited 2,554 articles.  
Reviewing article titles to confirm that they met the search criteria left 374, and this number 
was reduced to 55 after reading abstracts. Further searching was undertaken using reference 
lists and cited reference search, yielding 12 potential articles. Review papers were examined 
(Carballo, et al., 2007; Dutra et al., 2008; Sobell, et al., 2000; Tanner-Smith, Wilson, & 
Lipsey, 2013) to identify any additional papers, but none were added from that procedure.  A 
final decision on inclusion was determined after reading the full paper, and any that raised 
potential questions on inclusion were reviewed by all authors, until consensus was reached. 
Studies by Copeland et al. (2001), Lozano et al. (2006), Kadden et al. (2007), Kay-Lambkin 
et al. (2009), Fernandes et al. (2010), Peters et al. (2011), Stein et al. (2011) and Litt et al. 
(2013) were excluded due to an inability to calculate a within-group effect size on CU per 
month from the data provided. The control groups of Stephens et al. (1994), Hendriks et al. 
(2011) and Budney et al. (2000) provided too much support for them to meet inclusion 
criteria as a control treatment condition.    
 The methodological details of the eight included studies are displayed in Table 3.1 
and their results are provided in Table 3.2. The studies had a total of 600 control participants. 
Average weighted mean days of use in the previous 30 days fell from 24.5 to 19.9 at 2-4 
months across the eight studies. Only one of the included studies (Fischer, Jones, Shuper, & 
Rehm, 2012) provided data over a longer follow-up, preventing an assessment of the degree 
of sustained change across the studies. That study saw little change in use at 12 months (M = 
22.1, SD = 9.2).  
 Results of the meta-analysis using a test-retest correlation of .70 are displayed in 
Figure 3.1. The figure displays the average effect using a fixed-effects model. With a random 
effects model, there was an average change in CU of -.442 SD (CI: -.657 to -.228), which was 
highly significant (p < .001). A test of heterogeneity gave Q (7) = 57.71, p < .001, providing 
support for the selection of the random effects model. Examination of the classic fail-safe N 
found that 293 missing studies would be required to give p > .05. Sensitivity analyses using 
random-effects effects models and test-retest correlations of .60 (-.460, CI: -.685 to -.235) 
and .80 (-.415, CI: -.613 to -.217) made little difference to the result. 
 An evaluation of the methodological quality of the control group data is in Table 3.2.  
A strength of the studies was their follow-up rates over the control period, with six having 
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rates of 75% or above and four having rates above 90%. None clearly had single-blind 
follow-up, but two studies had an independent assessor conducting the follow-up, and three 
used only self-report. Four studies checked participant reports of CU during follow-up 
against collateral data or urinalysis. All but two studies verified that most participants had a 
CUD, although only two used a gold-standard structured clinical interview. A significant 
potential threat to the interpretation of results as being reflective of unassisted recovery was 
the lack of reports on other concurrent treatment in four trials, and a high level of reported 
treatment in one (Gates, Norberg, Copeland, & Digiusto, 2012). Every study had at least one 
significant issue that should induce caution in the interpretation of its results. 
3.5 DISCUSSION  
Control groups from the eight RCTs showed a significant mean reduction in days of 
CU. At 2-4 months’ follow up, participants used cannabis on 4.6 fewer days a month than at 
baseline, reflecting over one additional day of abstinence each week, and giving a total of 
more than a week of total abstinence each month. The average effect size of -.415 to -.442 SD 
offers a challenging base from which treatment effects are to be obtained. Our results will 
assist in minimum sample size calculations for RCTs, and provide a yardstick for the 
evaluation of changes from services for cannabis misuse.   
Interpretation of our results must be moderated by the issues raised in our 
methodological review of the studies, which identified at least one significant limitation in 
every study. Perhaps most important was the potential for other treatment to have been 
responsible for at least some of the observed reductions in CU. The results highlight areas for 
future improvement of RCTs on CUD that will not only provide increased confidence in the 
estimates of change in control groups, but also in the reported outcomes of the whole trial.  
While there has been research into unassisted cessation of substance misuse for more 
than 40 years (Carballo, et al., 2007; Sobell, et al., 2000), it is only in the last 15 that this 
work that has focused specifically on cannabis. To our knowledge, the current review is the 
first to examine ‘natural recovery’ in the control groups of RCTs. Regression to the mean 
may account for some of the observed change, but our results are consistent with population 
studies (Agosti & Levin, 2007; Perkonigg, et al., 1999), which have similarly observed the 
potential for recovery from both CU and cannabis dependence, suggesting that at least some 
individuals can reduce their CU without significant help. 
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A limitation of this review was the fact that the initial literature search relied on one 
author, although the resolution of any identified issues and final decisions on inclusion were 
by consensus of all authors, and no additional papers were identified from reviews. Other 
limitations included the small number of identified trials with control groups that had no or 
minimal treatment, and the fact that minimal treatment controls can typically be conducted 
for periods of only 2-4 months at most. We excluded eight studies because of an absence of 
data on cannabis consumption over a specific period, in order to preserve comparability of 
the results across studies: if those studies had provided consumption data, we could 
potentially have doubled the number of studies in our review. We recommend that future 
studies routinely include both abstinence rates and average consumption data as part of their 
results (Peters, et al., 2011). However, despite the restricted number of studies, the total 
sample size of 600 provided a substantial group for estimation of consumption changes.  
3.6 CONCLUSIONS 
This is the first meta-analysis to explore changes in CU in control conditions of 
treatment studies. Results of the current study demonstrate that modest average reductions in 
the frequency of average CU can be seen, although there was substantial variability in effect 
size between studies, and some uncertainty over the potential role of outside treatment in the 
effects. The study gives weight to further exploration of the concept of natural recovery in 
people with CUDs and provides researchers and practitioners a baseline from which to 
estimate likely changes or needed effects sizes in intervention studies. 
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3.7 COMMENTARY (SUMMARY AND IMPLICATIONS) 
Our results suggest that individuals with CUD slowly reduce their CU over time. This 
reduction on average of one day per week is interesting for multiple reasons. From a clinical 
view it supports the notion of natural recovery and allows clinicians to capitalise on the goal 
of cessation/reduction in treatment. As individuals with psychosis have added difficulties 
pertaining to recovery it is necessary to explore if a similar reduction occurs in this group.  
As the study excluded those that did not allow a calculation of CU in the previous 30 
days, eight were excluded due to this criteria [Studies by Copeland et al. (2001), Lozano et al. 
(2006), Kadden et al. (2007), Kay-Lambkin et al. (2009), Fernandes et al. (2010), Peters et al. 
(2011), Stein et al. (2011) and Litt et al. (2013) were excluded due to an inability to calculate 
a within-group effect size on CU per month from the data provided.] The above authors were 
contacted to ascertain further data for inclusion in the paper with nil response from the 
authors.  
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Table 3.1  Studies on treatment of cannabis use in the past 30 days within control groups of general populations: Studies reporting mean values. 
Author (Date) Sample type Disorder Country Control Group Measure 
Stephens et al. (2000) COM 98% current CUD US Delayed treatment # days used cannabis per month 
Litt et al. (2005) COM 100% current CUD US Delayed treatment % days used cannabis in the past 90 
Walker et al. (2006) 
 
SCH 68% current CUD 
(86% lifetime 
CUD) 
US Delayed treatment # days used cannabis in the past 60 
Stephens et al. (2007) 
 
COM 93% current CUD US Delayed feedback # days used cannabis per week 
Martin & Copeland (2008) COM + OP 
 
85% CUD AU Delayed treatment # days used cannabis in the past 90 
Fischer et al. (2012) UNI 
 
CU CAN General health 
information 
# days used cannabis in the past 30 
Gates et al. (2012) 
 
COM 98% probable CUD 
on SDS 
AU Delayed treatment # days used cannabis in the past 28 
Rooke et al. (2013) COM CU AU Cannabis information # days used cannabis in past month 
AU: Australia  CAN: Canada   US: United States of America    
OP: Outpatients COM: Community  HM: Homeless/unstably housed SCH: School UNI: University   
CU: Cannabis use  CUD: Cannabis use disorder (DSM-IIR or DSM-IV Cannabis Dependence or Abuse)   
SDS: Severity of Dependence Scale (Gossop et al., 1992) 
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Table 3.2. Mean days of cannabis use in the past 30 days, in control groups of treatment trials on people with cannabis use disorders   
 
Study Baseline 2-4 months  
    N     M    SD N       M    SD 
Stephens et al., 2000   86 24.9 6.1 79 17.1   10.7 
Litt et al., 20051 148 30.0 4.7 148 25.2   10.2 
Walker et al., 20062   50 18.4 8.5 50 16.4   10.3 
Stephens et al., 20073   64 26.0 8.2 64 24.6     8.2 
Martin & Copeland, 20084   20 18.5 10.5 20 18.2   10.5 
Fischer et al, 2012   32 23.9 6.1 32 23.1     6.9 
Gates et al., 20121   81 23.9 6.3 61 13.4   12.2 
Rooke et al., 2013 119 20.8 8.7 58 14.1     8.8 
Total N, Weighted mean 600 24.5  512 19.9  
 
Conversion formulae from reported means (M) to give days of use in the past 30 days:  
(1) % days used in past 90: M x 30 
(2) Days used in past 60: M/2 
(3) Days per week: (M/7) x 30 
(4) Days used in past 90: M/3;  
(5) Days used in past 28: (M/28) x 30. 
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Table 3.3  Methodological review of control treatments from the included randomised controlled trials  
Study Symptom/Diagnostic 
Measure 
Treatment received by Controls Follow-up 
retention 
Intention to treat 
(and management of 
missing data) 
Single-Blind 
follow-up 
Stephens et al. 
(2000) 
CUD: Self-report  
CU: Self & collateral report 
BL: No current formal treatment 
4 mth:    6% had treatment  
               18% in self-help groups 
92% to 4 mths 
 
No 
 
No—Self-report 
(phone interview 
if no response) 
Litt et al. (2005) CUD: SCID  
CU: TLFB, Self & collateral 
report, urinalysis. 
BL:  No current Mj therapy, self-help group  
4 mth:   NR 
 
93% to 4 mths No (Secondary 
analyses: BL 
substitution) 
No 
Walker et al. (2006) 
 
CUD: GAIN 
CU: Self-report 
NR 98% to 3 mths No NR—Self-report; 
different staff at 
follow-up  
Stephens et al. 
(2007) 
 
CUD: SCID 
CU: TLFB, self-report, 
urinalysis. 
BL:  No current  Mj therapy, self-help group 
At 7-wks, 6 & 12 mths:  
1-4% of whole sample in treatment 
2-7% in self-help groups 
97% at  7 wks Yes 
(BL substitution. 
Checked with 
imputation, omission) 
No 
Martin & Copeland 
(2008) 
CUD: Structured interview 
(GAIN) & self-report (SDS) 
CU: TLFB, self-report, 
urinalysis. 
BL: No treatment in previous 90 days 
3 mths: NR 
80% at 3 mths Yes 
(BL substitution) 
NR (Independent 
researcher) 
Fischer et al. (2012) CU: Interviewer-administered 
questionnaire 
NR 52% at 12 mths No. 
Analysed completers 
of all assessments 
NR 
Gates et al. (2012) 
 
Probable CUD:  SDS 
CU: TLFB, self-report. 
BL: No current Mj therapy 
3 mths: 46% sought treatment, 39% used 
medication 
75% at 3 mths Yes 
(Multiple imputation) 
No 
Rooke et al. (2013) CUD: GAIN 
CU: TLFB, Self-report 
BL: No formal Mj treatment in last 3 mths 
3 mths: Excluded 4% who had treatment 
 
66% at 6 wks 
52% at 3 mths 
No (Complier average 
causal effect analyses. 
Checked  with LOCF, 
omission) 
Automated self-
report 
CU:  Cannabis use CUD: Cannabis Use Disorder   
SCID:  Structured Interview for DSM-IV GAIN: Global Appraisal of Individual Needs (Initial or final) (Dennis, 1998, 1999) 
TLFB:  Timeline Follow-Back   SDS: Severity of Dependence Scale (Gossop, Griffiths, Powis, & Strang, 1992)  
LOCF: Last observation carried forward BL:  Baseline  Mj:  Marijuana   NR: Not Reported  
 50 Chapter 3: Paper 2 
Figure 3.1 Control group changes over 2-4 months in non-psychotic groups. 
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Overview of this paper: 
This paper adds to the growing understanding that people without specialised SU 
treatments make substantial recovery gains. It was the first to explore change in control 
groups of treatment trials of SU interventions in people with psychosis. This provided a 
baseline for assessment of required treatment effects as well as giving additional support for 
the presence of natural recovery of SU in individuals with psychosis.  
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Abstract 
The need to address SU among people with psychosis has been well established. 
However, treatment studies targeting SU in this population have reported mixed results. 
Substance users with psychosis in no or minimal treatment control groups achieve similar 
reductions in SU compared to those in more active SU treatment, suggesting a role for natural 
recovery from SU. This meta-analysis aims to quantify the amount of natural recovery from 
SU within control groups of treatment studies containing samples of psychotic substance 
users, with a particular focus on changes in CU. A systematic search was conducted to 
identify SU treatment studies. Meta-analyses were performed to quantify reductions in the 
frequency of SU in the past 30 days. Significant but modest reductions (mean reduction of 
0.3-0.4 SD across the time points) in the frequency of SU were found at 6 to 24 months 
follow up. The current study is the first to quantify changes in SU in samples enrolled in no 
treatment or minimal treatment control conditions. These findings highlight the potential role 
of natural recovery from SU among individuals with psychosis, although they do not rule out 
effects of regression to the mean. Additionally, the results provide a baseline from which to 
estimate likely changes or needed effects sizes in intervention studies. Future research is 
required to identify the processes underpinning these changes, in order to identify strategies 
that may better support self-management of SU in people with psychosis. 
 
Keywords:  Cannabis; self-management; psychosis; natural recovery; substance use; 
Comorbidity 
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4.2 INTRODUCTION 
 Rates of psychoactive SU in psychotic populations are much higher than those in the 
general population, and this use has been associated with detrimental psychological, social, 
and physical effects (Hjorthøj, et al., 2009). These observations have led to concerted efforts 
to develop effective psychological treatments to reduce this consumption and its associated 
harm. However, the results of clinical trials on these treatments have been mixed (Hjorthøj, et 
al., 2014; Hjorthøj, et al., 2009; Kavanagh, Young, et al., 2004; Madigan et al., 2013).  
 An issue with efforts to address this problem is the extent of change in control 
conditions. Similar reductions in SU among people with psychosis are often seen after these 
treatments and in assessment only, minimal treatment or treatment-as-usual control 
conditions (Kavanagh & Mueser, 2007). A recent review of treatment studies of first episode 
psychosis groups, including five with and nine without specialised SU treatment, found that 
participants were able to reduce their average consumption, regardless of whether they 
received specialist SU treatment or not (Wisdom, et al., 2011). Receipt of specialised SU 
treatment did not result in larger reductions or better rates of abstinence (Wisdom, et al., 
2011). In fact, follow up research on patients with psychosis not treated for SU (Baeza et al., 
2009; Caspari, 1999; Lambert, et al., 2005; Wade et al., 2006) have reported abstinence rates 
of 21%—63% over 15 months to 5 years (Caspari, 1999; Lambert, et al., 2005; Wade, et al., 
2006).  
These results highlight the potential role of natural recovery from SU in psychotic 
populations (Wisdom, et al., 2011). While these improvements may reflect effective self-
management of SU, they may also reflect regression to the mean (if participants entered 
treatment during a period of unusually heavy substance use). Observations of reduced 
consumption in the first month after a negative experience from cannabis, of similar or 
greater size as in the general population are consistent with both of these suggestions (Green, 
et al., 2007). Regardless of the phenomenon’s determinants, clarifying its extent is important 
in the interpretation of clinical outcomes and in planning treatment trials.  
A gap in current knowledge is that research is yet to quantify the extent of untreated 
improvements from SU that occurs. Accordingly, the current study conducts a meta-analysis 
that aims to quantify the reductions in the frequency of SU that is achieved within control 
groups of treatment studies targeting psychotic clients. It focuses particularly on changes in 
use of cannabis, the most commonly used illicit substance worldwide (United Nations Office 
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on Drugs and Crime, 2014), and a substance that has been linked to increased risk of 
psychotic symptomatic exacerbations and relapse (Hides, et al., 2006). 
4.3 METHODS 
Electronic searches were performed in January 2016 to find studies that included a 
control group and had tested treatment for current CU in people with both a psychotic and 
SUD. The searches used title, abstract and keywords of Medline, PsycINFO, Psychology 
Journals, and Psychology Subject Corner. The search was expanded to include other 
substances (due to limited results for cannabis alone), giving the search terms: (cannabis OR 
marijuana OR marihuana OR addiction OR abuse OR substance OR cocaine OR dual 
diagnosis OR comorbid OR comorbidity OR co-occurring) AND (psychosis OR psychoses 
OR schizophren* OR schizotypal OR psychotic OR bipolar) AND (treatment OR randomi* 
control).   
Potential studies were evaluated for inclusion in this review, based on whether they: (a) 
provided data that allowed the calculation of pre-post effect sizes in a group of participants 
receiving inactive (e.g. waitlist) or routine care (excluding SU treatment); (b) were in 
English; (c) did not comprise case studies or personal accounts. In order to report results on a 
single measure, we restricted the studies to those reporting days of SU in the past 30 (or 
equivalent). If this data was not reported, attempts were made to contact the authors to obtain 
it. Due to limited number of trials, studies that had some participants who used substances 
(including cannabis) and only reported days of  SU (as a global measure) were also included. 
However, studies that were solely focused on alcohol or nicotine were excluded. 
The examination of effect sizes used Comprehensive Meta-Analysis (Borenstein, et al., 
2005). A random effects model was applied as it is a more conservative approach and is the 
appropriate method to use when samples or treatments are different, irrespective of whether 
significant heterogeneity is demonstrated (Borenstein, et al., 2009). Effects are reported as 
standardised mean differences (Cohen’s d). Analyses of degree of change require estimates of 
test-retest correlations of the measures, or reported analyses of changes within groups. While 
Timeline Followback assessments of cannabis use can have a 7-14 day test-retest reliability 
of 0.92 (Robinson, et al., 2014), the reliability of the 3-12 month assessments of CU in the 
current trials is unknown. As a result an estimate of 0.70 was used for the primary analyses. 
Sensitivity analyses were also undertaken using test-retest correlations of .60 and .80. Where 
means and standard deviations were reported on different sample sizes at baseline and 
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follow-up, the follow-up sample size for the analysis was used, estimating baseline scores for 
retained participants using the full sample. Sample-weighted mean days of use at baseline, 
post and follow-up assessments are displayed in Appendix A. 
4.4 RESULTS 
The search elicited 1,492 articles (See Figure 4.1). Based on reviews in the area, no 
relevant articles appeared to be missed (e.g., Hjorthøj, et al., 2014; Wisdom, et al., 2011). A 
final decision on the inclusion of all papers was made after reading the full paper. Any 
ambiguous articles were reviewed until consensus was reached. Some studies reported 
substance use in general, but reported the number of cannabis users in the sample and were 
therefore retained in this study. 
Of the 30 papers identified, those by Lehman, Herron, Schwartz, & Myers (1993), 
Hellerstein, Rosenheck, & Miner (1995), Baker et al. (2006; 2002), James et al. (2004) and 
Hjorthøj et al (2013) were excluded due to an inability to estimate days of CU in the previous 
30. A further 16 studies were excluded due to an inability to calculate a within-group effect 
size from the data provided (Bellack, Bennett, Gearon, Brown, & Ye Yang, 2006; Bonsack et 
al., 2011; Burman, 1997; Calsyn, Yonker, Lemming, Morse, & Klinkenberg, 2005; Castle & 
Ho, 2003; Clark, 2001; Craig, Johnson, McCrone, Afuwape, & Hughes, 2008; Drebing et al., 
2005; Haddock, et al., 2003; Hellerstein, Rosenthal, & Miner, 2001; Herman et al., 1997; 
Kavanagh, Young, et al., 2004; Martino, Carroll, Nich, & Rounsaville, 2006; Ries et al., 
2004; Sigmon & Higgins, 2006; Weiss et al., 2007). Essock et al., (2006) was included after 
consensus by all authors that the standard case management provided to participants was part 
of routine care and was unlikely to have included extensive SU treatment. The final eight 
articles meeting full inclusion criteria are described in Table 4.1 and the methodological 
details in Table 4.2.      
Over 6 months, weighted mean days fell from 13.2 to 10.6 across 6 studies (a summary 
of the mean effects is provided in Appendix A). Using a test-retest correlation of .70, the 
random effects meta-analysis gave a mean reduction of 0.332 SD (p < .001; Figure 4.2), and 
80 missing studies would be required to take the result to p > .05.  There was no significant 
heterogeneity (Q(5) = 10.23, p  = .069). Sensitivity analyses using test-retest correlations of 
.60 (-.330, CI: -.460 to -.200) and .80 (-.332, CI: -.461 to -.204) made little difference to the 
obtained effect. 
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Figure 4.1 Flow chart of inclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant, published 
articles identified (n=1492) 
Articles screened on the basis of 
title (n=171) 
Articles screened on the basis of 
abstracts (n=74) 
Articles identified through 
reference searches (n=22) 
Articles reviewed in detail 
(n=30) 
Articles included in the meta-
analysis (n=8) 
Articles excluded (n=22) 
  Inability to estimate days of    
  cannabis use in the past 30 
  days:6 
  Inability to calculate a within- 
  group effect size: 16 
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Table 4.1. Methodological characteristics of cannabis and other substance use treatment trials in psychotic populations: Studies reporting the days of cannabis or other substance use in the past 
30 days  
Author (Date) Sample 
Type at 
Baseline 
Disorder Country Control Group Measure Substance Retention rates 
        
Drake et al., 1998  OP 
 
SCZ/SA/BP  
SUD 
US SCM, team approach in 
community targeting MH & 
SUD 
 
Days of use in past 6 months 
 
Illicit 91% at 3 years 
Edwards et al., 2006 OP 
 
PDNOS  
CUD 
AU 10 week group  
psychoeducation on 
psychosis 
Percent days used Cannabis in 
past 4 weeks 
Cannabis 71% at 6-months 
Essock et al., 2006 OP 
HM  
SCZ/ SA/BP/MD 
SUD 
US SCM, team approach in 
community targeting MH & 
SUD 
Number of days of drug use in 
past 6 months  
Illicit 96% at 3 years 
Morse et al., 2006 OP 
HM 
 
SCZ/PDNOS/BP/ 
MD/SA  
SUD 
US Shown a list of MH & 
SU treatment agencies 
 
Days used substances 
In past 90 
Illicit 
(19% Cannabis) 
88% at 2 years 
Barrowclough et al., 
2010 
OP  
 
SCZ/SA  
SUD 
UK Psychiatric care 
(medication, case 
management) 
Proportion of days abstinent 
from main substance in past 90 
days 
Any (50% 
Cannabis) 
72% at 2 years 
Morrens et al., 2011 IP 
 
PDNOS  
SUD 
BE TAU focused on psychotic 
symptoms 
Frequency of cannabis use over 
past 30 days 
Illicit (60% 
Cannabis) 
71% at 3-months 
20% at 1 year 
Smeerdijk et al., 2012 OP 
 
SCZ/PDNOS  
CUD 
NL Routine family support Mean days of cannabis use in 
the past 90 
Cannabis 86% at 10-months 
Madigan et al., 2013  OP 
 
PDNOS  
SUD 
IE Multidisciplinary care, 
antipsychotic treatment 
Frequency of cannabis use over 
past 30 days 
Cannabis 76% at 3-months 
66% at 1 year 
AU: Australia  BE: Belgium    IE: Ireland  NL: The Netherlands  US: United States of America UK: United Kingdom 
IP: Inpatients  HM: Homeless/unstably housed  OP: Outpatients  
BP: Bipolar  MD: Major Depression    SCZ: Schizophrenia/schizophreniform  SA: Schizoaffective  
PDNOS: Psychotic Disorder Not Otherwise Specified/psychotic disorder spectrum  
SUD: Substance Use Disorder (abuse or dependence)  CUD: Cannabis Use Disorder (abuse or dependence) SCM: Standard Case Management                    
TAU: Treatment As Usual 
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Table 4.2. Methodological review of control treatments from the included randomised controlled trials 
Study Symptom/Diagnostic 
Measure 
Treatment received by Controls Follow-up retention Intention to treat (and 
management of 
missing data) 
Single-Blind 
follow-up 
      
Drake et al., 1998  SUD: SCID 
SU: TLFB, ASI, 
Urinalysis 
Standard Case Management NR NR NR 
Edwards et al., 2006 SUD: SCID   
CU: CASUAS, self-
report 
10 individual PE sessions focused on 
psychosis, avoiding explicit discussion of 
cannabis 
Standard Case Management 
74% to 6 mths Yes 
(LOCF) 
Yes 
Essock et al., 2006 SUD: SCID 
SU: TLFB, ASI, 
urinalysis 
Standard Case Management:  NR NR NR 
Morse et al., 2006 SUD: SCID 
CU: self-report 
NR 
Between 0.39 and 0.16 contacts per month in 
regards to substance abuse treatment 
NR Yes 
(NR) 
No 
Barrowclough et al., 2010 SUD: SCID 
CU: TLFB self-
report, hair analysis 
(25%) 
Standard Case Management 91% to 6 mths 
71% to 24 mths 
Yes 
(Secondary analyses) 
Yes 
Morrens et al., 2011 SUD: Clinical 
interview 
CU: ASI, self-report 
Standard Case Management with no formal 
for substance use 
71% to 6 mths 
20% to 12 mths 
Yes 
(Carried previous data 
forward) 
Open label 
Smeerdijk et al., 2012 SUD: Clinical 
interview 
CU: TLFB 
Meetings with a family therapist. No formal 
skills provided 
77% to 10 mths Yes (means of the 
multiple imputation 
method) 
Yes 
Madigan et al., 2013  SUD: SCID 
CU: ASI 
Standard care. Five participants previous 
addiction counselling (more than 12 months 
ago) 
76% to 3 mths 
65% to 12 mths 
Yes (NR) Yes 
SUD: Substance Use Disorder   CU: Cannabis use   SU: Substance use 
SUD: Substance Use Disorder (abuse or dependence)  CUD: Cannabis Use Disorder (abuse or dependence) 
TLFB: Timeline Follow-Back   ASI: Addiction Severity Index  SCID: The Structured Clinical Interview for Diagnosis    
CASUAS: Cannabis and Substance Use Assessment Schedule    NR: Not Reported LOCF: Last Observation Carried Forward  
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Over 10-12 months, the random effects meta-analysis produced a mean reduction of 
0.328 SD over 7 studies (p < .001; Figure 4.3), and 82 missing studies would be required for 
the result to reach p > .05. Heterogeneity fell short of significance (Q(6) = 7.91, p  = .245). 
Sensitivity analyses using test-retest correlations of .60 (-.337, CI: -.433 to -.241) and .80 (-
.318, CI: -.422 to -.215) again had little impact.  
The four studies with data to 24 months had a mean reduction of 0.450 SD (p < .001; 
Figure 4.4), and 81 missing studies would be required to take the result to p > .05.  There was 
significant heterogeneity in this subgroup (Q(3) = 22.99, p  < .001). Sensitivity analyses 
using test-retest correlations of .60 (-.452, CI: -.723 to -.182) and .80 (-.444, CI: -.699 to -
.189) did not substantially change the results.  
A review of the methodological quality of the control group data is in Table 4.2. 
Retention rates for 4 of the studies were at least 70% at 6 months, which is an overall strength 
of the studies. Another strength was that 5 had single-blind follow-up. All of the studies 
verified SUD and SU across the studies using structured methods with 3 studies verifying SU 
with urine or hair analysis. A significant weakness of the results being interpreted as natural 
recovery was the limited information pertaining to SU interventions within standard case 
management. Every study had at least one significant issue that should induce caution in the 
interpretation of its results.  
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Figure 4.2 Control group effects over 6 months 
Study name Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Drake et al., 1998 -0.578 0.132 0.018 -0.838 -0.319 -4.371 0.000
Edwards et al., 2006 -0.247 0.161 0.026 -0.562 0.067 -1.542 0.123
Essock et al., 2006 -0.138 0.078 0.006 -0.291 0.016 -1.759 0.079
Morse et al., 2006 -0.370 0.114 0.013 -0.595 -0.146 -3.239 0.001
Barrowclough et al., 2010 -0.358 0.066 0.004 -0.487 -0.230 -5.456 0.000
Morrens et al., 2011 -0.449 0.257 0.066 -0.952 0.055 -1.746 0.081
-0.332 0.066 0.004 -0.462 -0.202 -5.004 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
 
Figure 4.3 Control group effects over 12 months 
Study name Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Drake et al., 1998 -0.516 0.130 0.017 -0.772 -0.261 -3.959 0.000
Essock et al., 2006 -0.254 0.079 0.006 -0.409 -0.099 -3.215 0.001
Morse et al., 2006 -0.233 0.112 0.013 -0.452 -0.013 -2.074 0.038
Barrowclough et al., 2010 -0.416 0.069 0.005 -0.551 -0.281 -6.031 0.000
Morrens et al., 2011 -0.289 0.299 0.089 -0.874 0.297 -0.966 0.334
Smeerdijk et al., 2012 -0.387 0.180 0.032 -0.739 -0.035 -2.155 0.031
Madigan et al., 2013 0.000 0.207 0.043 -0.406 0.406 0.000 1.000
-0.328 0.052 0.003 -0.431 -0.226 -6.292 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Figure 4.4 Control group effects over 24 months 
Study name Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Drake et al., 1998 -0.735 0.138 0.019 -1.006 -0.465 -5.328 0.000
Essock et al., 2006 -0.141 0.078 0.006 -0.295 0.012 -1.808 0.071
Morse et al., 2006 -0.368 0.114 0.013 -0.592 -0.144 -3.221 0.001
Barrowclough et al., 2010 -0.592 0.078 0.006 -0.745 -0.440 -7.630 0.000
-0.450 0.135 0.018 -0.715 -0.185 -3.333 0.001
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
 
 
4.5 DISCUSSION  
The current review found significant reductions in the frequency of CU among users 
with psychosis. At 6 months, patients were only using 11 days per month with an average 
reduction of 0.3 SD. This result provides the degree of change in treatment trials potentially 
due to natural recovery and the effect required to enhance future specialised SU treatment 
trials. The results remained modest over time, at 10-12 months an average reduction of 0.3 
SD and 24 months 0.4 SD. These results need to be interpreted with caution due to the 
methodological limitations outlined.  
While treatment of CU in people with psychosis has limited differential effectiveness 
above self-management, results of the current study demonstrate that on average, this 
population may have potential to self-manage their consumption if they are sufficiently 
motivated to do so. It is possible that part or all of the observed changes were due to 
regression to the mean, although the maintenance of the changes over as long as 24 months 
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suggests concerted self-management rather than statistical aberration. Further research is also 
needed to determine the extent that the observed improvements across studies have 
substantial functional or clinical impact.  
In our recent review examining reductions in days of CU within control groups of 
treatment studies we found that average weighted mean days of use in the previous 30 days 
fell from 24.8 to 18.6 at 2-4 months across nine studies (Rebgetz, Kavanagh, & Hides, 
2015b). A meta-analysis could only be undertaken to 2-4 months (due to limited studies 
providing data on longer follow up periods), which showed an average reduction of .540 SD, 
which was highly significant (p  < .001). While the reduction over 6 months in the psychosis 
samples (0.33 SD) was 40% less than non-psychotic samples obtained over 2-4 months (0.54 
SD), the higher level of  baseline consumption frequency in the non-psychotic group may 
have allowed greater regression to the mean. However, due to different time periods a direct 
comparison between those with and without psychosis cannot be made.  
Research into natural recovery from substance misuse in the general population has 
provided valuable insights into recovery strategies for enhancing treatments. Since at least a 
partial average recovery appears to also occur in people with psychosis, a similar research 
approach may also identify new ways to support self-management of SU among this 
population. A handful of studies have attempted to explore this area, although due to their 
limited number and methodological limitations,  further well-designed research is required 
(Rebgetz, Kavanagh, & Hides, 2015a).  
 An important limitation to the current study was the need to exclude 22 papers that 
did not allow a calculation of effect sizes on the frequency of cannabis or other SU in the 
previous 30 days. While this criterion ensured comparability across studies, the substantial 
loss of potential studies highlighted the need for common minimum data reporting in 
treatment trials across this field. Other methodological limitations include the fact that only 
one author conducted the main literature search, although any issues on inclusions were 
referred to all authors for collective decision, and no additional papers were identified from 
reviews. The presence of differing psychiatric diagnoses or problem substances, and a lack of 
control for symptom severity or for multiple SU also raise issues. The Essock et al., (2006) 
paper was included despite some SU treatment being provided to the participants, but the 
study showed less change than most others and therefore its inclusion did not inflate the size 
of the obtained effect. Several other studies involved treated samples in which informal SU 
interventions may have occurred, although specialist treatment for SU was not provided. 
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Retention rates across the studies appeared to be adequate, although it is possible that 
participants with more severe SU problems were more likely to drop out, which may have 
inflated positive outcomes. However if this did occur, it is also likely in future research and 
clinical applications. Lastly, most studies only included self-reports of SU without urine drug 
screening. Urine drug screening may have assisted to verify self-reports of CU. However, our 
previous study, reported high levels of agreement between cannabis immunoassays or gas 
chromatography/mass spectrometry and self-reported CU (Cohen’s kappa = 0.90), which 
suggests that self-reports are reliable (Hides, et al., 2006; Rebgetz, Hides, et al., 2014). While 
inflation of the currently observed effects due to reporting biases cannot entirely be ruled out, 
this research on the reliability of self-reports suggests that any such influence is likely to be 
minor. 
This is the first meta-analysis to explore changes in cannabis/substance use in minimal 
or no treatment control conditions of clinical trials targeting SU in psychotic patients. Its 
findings are important: It shows that modest but well-maintained reductions in the frequency 
of average CU can be seen in patients with psychosis who did not receive specialist SU 
treatment. A more detailed understanding of strategies that are perceived to assist self-control 
of SU in these populations could inform the development of new more effective SU 
treatment.  
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4.6 COMMENTARY (SUMMARY AND IMPLICATIONS) 
The aim of this study was to quantify the change which could be associated to natural 
recovery in minimal or no treatment control conditions of clinical trials targeting SU in 
psychotic patients. Significant but modest reductions (mean reduction of 0.3 to 0.4 SD across 
the time points) in the frequency of SU were found at 6, 10-12 and 24 months follow up. This 
highlights that individuals who use substances with psychosis who are not receiving 
specialised SU treatment engage in self-change. The results allow a baseline from which to 
estimate likely changes or needed effects sizes in intervention studies. Understanding this 
change and which factors contribute to the change is important to refine current treatment 
approaches.  
In this original paper we assumed that participants in the control conditions of both the 
Drake et al. (1998) and Essock et al. (2006) studies received little or no SU treatment aside 
from usual treatment for their mental illness. However, both of these studies did provide 
integrated treatment for co‐occurring disorders to participants in both groups. The standard 
case management groups in these studies did receive some targeted treatment for their SU. 
Perhaps this is one of the reasons both studies found few differences in SU outcomes between 
the two groups. 
None of the studies appeared to report on continuous SU abstinence. As we would 
expect the prevalence of continuous abstinence to reduce over time, having an increased 
understanding of this processes is warranted.   
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5.1 NOTES 
Citation for this paper:  
Rebgetz, S., Conus, P., Hides, L., Kavanagh, D. J., Cotton, S., Schimmelmann, B. G., 
McGorry, P. D. & Lambert, M. (2014). Predictors of substance use reduction in an 
epidemiological first-episode psychosis cohort. Early Intervention in Psychiatry, 8, 358-365. 
doi: 10.111/eip.12067. Journal Impact Factor = 1.95. Accepted 20 May 2013.  
Authors’ contribution to this paper: 
The candidate is the first author and developed the research questions in this paper, 
conducted the data analysis, drafted the manuscript and finalised the manuscript based on co-
authors’ editorial feedback. The second and eighth authors wrote the original research 
protocol for the FEPOS study, conducted the file audit and provided editorial feedback on the 
manuscript. The third and fourth authors assisted in the development on the research 
questions in this paper and data analysis and provided editorial feedback on the manuscript. 
The fifth author assisted in the data analysis and provided editorial feedback on the 
manuscript. The sixth and seventh authors provided editorial feedback on the manuscript.         
Overview of this paper: 
The current paper explored quantitatively which baseline factors were associated with a 
reduction/cessation in SU overtime. A data set from EPPIC was used which explored 432 
individuals with FEP and SU over an 18-month period. Using multivariate analysis, two 
predictors were significant at follow-up; an absence of polysubstance use disorder and a 
greater premorbid functioning. While there were many limitations to the study, including its 
reliance on file audits and a lack of data on specific substances or on the timing of substance 
use and psychosis onset, the study suggested that people with psychosis and poor premorbid 
functioning may need more than standard treatment for psychotic symptoms to have optimal 
substance use outcomes.      
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Abstract 
Objective: To assess the predictors of a significant decrease or cessation of SU in a 
treated epidemiological cohort of FEP patients.  
Method: Participants were FEP patients of the Early Psychosis Prevention and 
Intervention Centre (EPPIC) in Australia. Patients’ medical files were reviewed using a 
standardised file audit. Data on 432 patients with FEP and baseline comorbid SUD were 
available for analysis. Predictors of reduction/cessation of SU at follow-up were examined 
using logistic regression analyses.   
Results: In univariate analyses, a reduction/cessation of SU was predicted by baseline 
measures reflecting higher education, employment, accommodation with others, CUD only 
(rather than polysubstance use disorders), better global functioning and better premorbid 
social and occupational functioning, later age at onset of psychosis, and a diagnosis of non-
affective psychosis. In multivariate analysis, CUD alone and better premorbid social and 
occupational functioning remained significant predictors.  
Conclusions: Addressing SUDs and social and occupational goals in people with FEP 
may offer opportunities to prevent SUDs becoming more severe or entrenched. Further 
longitudinal research on recovery from SU and FEP is needed to disentangle directions of 
influence and identify key targets for intervention. 
 
Keywords: Psychosis, schizophrenia, first-episode, substance use disorder, recovery   
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5.2 INTRODUCTION 
 High rates of SU among people with psychosis, and the negative biological, 
psychological, and social consequences of this use are well established (Cleary, Hunt, 
Matheson, & Walter, 2009; Horsfall, et al., 2009; Kavanagh & Mueser, 2007). Increased rates 
of treatment noncompliance, relapse, distorted perception and cognition, suicidal ideation, 
social exclusion, homelessness, aggression, injury, HIV, hepatitis, and cardiovascular, liver, 
and gastrointestinal disease have been reported as ill effects (Horsfall, et al., 2009; Sheidow, 
McCart, Zajac, & Davis, 2012). Current treatment approaches to SU in people with psychosis 
have shown mixed results and unstable long-term outcomes (Cleary, et al., 2008b; Hjorthøj, 
et al., 2009; Kavanagh, Young, et al., 2004; Lambert, et al., 2005). More puzzling are results 
indicating substance users with psychosis in assessment only or minimal treatment control 
conditions achieve similar reductions in SU over time, compared to those in more active SU 
treatments (Archie, et al., 2007; Edwards, et al., 2006; Gleeson et al., 2009). These findings 
suggest a role for recovery from SU. A detailed understanding of the processes that support 
recovery from SU in psychosis may offer important insights into the design of new 
interventions. However, a recent systematic review conducted by Rebgetz et al (2015a) 
identified only six studies on this subject.   
Some insights are provided by several studies examining predictors of SU in psychosis. 
Hides et al. (2006) examined the influence of psychotic symptom severity on CU in 84 
patients with early psychosis in the 6 months following hospitalisation. Increased psychotic 
symptom severity and less medication adherence during follow-up were predictive of time to 
cannabis relapse. A study of FEP patients found those who ceased SU (N=20) between 
baseline and 15 months follow-up were significantly older, more likely to be in a relationship, 
to have completed secondary school, and had less severe CU at baseline, than patients with 
continued SU (N=53; Wade, et al., 2006). However, none of these variables were predictive 
of SU status in a multivariate analysis. Bartels et al. (1995) reported that patients with chronic 
schizophrenia and substance dependence (N=148) were less likely to have a remission of SU 
at a 7-year follow-up than were those who satisfied criteria for abuse. A review by the current 
authors found that other predictors of recovery from SU included receipt of treatment for 
mental health problems and improved mental health symptoms (Rebgetz, Kavanagh, et al., 
2015a). Reported reasons for reducing or ceasing SU included health, financial, family, 
social, legal or religious issues, influence from significant others, negative feelings about 
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themselves as substance users and an awareness that the payoffs of their SU were more than 
offset by the problems it caused (Rebgetz, Kavanagh, et al., 2015a). Due to inconsistent 
findings, it was concluded that further research on recovery from SU in psychosis was 
urgently required, using larger and more representative cohorts of FEP patients.   
 The First Episode Psychosis Outcome Study (FEPOS) conducted a file audit of a 
treated epidemiological sample of 786 FEP patients in Melbourne, Australia (Conus, Cotton, 
Schimmelmann, McGorry, & Lambert, 2007). Results indicated that 61% of FEP patients 
who had a SUD at admission, had ceased or reduced SU at 18 months follow-up, and 39% 
continued to use substances. The current paper presents additional analyses on that dataset. 
This paper focuses on the distinction between CU only and poly SU, as cannabis is the most 
commonly used illegal drug and other drug use without concurrent CU is uncommon in this 
population.  
 This study identifies predictors of a significant reduction/cessation of SU in the 
FEPOS sample at 18 months’ follow-up. Based on previous research, we hypothesised that 
the presence of a CU disorder at baseline, completion of secondary school, female gender, 
older age, in a relationship and employed would be among the significant predictors of 
reduction/cessation of SU at 18 months. 
5.3 MATERIAL AND METHODS 
Context and sample 
The potential sample comprised a population-based cohort of 786 young people 
experiencing FEP who were consecutively admitted to the Early Psychosis Prevention and 
Intervention Centre (EPPIC) service between January 1998 and December 2000 (Conus et al., 
2010; Lambert, et al., 2005; Schimmelmann, Conus, Cotton, McGorry, & Lambert, 2007).  
EPPIC is mandated to engage all publicly treated 16-29 year olds with FEP from the 
northwestern and western suburbs of Melbourne (Conus, et al., 2010; Lambert, et al., 2005; 
Schimmelmann, et al., 2007). At the time of the study, the catchment area had a population of 
approximately 880,000 people, predominantly of lower socioeconomic status, a large 
proportion of whom were born overseas or had parents who were born overseas (Conus, et 
al., 2007). The comprehensive EPPIC program focuses on early intervention and is provided 
for approximately 18 months. It includes extensive psychiatric assessments, outpatient case 
management, cognitive behavioural therapy, low-dose antipsychotic therapy, access to a 
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specialised inpatient unit for acute care, mobile crisis intervention and community treatment 
teams, group programs, family support groups and group treatment of enduring positive 
psychotic symptoms (Edwards & McGorry, 2002). While some case managers may have 
addressed SU, the EPPIC program does not include formal SU treatment as a routine 
component. Data was collected using a retrospective standardised file audit. Baseline 
variables were rated on information provided at admission and 18 months follow up or 
discharge from the service (Conus, et al., 2007; Conus, et al., 2010; Lambert, et al., 2005; 
Schimmelmann, et al., 2007).     
 Inclusion criteria for the study were a first episode of any DSM-IV psychotic disorder 
(APA, 2000), except Drug-Induced Psychotic Disorder, Brief Psychotic Disorder, or 
Psychotic Disorder Due to a General Medical Condition (unless there was a change in 
diagnosis to another psychotic disorder prior to EPPIC discharge). Participants had to be aged 
15–29 years, and have an IQ > 70. 
 From the original file audit, 84% of available medical records were assessed: the 
remaining 82 files had been sent to other services and were unavailable for review (these 
patients did not differ on psychotic, SUD, or demographic variables from the included 
sample). Five percent of potential participants (n = 43) were excluded due to not meeting 
diagnostic criteria for inclusion as there was a change in diagnosis to a non-psychotic 
disorder. The available dataset therefore comprised 661 patients. This paper focuses on 432 
patients with SUD at service entry (i.e. 65.4% of the overall dataset). Of the 432, 135 met 
criteria for substance abuse and 297 for substance dependence.  
Diagnostic assessment 
Initial assessment at EPPIC was conducted by two clinicians and reviewed by a senior 
psychiatrist. It was based on the Royal Park Multi-diagnostic Instrument for Psychosis 
(RPMIP; McGorry, Copolov, & Singh, 1990; McGorry et al., 1990). Clinical diagnoses 
(psychoses and SUD) were based on DSM-IV (APA, 2000) and were consensus diagnoses of 
research psychiatrists (PC and ML), based on medical records across an intensive 6-week 
assessment period.  [Inter rater] Reliability of diagnosis was assessed on a randomly selected 
subset of 115 patients, which yielded a good reliability for both psychosis (kappa = 0.80) and 
comorbid substance abuse (kappa = 0.74) diagnoses (Conus, et al., 2007). 
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Assessment of SUD  
 SUD was assessed using the Drug and Alcohol Assessment Schedule (DAAS; 
McGorry, Copolov, et al., 1990; McGorry, Singh, et al., 1990) at baseline, during the 
treatment period (at 1,2,4 and 6 weeks, and 3,6,12, and 18 months, or discharge if prior to 18 
months). In the original dataset, the course of SUD was differentiated into: (1) no SUD (at 
baseline or during EPPIC treatment); (2) significant reduction or cessation of SUD (decrease 
in quantity and frequency of  ≥ 50% or cessation of baseline SUD at 18 months or at 
discharge); or  (3) persistent SUD defined as either 3(a) increased SU (≥ 50% increase in 
quantity and frequency of substances used), 3(b) unchanged use (< 50% decrease or < 50% 
increase from baseline SUD), 3(c) restarted (SU stopped or decreased, but restarted before 
discharge, and involved comparable consumption to baseline, or 3(d) newly started ; without 
baseline SUD) (Lambert, et al., 2005). In the original data set 265 people were in category 1, 
167 in category 2 and 229 in category 3. In order to obtain sufficient cases in each category 
for predictive analyses, these data were recategorised as (a) unchanged, restarted or increased 
SU and (b) reduced or ceased SU. The polysubstance group consisted of those having a CUD 
and either an amphetamine, alcohol, opioid, or solvent use disorder.  
Assessment of baseline, treatment and outcome variables 
Baseline, treatment and outcome (at 18-months follow-up or discharge) variables were 
retrieved from patient records, using the Early Psychosis File Questionnaire (EPFQ; Conus, 
et al., 2007; McGorry, Copolov, et al., 1990; McGorry, Singh, et al., 1990), which included a 
number of standardised scales and questions derived from the RPMIP. Duration of untreated 
psychosis (DUP) was assessed with the DUP Scale (McGorry, Copolov, et al., 1990; 
McGorry, Singh, et al., 1990). Global Assessment of Functioning (GAF; APA, 2000) was 
used to assess premorbid functioning (best GAF in the year preceding illness onset) and 
baseline functioning. The Scale of Occupational and Functional Assessment (SOFAS; APA, 
2000) was used to assess premorbid functioning (best SOFAS in the year preceding illness 
onset) and baseline functioning. Severity of illness at baseline and discharge was assessed 
using the Clinical Global Impressions-Severity of Illness (CGI-S; Guy, 1976) and Clinical 
Global Impressions-Severity of Illness – Bipolar Illness (CGI-BP; Spearing, Post, Leverich, 
Brandt, & Nolen, 1997) scales. Employment at entry was assessed based on the Modified 
Vocational Status Index (MVSI; Tohen et al., 2000) and accommodation at entry used the 
 78 Chapter 5: Paper 4 
Modified Location Code Index (MLCI; Tohen, et al., 2000). These scales are well recognised 
as established ways of measuring these variables.  
Procedure 
 Patient information was derived from standardised medical records.  Using the EPFQ, 
two psychiatrists assessed the files (ML and PC). Data on the EPFQ was available for 
baseline (at admission) and at 18 months or earlier discharge from EPPIC. 
Data analysis 
 Univariate logistic regressions were conducted to identify potential predictors of a 
reduction or cessation of SU at discharge, among the 432 FEP patients with SUD at service 
entry. Predictors with uncorrected p-values ≤ 0.05 were selected for a multivariate binary 
logistic regression to identify those offering unique predictions. Analyses were performed 
using IBM® SPSS® Version 20.0.  
5.4 RESULTS 
Patient characteristics 
Demographic information for the 432 patients is shown in Table 5.1. The sample was 
73% male and 72% had a diagnosis of a non-affective psychosis (e.g., schizophrenia, 
schizophreniform disorder, delusional disorder). Over the treatment period, 265 patients 
(61%) decreased or ceased their SU, while the remaining 167 had no change, restarted or 
increased SU. The mean follow-up period was 14.5 months (7.7 months); the median was 
17.9 months, with a range of 0-48 months. 
Candidate predictors of reduction/cessation in SU 
Candidate predictors at baseline included gender, age, employment (employed, student 
or home duties vs. unemployed); history of physical or sexual abuse (no/yes); 
accommodation (independent/non-independent); ethnicity (born in Australia/Born Overseas); 
insight into psychotic illness (none, partial, full); marital status (married or partnered vs. 
single); diagnosis (non-affective psychosis - schizophrenia, schizophreniform, delusional vs. 
affective psychosis - schizoaffective, bipolar I disorder, major depression); family history of 
schizophrenia (no/yes); history of parental separation (no/yes); SUD (CUD, poly SUD 
(including CU)), CGI-S at entry (normal, not ill, borderline, mild, moderate, marked, severe, 
extreme), years of completed secondary school; DUP (in days), age of disorder onset (in 
days), premorbid GAF and SOFAS (each 0-100); age of onset of psychosis; CGI-BP 
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depression and mania scores. Service time in months was added to control for the length of 
time at EPPIC. 
Univariate predictors of reduction/cessation in SU 
Separate univariate logistic regressions identified eight predictors with a p < 0.05 on the 
Wald Test: psychotic diagnosis, CUD only at baseline, increased number of completed years 
of secondary school, older age at onset of illness, better premorbid GAF and SOFAS, 
employed at baseline and supported accommodation at baseline  (see Table 5.2). Female 
gender, parental separation and shorter DUP were associated with SU outcomes at the p < 
0.10 level. Service time (in months) was significant (p < 0.05 on the Wald Test).  
Multivariate predictors of reduction/cessation in SU 
Multivariate logistic regression was performed to assess the collective prediction of 
reduction/cessation in SU, from the eight variables with univariate p < 0.05. Simultaneous 
entry allowed a test of whether variables retained significance when predictions from other 
variables were controlled. This model was statistically significant χ2(8, N = 371 ) = 42.79, p< 
.001, explaining between 10.9% (Cox and Snell R2) and 14.9% (Nagelkerke R2) of the 
variance, and correctly classifying 69% of cases. As shown in Table 5.3, only two 
independent variables made a unique, statistically significant contribution to the model.  An 
absence of polysubstance use disorder at baseline gave the largest odds ratio (1.574) for a 
positive outcome, but the most statistically significant contribution was greater premorbid 
functioning on the SOFAS (p = .024), recording an odds ratio of 1.05. The correlation 
between the two significant predictors was small but statistically significant (Spearman’s rho 
= -.22, p < .001).  
 Little change in the model was found if the predictors were expanded to those with 
univariate p < 0.10:  χ2(11, N = 369 ) = 46.96, p< .001, explaining between 12% (Cox and 
Snell R2) and 16.4% (Nagelkerke R2) of the variance, and correctly classifying 67% of cases 
or service time (in months) p < 0.10:  χ2(9, N = 371 ) = 52.84, p< .000, explaining between 
13.9% (Cox and Snell R2) and 19.1% (Nagelkerke R2) of the variance, and correctly 
classifying 69% of cases . The variables with significant unique prediction remained the 
same. 
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5.5 DISCUSSION 
This is the first study to examine predictors of substance reduction/cessation in a treated 
epidemiological cohort of FEP patients. Higher levels of premorbid social and occupational 
functioning and CUD (rather than poly SUD) at baseline emerged as the only predictors of a 
reduction or cessation of SU at 18-months follow-up.   
Premorbid functioning had previously been found to predict better SU outcomes in a 
chronic (Dixon, et al., 1991), but not FEP sample (Wade et al., 2005). Premorbid social and 
occupational functioning may potentially have conflicting effects on risk of increased SU. 
Poor functioning may sometimes increase risk; cognitive and social skill deficits may reflect 
poor self-control skills, or impair the person’s ability to comprehend and apply 
psychoeducation about SUD. An absence of competing activities such as employment may 
increase the potential time spent on SU, or unemployment may increase exposure to other 
heavy substance users. However, in some contexts poor functioning may reduce risk; for 
example, severely impoverished social activities and networks may reduce exposure to 
situations where substances are available and consumption is reinforced. Whether 
acquaintances are substance users and the extent that personal control or substance refusal 
skills are tested are likely to vary across individuals and social contexts. 
 It is possible that SU was linked more directly to the presence of acute positive 
symptoms in patients with higher premorbid SOFAS, and that treatment of these symptoms 
more effectively contributed to SU reduction or cessation in that group. For example, low 
premorbid SOFAS may sometimes be driven by factors other than psychosis itself, such as a 
more deprived and/or less supportive early childhood environment. The treatment of 
psychotic symptoms in patients where SU is primarily driven by issues other than positive 
psychotic symptoms is likely to have less influence. Research that drills down into the bases 
of low SOFAS scores may be important in disambiguating the association with better SU 
outcomes. 
 Patients with only a CUD were more likely to reduce or stop using substances at 
follow-up. This result is open to several interpretations. It is possible that poly SUD is a 
proxy for more severe substance-related problems. If so, the result is consistent with findings 
that poly SUD or other severity indicators (e.g., dependence) are linked with continued use 
(Bartels, et al., 1995; Wade, et al., 2006). Alternatively, poly SUD may increase the risk of 
continued use of cannabis via a physiological mechanism (e.g. increased impulsivity when 
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intoxicated by other drugs), through common sources of supply, or via social cues and 
reinforcers. CU might also be maintained in users of other substances, in order to moderate 
unwanted effects of those drugs. 
 Several potential predictors were significant (or approached significance) in 
univariate analyses, but did not significantly contribute to the prediction of a 
reduction/cessation of SU in the multivariate analyses. It is perhaps unsurprising that the 
predictive influence of fewer years of education, higher unemployment and less stable 
accommodation were captured by the presence of poly SUD or a CUD once it was entered 
into the analysis, as these variables are often associated with this disorder (Horsfall, et al., 
2009; Kavanagh & Mueser, 2007). Similarly, the association of better outcomes from 
participants with schizophreniform disorder rather than schizophrenia may reflect a greater 
capacity for change in a group with earlier onset of psychosis. Males were marginally more 
likely to be substance users at follow-up, but these effects were also fully accounted for by 
other predictors. In retrospect, this should not have been surprising; gender often drops out of 
predictions of post-treatment SU in general population samples, once higher SU by males at 
baseline is accounted for (e.g., Kavanagh & Connolly, 2009). 
Consistent with other FEP studies, baseline symptom severity was not predictive of SU 
status at follow-up (Linszen, Dingemans, & Lenior, 1994; Sevy et al., 2001; Wade, et al., 
2005, 2006). This may reflect the instability of symptoms in treated FEP, such that symptom 
severity at an initial episode may not be a reliable predictor of subsequent symptom severity. 
This was also a treated FEP sample, which may have (inter alia) focused on SU through 
psychoeducation. Symptoms may have countervailing effects. For example, when patients are 
distressed, some may use substances to alleviate this distress. On the other hand, they may 
also be less likely to mix with others when distressed, which may result in less exposure to 
SU. Recently Cotton and colleagues (2012) found that participants from the FEPOS sample 
with depressive symptoms and FEP were less likely to be using substances, suggesting that 
greater insight may lead to increased understanding of the negative effects of SU on 
functioning. However in the current study, insight was not related to SU at outcome.  
Limitations and strengths 
This is the largest study of predictors of recovery from SUD in FEP conducted to date 
exploring numerous putative predictors. The use of a treated epidemiological cohort of FEP is 
a further strength of the study. The study used a retrospective file audit, which relies on the 
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quality of information obtained and recorded by the researchers and clinicians involved. File 
audits have been criticised for problems with inter-rater reliability and validity; however, as 
discussed elsewhere, all efforts were made to reduce the limitations of the file audit (Conus, 
et al., 2010; Lambert, et al., 2005; Schimmelmann, et al., 2007), including all medical records 
being assessed by two experienced psychiatrists and inter-rater reliability being established 
with good reliability.   
 Other limitations of the data set include the use of a combined variable for a reduction 
or cessation of SU at 18-months follow-up, and the use of SU in general as an outcome 
variable, which did not allow for the impact of specific substances to be determined. No data 
on the specific frequency or quantity of substances consumed at baseline or follow-up was 
available for analysis. In addition, the presence and nature of any treatment for SUD received 
was not recorded, and this may have affected the results. Relationships between the timing of 
SUD and psychosis onsets should be taken into account, but there was no reliable data on this 
variable. Premorbid SOFAS is limited by the difficulties in defining prodrome onset, and a 
separation of social and role functioning assessment would have been preferable, since 
substance users with psychosis often have better premorbid social functioning than non-users 
(Wade, et al., 2006). Since the present cohort comprised young people during their first 18 
months treatment for FEP, the results may also be specific to early phases of the illness. 
However, the inclusion of participants with SUD gives the results a high level of relevance to 
many other clinical contexts where FEP patients are seen (Conus, et al., 2007; Conus, et al., 
2010; Schimmelmann, et al., 2007).  
Clinical implications and future research directions 
This study suggests that prevention or effective treatment of poly SUD may be 
important in maximising the chance of reduction or cessation of CU in people with EP 
(Bennett, et al., 2009; Mueser, et al., 2007). Furthermore, people with poor premorbid 
functioning may need more than standard symptomatic care to achieve better CU outcomes.  
While the current study is unable to identify what this additional treatment should be, we can 
speculate that it may need to accommodate the presence of pre-existing cognitive 
dysfunction, if that was a strong contributor to the premorbid functional deficits. Treatment 
for those with poor premorbid functioning may also need to have an increased focus on 
addressing functional deficits and developing social or occupational activities and goals that 
can then compete with SU, although these foci were already present in the standard 
interventions offered to this sample.  
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Further longitudinal research on the predictors of recovery from SU in EP is clearly 
required, to refine our understanding of key targets for intervention and maximise positive 
outcomes. In addition, examination of outcomes with different substances is warranted and 
may lead to different treatments for different substances.  
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5.6 COMMENTARY (SUMMARY AND IMPLICATIONS) 
 This study was the largest to date which explored baseline predictors of SU 
reduction/cessation over 18 months. The two factors of only having a CUD and greater 
premorbid social and occupational functioning were the only two factors which significantly 
contributed to SU reduction/cessation. This suggests that incorporating these factors during 
treatment for SU in a FEP population is required to maximize outcomes. The limitations of 
data collection via a chart audit and not having data on CU at follow-up are required to be 
addressed.  
Due to the data available we were unable to report how many polysubstance users 
didn’t use cannabis. 
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Table 5.1 Demographics of the 432 FEP patients with SUDs 
 M (SD) 
Age, years 21.6 (3.3) 
Educational level, completed high school in years 10.4 (1.5) 
Premorbid GAFa, points 68.4 (10.6) 
Premorbid SOFASb, points 68.0 (11.6) 
Duration of untreated psychosis, days 253.8 (494.3) 
Service time (in months) 14.5 (7.77) 
 N (%) 
Gender, female 118 (27%) 
Parental separation, no 233 (54%) 
Employment at baseline, yes 181 (42%) 
Accommodation 398 (94%) 
Non-affective psychosis  308 (72%) 
Cannabis use disorder only (not poly SUD) 180 (45%) 
Cannabis use/dependence 307 (71%) 
  
 a
 Global Assessment of Functioning (GAF; APA, 2000) 
 b
 The Scale of Occupational and Functional Assessment (SOFAS; APA, 2000) 
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Table 5.2 Univariate predictors 
Variable Beta SE (Beta) Wald Significance Level Odds 
Ratio 
95% CI for  
Odds Ratio 
Psychotic diagnosis 
  Non-affective 
 
-.516 
 
.228 
 
5.118 
 
.024 
 
0.597 
 
0.382 
 
0.933 
Poly substance use disorder 
 Cannabis use disorder (not poly SUD) 
 
.718 
 
.215 
 
11.176 
 
.001 
 
2.050 
 
1.346 
 
3.124 
Gender 
 Female 
 
.384 
 
.228 
 
2.836 
 
.092 
 
1.468 
 
0.939 
 
2.295 
Education level  .225 .070 10.397 .001 1.252 1.092 1.436 
Parental separation  
 No 
 
.354 
 
.199 
 
3.156 
 
.076 
 
1.424 
 
0.964 
 
2.104 
Age at onset of illness .066 .029 5.021 .025 1.068 1.008 1.132 
Duration of untreated psychosis .000 .000 2.791 .095 1.000 0.999 1.000 
Premorbid GAFa .056 .010 29.300 .000 1.057 1.036 1.079 
Premorbid SOFASb .060 .101 37.159 .000 1.062 1.042 1.083 
Employment at baseline  
 Yes 
 
-.585 
 
.205 
 
8.133 
 
.004 
 
0.557 
 
0.373 
 
0.833 
Accommodation 
 Non-independent living  
 
1.066 
 
.412 
 
6.695 
 
.010 
 
2.903 
 
1.295 
 
6.507 
Service time (in months) .052 .013 14.906 .000 1.053 1.026 1.081 
a
 Global Assessment of Functioning (GAF; APA, 2000) 
b
 The Scale of Occupational and Functional Assessment (SOFAS; APA, 2000) 
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Table 5.3 Results of a multivariate logistic regression, with simultaneous entry of univariate predictors with significance of p < .05. 
Variable Beta SE (Beta) Wald  Significance Level Odds 
Ratio 
95% CI for Odds Ratio 
Psychotic diagnosis  
 Non-affective 
 
-3.24 
 
.276 
 
1.376 
 
.241 
 
0.723 
 
0.421 
 
1.243 
Poly substance use disorder 
 Cannabis use disorder (not poly SUD) 
 
.454 
 
.236 
 
3.683 
 
.050 
 
1.574 
 
0.990 
 
2.502 
Education level .020 .087 0.050 .822 1.020 0.859 1.210 
Age at onset of illness .000 .000 0.537 .463 1.000 1.000 1.001 
Premorbid GAFa -.001 .023 0.002 .965 0.999 0.955 1.046 
Premorbid SOFASb .051 .023 5.109 .024 1.053 1.007 1.101 
Vocation  
 Unemployed 
 
.033 
 
.256 
 
0.017 
 
.897 
 
1.034 
 
0.626 
 
1.707 
Accommodation  
 Non-Independent Living 
. 
551 
 
.474 
 
1.352 
 
.245 
 
1.735 
 
0.685 
 
4.394 
a
 Global Assessment of Functioning (GAF; APA, 2000) 
b
 The Scale of Occupational and Functional Assessment (SOFAS; APA, 2000) 
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Overview of this paper: 
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receiving an income. Treatment interventions should consider addressing these issues to 
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Abstract 
Background and Objectives: CU is common in early psychosis and has been linked to 
adverse outcomes. However, factors that influence and maintain change in CU in this 
population are poorly understood. An existing prospective dataset was used to predict 
abstinence from CU over the 6 months following inpatient admission for early psychosis. 
Methods: Participants were 67 inpatients with early psychosis who had used cannabis in the 6 
weeks prior to admission. Current diagnoses of psychotic and SU disorders were confirmed 
using a clinical checklist and structured diagnostic interview. Measures of clinical, SU and 
social and occupational functioning were administered at baseline and at least fortnightly 
over the 6-month follow up.  Results: No SU or clinical variables were associated with 6-
months’ of cannabis abstinence. Only Caucasian ethnicity, living in private accommodation 
and receiving an income before the admission were predictive. Only private accommodation 
and receiving an income were significant predictors of abstinence when these variables were 
entered into a multivariate analysis. Conclusions: While the observed relationships do not 
necessarily imply causation, they suggest that more optimal SU outcomes could be achieved 
by addressing the accommodation and employment needs of patients.  
 
Keywords: psychosis; substance use; recovery   
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6.2 INTRODUCTION 
Both a heightened risk of CU in psychosis and the adverse biological, psychological, 
and social consequences of CU in psychosis are well established (Cleary, et al., 2009; 
Horsfall, et al., 2009; Kavanagh & Mueser, 2007). However, clinical trials examining the 
impact of SU interventions for people with psychosis have given inconsistent and 
disappointing results (Cleary, et al., 2008b; Hjorthøj, et al., 2009; Kavanagh, Young, et al., 
2004). Several studies have found that substance users with psychosis who undergo 
assessment only or minimal treatment achieve similar reductions in SU over time, to those 
receiving more intensive SU treatments (Archie, et al., 2007; Edwards, et al., 2006; Gleeson, 
et al., 2009). A greater understanding of natural recovery from SU in people with psychosis 
may offer new insights into more effective strategies for addressing it in this population.   
Previous research has suggested that continued SU in people with early psychosis  is 
associated a number of variables, such as younger age, male gender, unemployment, non-
completion of secondary school, single marital status and greater CU at baseline (Lambert, et 
al., 2005; Wade, et al., 2006). Unsurprisingly, more severe SU at baseline (e.g. severe 
substance dependence) also predicts later SU among people with more chronic psychotic 
disorders (Bartels, et al., 1995). It therefore may be expected that reduction in these risk 
factors may be associated with a lower rate of SU in early psychosis. To our knowledge no 
studies have examined which factors predict abstinence of CU in an early psychosis 
population.    
Only a handful of studies have examined predictors of cannabis cessation in people 
with psychotic disorders (Childs, et al., 2011; Rebgetz, Kavanagh, et al., 2015a). Few 
findings have been replicated. A recent study conducted by the investigators, found that the 
presence of a CUD only (i.e. without other concurrent substance misuse) and higher levels of 
premorbid social and occupational functioning were significant predictors of later cessation 
or reduction of SU in a treated cohort of first episode patients with psychosis and SUD 
(Rebgetz, Conus, et al., 2014). However, no distinction between those who ceased and those 
who reduced their use was made. The identification of factors that lead to continuous 
abstinence is of particular interest, as any use is likely to be problematic in this group.        
Lifestyle factors that enable maintenance of abstinence include the avoidance of 
situations in which cannabis was previously used, and the development of interests (e.g., diet, 
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exercise, sport) that are inconsistent with CU (Ellingstad, et al., 2006). Such factors have 
been implicated in sustained abstinence in people with SMI and alcohol dependence 
(Stasiewicz, et al., 1997).  
In summary, previous research has identified the following predictors of reduction in 
SU among people with psychosis: older age, female gender, being employed, less severe 
cannabis and other SU, engagement in social activities, better premorbid adjustment and less 
severe mental health symptoms. This is the first study to identify demographic, SU, clinical, 
family and social predictors (assessed at the time of psychiatric admission) of cannabis 
cessation over the following 6 months in an early psychosis sample.  
6.3 METHODS 
Sample and Context 
An existing prospective data set collected by Hides et al. (2006) to examine the 
influence of CU on psychotic relapse over a 6-month follow-up was used for this study. The 
original sample consisted of 121 consecutively admitted patients with early psychosis 
recruited from three public hospitals in Brisbane’s Inner, Western and Southern Suburbs 
between March and October 2000. These participants consented to all assessment periods and 
ethical approval to conduct the study was granted by the Griffith University Human Research 
Ethics Committee (HREC), and the relevant hospital HREC’s. Inclusion criteria included 
meeting DSM-IV criteria for a current Psychotic Disorder or Mood Disorder with Psychotic 
Features (APA, 2000) and having less than three previous psychotic episodes. A mixed 
sample of patients (i.e., psychosis and affective psychosis) was selected, as they represent 
typical clinical presentations to mental health services in early stages of psychosis, when 
diagnosis is often unclear. Exclusion criteria included diagnoses of Psychotic Disorder Due to 
a General Medical Condition or Intellectual Disability. Eighty-one (67%) people agreed to 
participate in the baseline assessment in hospital and a 6-month follow up, comprising 
monthly face-to-face visits, interspersed with telephone calls, to provide weekly contact for 
the first 3 months, followed by fortnightly contact for another 3 months [see Hides et al 
(2006) for further information]. The present study focused on a subset of 67 participants 
(83% of the follow-up sample) who had current cannabis dependence (N=57) or had used 
cannabis in the 6 weeks prior to admission (N=10). Cannabis cessation, the key outcome 
measure, was defined as abstinence from CU throughout the study period from baseline to a 
6-month follow-up.  
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Baseline Measures 
Demographic assessments included age, gender, employment, receiving an income 
(through employment and government benefits), marital status, parental occupation, current 
living arrangements, education, ethnicity, diagnosis, age of first diagnosed and admitted, 
number of episodes and hospital admissions, length of current and previous hospitalisations, 
current and discharge medication, family history of psychosis and other psychiatric disorders.  
This information was verified against medical records.   
The Operational Criteria Checklist (OPCRIT; McGuffin, Farmer, & Harvey, 1991) was 
used to confirm psychotic diagnoses, based on the medical record. The Interview for 
Retrospective Assessment of Schizophrenia (IRAOS; Hafner et al., 1992) verified 
participants’ age at onset of psychotic symptoms. The IRAOS is an objective, reliable and 
valid assessment tool in studying onset, pre-psychotic prodrome and early course of 
psychosis (Hafner, et al., 1992). The 24-item Brief Psychiatric Rating Scale (BPRS; Overall 
& Gorham, 1962) was administered to assess current psychiatric symptoms and has shown 
high levels of reliability and validity in dual diagnosis populations (Lykke, Hesse, Austin, & 
Oestrich, 2008).  
The Composite International Diagnostic Interview Version 2.1 (CIDI; World Health 
Organization, 1997) Section L identified whether substance abuse or dependence was present 
in the 12 months prior to admission. A Timeline Followback (TLFB; Sobell & Sobell, 1992) 
measured the frequency (days) and quantity of cannabis and other SU in the 6 weeks prior to 
admission by anchoring SU against key life events to assist recall (Fals-Stewart, O’Farrell, 
Freitas, McFarlin, & Rutigliano, 2000; Sobell & Sobell, 1992). TLFBs have well-established 
reliability and validity (Fals-Stewart, et al., 2000; Sobell & Sobell, 1992). Cannabis effect 
expectancies were identified using the 23-item Cannabis Expectancy Questionnaire (CEQ; 
Young & Kavanagh, 1997). Positive and negative expectancies on the CEQ have 
demonstrated concurrent validity with CU and dependence in a treatment sample of cannabis 
users. In a treatment sample of cannabis users, higher positive cannabis expectancy scores 
were associated with greater CU, while higher negative expectancy scores predicted greater 
cannabis dependence (Connor, Gullo, Feeney, & Young, 2011).   
Key life events were defined according to the Psychiatric Epidemiological Interview–
Life Events Scale (PERI–LES; Dohrenwend, Krasnoff, Askenasy, & Dohrenwend, 1978) 
measured on the TLFB. The Family Environment Scale (FES; Moos & Moos, 1994) was 
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used to measure family relationships (conflict, expressiveness, cohesion) in current family 
functioning for those participants’ in regular contact with their families. The FES has 
demonstrated discriminative and predictive validity in psychotic populations (Phillips, West, 
Shen, & Zheng, 1998). The Quality of Life (QOL-Brief Version; Lehman, 1995) scale 
measured objective quality of life and global wellbeing in the previous 12 months. The scale 
has shown good levels of inter-rater reliability and validity in people with schizophrenia 
(Gupta, Mattoo, Basu, & Lobana, 2000). The Premorbid Adjustment Scale (PAS; Cannon-
Spoor, Potkin, & Wyatt, 1982) assessed premorbid functioning in the 6 months preceding 
first admission. It has demonstrated good levels of inter-rater reliability and validity amongst 
people with schizophrenia (Cannon-Spoor, et al., 1982).   
Monitoring Measures 
Psychiatric symptoms were monitored using the BPRS (Overall & Gorham, 1962) 
throughout the 6-month follow-up. Only BPRS items that did not require interviewer 
observation could be included in telephone interviews. BPRS positive, negative and 
depression-anxiety symptom scores were derived (Ventura, Nuechterlein, Subotnik, Gutkind, 
& Gilbert, 2000).  TLFBs measured the frequency (days) and quantity of cannabis and other 
SU, life events, life stress (subjectively rated from 0 to 10) and medication adherence (in 
days) at least fortnightly over the 6-month follow-up. 
Participants underwent urine drug screening at 6 months or while in hospital, to verify 
self-reports of recent SU and antipsychotic medication adherence. Urine was screened using a 
cannabis immunoassay and gas chromatography/mass spectrometry. There was a high level 
of agreement between these assays and self-reported CU (Cohen’s kappa = 0.90). 
Statistical analysis 
Candidate predictors of cannabis cessation identified in the literature to date (listed in 
Table 6.2) were initially entered into a series of univariate logistic regressions to identify 
predictors of cannabis cessation. Other plausible predictors that were also examined included 
living arrangements (living in private accommodation), ethnicity (being Caucasian), financial 
status (having an income), total cannabis expectancy score, age of onset of CU, family 
relationships (conflict, expressiveness, cohesion) and family history of psychosis or other 
mental illness. Significant predictors (p < .05) were entered simultaneously into a 
multivariate logistic regression, to identify which variables retained significance (p < .05) 
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when other predictors were controlled for. Analyses were performed using IBM® SPPS® 
Version 22.0. 
6.4 RESULTS 
Participant characteristics 
The sample had a mean age of 24.5 (SD 5.2) years, and the majority were male 
(N=52/67; 78%), with a diagnosis of schizophrenia or schizophreniform disorder (N=48/67; 
72%). The demographic, SU and clinical characteristics of the patients who did and not cease 
CU from baseline to the 6-month follow up assessment are displayed in Table 6.1. While data 
were not available on whether they received brief advice concerning their SU, none received 
extensive inpatient or outpatient specialist treatment for addiction, and 66% (N = 44) did not 
see a psychiatrist or case manager during the follow-up period.  
Despite the absence of specific SU treatment, 19 participants (28%) did not use 
cannabis at all over the 6-month follow-up. In fact, 27% (18/67) refrained from any illicit SU 
during the follow up period. Almost 80% (N=53/67; 79%) abstained from methamphetamine 
use over the 6-months, but only 10/67 (15%) abstained from alcohol.  
Univariate predictors of cessation in CU 
Separate univariate logistic regressions identified three predictors of cannabis cessation 
(See Table 6.2). Only living in private accommodation, receiving an income at baseline and 
Caucasian ethnicity predicted cessation with p < .05 on the Wald Test. Notably, neither 
baseline symptoms (on the BPRS) nor any baseline SU measure (including baseline measures 
of quantity/frequency of cannabis, other illicit drug or alcohol use, the severity of cannabis 
dependence or cannabis expectancies on the CEQ) predicted subsequent cannabis cessation.  
Multivariate predictors of cessation in CU 
A multivariate logistic regression was performed to identify which of these univariate 
predictors retained significance when entered simultaneously into the analysis (see Table 
6.3). The full model significantly distinguished between participants who had ceased and 
continued CU post-admission (χ2(3, N = 67) = 21.26, p < .001). The model explained 27% 
(Cox and Snell R square) to 39% (Nagelkerke R squared) of the variance, and correctly 
classified 81% of cases. As shown in Table 6.3, only private accommodation and receiving 
an income made a significant unique contribution. The strongest predictor of cannabis 
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cessation was private accommodation, recording an odds ratio of 11.87, while receiving an 
income increased the odds by 9.51.  
Little change in the model was found if participants with only cannabis dependence 
(N=57; i.e. excluding abuse) were included, χ2(3, N = 57) = 17.83, p< .001.  The equation 
explained between 27% (Cox and Snell R2) and 38% (Nagelkerke R2) of the variance, and 
correctly classified 79% of cases. The same unique predictors emerged.   
6.5 DISCUSSION  
This was the first prospective naturalistic study to examine predictors of cannabis 
cessation, in an early psychosis sample. Almost 30% of cannabis using early psychosis 
patients ceased CU for at least 6 months following an inpatient admission for acute 
psychosis. A similar proportion refrained from any illicit SU at all during the follow up. 
These results are consistent with a growing body of work indicating that recovery from SU 
can occur in early psychosis in the absence of significant SU treatment (Addington & 
Addington, 2001; Carr, et al., 2009; Cleary, et al., 2008b; Harrison, et al., 2008; Hinton, et 
al., 2007).   
In order to increase current understanding of natural recovery from CU in early 
psychosis, the current study examined the impact of a wide range of potential demographic, 
clinical, SU, social, treatment, functional and quality of life variables on cannabis cessation. 
Having private accommodation and an income at admission provided the only significant 
unique predictions of cannabis cessation in the multivariate analysis. Early psychosis patients 
living in private accommodation and those with an income were 11 and 9 times more likely 
to abstain from CU respectively. These findings were consistent with those of Maisto et al. 
(1999), who found that living in stable accommodation (group homes), which often restricted 
access to substances and provided structure, was a factor associated with changing SU 
patterns. Individuals who have stronger predictability in their lives may reduce their SU, due 
to the associated increases in positive social interactions outside of SU and decreased stress 
(Maisto, et al., 1999). Similarly, having an income may allow people to engage in other 
activities outside of CU (e.g., sport, hobbies), providing a sense of belonging and acceptance 
(Lobbana, et al., 2010). These activities may engage people in a positive social network, 
away from substance-using peers and provide an opportunity for a reappraisal of the value of 
more functional rewards and of the financial and opportunity costs associated with CU 
(Addington & Duchak, 1997; Ellingstad, et al., 2006; Lobbana, et al., 2010).   
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The protective effects of both private accommodation and an income are open to other 
interpretations. For example, they may reflect higher levels of cognitive and social 
functioning, which may then allow greater control over CU. While cognitive functioning was 
not assessed, it is notable that the presence of social activities and premorbid adjustment were 
not significant univariate predictors. These characteristics might also be expected among 
individuals with less severe levels of CU and cannabis-related problems (e.g. less interference 
with an ability to obtain financial support, a greater proportion of income being available for 
accommodation). However, the fact that neither the extent of cannabis and other SU nor the 
presence of cannabis dependence at baseline predicted later cannabis cessation renders this 
hypothesis unlikely.  
The finding that neither baseline cannabis nor other SU was associated with cannabis 
cessation was both noteworthy and surprising. It differs from the observation of Wade et al 
(2006) that continued SU at 15 months was associated with heavy CU prior to baseline, but 
was consistent with a chart audit by Dekker et al  (2008) that found no association.  
The presence of polysubstance use is often used as an indicator of severity. While 
almost 50% of the sample were polysubstance users (defined as cannabis plus other 
substances) in the 6 weeks prior to admission, there was no significant difference in the 
proportion of polysubstance users and cannabis users who achieved abstinence from CU or 
any SU over the 6-month follow-up. This does not accord with our recent finding that first-
episode patients with a CUD at baseline were more likely to have reduced or ceased SU at 
18-months follow-up than were those with polysubstance use disorders (Rebgetz, Conus, et 
al., 2014). However, that study relied on file audits and included reductions in consumption, 
whereas the current study focused on complete abstinence, and systematically measured SU 
at least fortnightly over 6 months follow-up.  
Unlike previous studies conducted by our group (Hides, Kavanagh, Dawe, & Young, 
2009) there was no association between positive and negative cannabis expectancies and 
cannabis cessation. Notably, however, the current study is the first to examine the association 
between cannabis expectancies and abstinence.  
Contrary to our hypotheses, neither male gender, younger age, incomplete secondary 
school, nor unemployment (Cuffel & Chase, 1994; Wade, et al., 2005) were significant 
predictors of cannabis cessation. These factors are typically associated with the risk of SU 
and related functional impacts rather than with cessation of use among substance users. 
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Equally, the severity of BPRS psychiatric symptoms at baseline was not associated with 
cannabis cessation.  
This study had a relatively small sample size, and while it was adequate—particularly 
for the univariate predictions (Tabachnick & Fidell, 2012)—greater confidence in our 
conclusions would be given by a replication using a larger sample. Abstinence from CU was 
assessed over 6 months, whereas some other studies have used a 12-month criterion for 
abstinence (Drake, et al., 2004). On the other hand, the current study had weekly assessments 
of CU for the first 3 months, followed by fortnightly assessments for 3 months—a level of 
monitoring that was much more intensive than is typically obtained. The high degree of 
concordance between self-reported SU and urine drug screens in the hospital and at 6 months 
gave further credence to the results. 
Finally, while it is plausible that treatment in the post discharge period may influence 
abstinence, it is noteable that this was a relatively uncommon occurrence. Only a third of 
participants received specialist psychiatric care during the follow-up, and none received SU 
treatment. While some participants may have received brief, opportunistic intervention, the 
study provides a close approximation of a naturalistic follow-up. 
Clinical Implications and Future Research Directions 
This was the first prospective study to examine the role of a range of demographic, 
clinical, SU, family/social, quality of life and functional variables on cannabis cessation in an 
early psychosis sample that did not receive substantial SU treatment. Only private 
accommodation and access to a regular income predicted cannabis cessation for 6-months 
following an inpatient admission.  
While the current results could be due to an unmeasured factor such as the level of 
cognitive functioning, the prospective design and the wide range of assessed predictors gave 
credence to the results. Addressing basic needs is likely to be a vital step in recovery. Our 
results suggest that optimal SU outcomes from early psychosis services may be achieved by 
address the accommodation and employment needs of patients as well as their mental health 
symptoms. Given the size of the effect found addressing the lack of suitable accommodation 
via policy and community advocacy is a key priority. Such an approach is consistent with 
comprehensive case management, and with a strengths-based approach to the challenges of 
early psychosis.  
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6.6 COMMENTARY (SUMMARY AND IMPLICATIONS) 
This study addressed the limitations of our previous study by prospectively following 
individuals over a 6-month period and measuring CU closely along the way. The findings of 
private accommodation and access to a regular income predicting cannabis cessation at 6-
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months was inconsistent with our previous findings. A number of methodological issues may 
account for such differences, however these differences are reported across numerous studies. 
A potential avenue to address these concerns is to explore qualitative accounts for 
reduction/cessation. Additionally, this would allow for specific exploration of factors leading 
to cessation/reduction as well as maintenance factors and relapse contexts. 
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Table 6.1 Demographic, substance use and clinical characteristics of the patients who ceased (N=19) and did not cease (N=48) cannabis use for 6 months   
   Cannabis  cessation 
  Yes                      No 
 Cannabis cessation 
 Yes                   No 
Demographics 
  Age, M (SD) 
 
24 (4.9) 
 
24.7 (5.3) 
Diagnosis, N (%) 
Schizophrenia/Schizophreniform 
 
14 (74%) 
 
34 (71%) 
  Gender, male, N (%) 15 (79%) 37 (77%)  Affective with psychotic features   4 (21%) 10 (21%) 
  Employed, N (%) 5 (26%) 15 (31%)  Substance-Induced   1 (5%)   4 (8%) 
  Private accommodation, N (%) 9 (47%) 41 (85%) Symptoms on BPRS  
 Total, M (SD)    
 
44.7 (9.1) 
 
46.0 (7.9) 
  Ethnicity, Caucasian, N (%) 15 (79%) 46 (95%)  Negative, M (SD)      4.4 (1.2)   4.6 (1.1) 
  Completed high school, N (%)  7 (37%)  9 (19%)  Positive, M (SD)    15.2 (3.9) 15.4 (3.8) 
  Receiving an income, N (%)  5 (26%) 28 (58%)  Depression-anxiety, M (SD)      7.4 (2.3)   7.9 (3.2) 
  Relationship, single, N (%) 18 (95) 41 (85%)  Manic-excitement, M (SD)    16.3 (4.0) 11.8 (3.9) 
Life events (LES Total), M (SD) 5.9 (2.1) 6.5 (1.9) Substance Use                             
Social activity, N (%) 11 (58%) 29 (60%)    Age of onset of cannabis use, M (SD) 15 (2.7) 14.9 (3.4) 
Clinical      Cannabis abuse, N (%)    2 (10%)   8 (17%) 
  Premorbid adjustment (PAS   Total), M (SD) 26.6 (10.9) 29.4 (12.4)    Cannabis dependence, N (%) 17 (90%) 40 (83%) 
  Duration of untreated psychosis (days), M (SD) 152.9 
(158.6) 
165.8 (302.5)    Days used cannabis, M (SD) 19.2 (15.4) 21.4 (16.2) 
  Age first diagnosed with psychosis, M (SD) 22.9 (5.0) 23.3 (5.0)    Cones per cannabis use day, M (SD)   8.3 (12.4)   4.6 (4.2) 
  First hospital admission, N (%) 5 (26%) 18 (38%)    Polysubstance use, N (%) 14 (74%) 44 (91%) 
  Family history of psychosis, N (%) 8 (42%) 11 (24%)    Amphetamine dependence, N (%)   7 (37%) 17 (35%) 
  Family history of other mental illness, N (%) 5 (26%) 23 (48%)    AUDIT total, M (SD) 10.4 (8.4)   9.8 (9.6) 
Family environment (FES), M (SD) 19.5 (3.0) 18.1 (3.9)    SDS total, M (SD)   4.7 (3.0)   5.3 (4.1) 
Note. Polysubstance use: cannabis plus other substance use. Substance use refers to use in 6 weeks prior to admission 
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Table 6.2 Results of univariate logistic regressions predicting cannabis cessation over the following 6 months  
Variable Beta SE (Beta) Wald Significance 
Level 
Odds Ratio 95% CI for Odds Ratio 
Demographics 
       
Age -0.028 0.055 0.259 0.611 0.973 0.874 1.082 
Male gender 0.109 0.659 0.027 0.869 1.115 0.306 4.059 
Employed 0.241 0.607 0.158 0.691 1.273 0.387 4.182 
Receiving an income 1.366 0.598 5.225 0.022 3.920 1.215 12.647 
Private accommodation 1.873 0.615 9.272 0.002 6.508 1.949 21.728 
Caucasian 1.814 0.916 3.924 0.048 0.163 0.027 0.981 
Completed high school -.927 .602 2.369 .124 .396 .121 1.288 
Relationship 1.123 1.106 1.031 .310 3.073 .352 26.844 
Substance Use 
       
Age onset of cannabis use 0.014 0.083 0.028 0.867 1.014 0.861 1.194 
Cannabis dependence -0.531 0.842 0.397 0.529 0.588 0.113 3.063 
Poly-SU, cannabis use only -0.296 0.554 0.286 0.593 0.743 0.251 2.203 
CEQ total -0.005 0.009 0.280 0.597 0.995 0.977 1.013 
Social 
       
 105 
 
Social activities 0.780 0.572 1.861 0.172 2.182 0.711 6.692 
Clinical 
       
Premorbid Adjustment (PAS total) -0.020 0.023 0.727 0.394 0.981 0.937 1.026 
Duration of untreated psychosis -0.066 0.004 2.638 0.104 0.994 0.987 1.001 
Family history of psychosis -0.839 0.579 2.099 0.147 0.432 0.139 1.345 
Family history of other mental illness 1.030 0.599 2.958 0.085 2.800 0.866 9.052 
BPRS total -0.021 0.035 0.352 0.553 0.979 0.914 1.049 
BPRS negative -0.127 0.274 0.217 0.624 0.880 0.515 1.505 
BPRS positive -0.018 0.072 0.064 0.800 0.982 0.852 1.131 
BPRS depression-anxiety -0.064 0.097 0.426 0.514 0.938 0.775 1.136 
BPRS manic-excitement -0.004 0.058 0.004 0.949 0.996 0.889 1.117 
Note. Bold indicates variables significant at <0.05.  Substance use refers to the 6 weeks prior to admission 
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Table 6.3 Multivariate logistic regression predicting a cessation in cannabis use 
Variable Beta SE 
(Beta) 
Wald Significance 
Level 
Odds 
Ratio 
95% CI for 
Odds Ratio 
Private 
accommodation 
2.474 0.854 8.403 0.004 11.874 2.228 63.271 
Caucasian 1.408 1.138 1.531 0.216 0.245 0.026 2.276 
Receiving an 
income 
2.253 0.845 7.108 0.008 9.513 1.816 49.833 
Note. Bold indicates variables significant at <0.05 
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7.1 NOTES 
Citation for this paper:  
Rebgetz, S., Hides, L., Kavanagh, D. J. & Choudhary, A. (2015). Natural recovery from 
cannabis use in people with psychosis: A qualitative study. Journal of Dual Diagnosis, 11, 
179-183. doi: 10.1080/15504263.2015.1100472. Journal Impact Factor = 0.80. Accepted 12 
October 2015.  
Authors’ contribution to this paper: 
The candidate is the first author and assisted in developing the research questions for 
this paper, conducted the data analysis, drafted the manuscript and finalised the manuscript 
based on co-authors’ editorial feedback. The other authors developed the original protocol, 
assisted in data analysis and provided editorial feedback. The last author assisted in data 
collection.  
Overview of this paper: 
Based on the previous quantitative paper, numerous factors have been identified that 
contribute to cessation of CU in individuals with psychosis. Research does not appear to 
identify consistent factors and an exploration of such factors using qualitative methodology 
may improve our understanding. This study retrospectively examines reasons for cannabis 
cessation, strategies that maintain cessation and relapse contexts in a group of individuals 
with early episodes of psychosis. 
See Appendix B for the demographic questionnaire, timeline and timeline questions 
and qualitative questions used in this paper.   
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Abstract 
Objective: There is rapidly growing evidence of natural recovery from CUe in people 
with psychosis, but little is known about how it occurs. This qualitative study explores what 
factors influence the decision to cease CU, maintain cessation and prevent relapse. 
Methods: Ten people with early psychosis and lifetime cannabis misuse, who had been 
abstinent for at least a month, were recruited from public adult mental health services. These 
six men and four women participated in a semi-structured qualitative interview assessing 
reasons for addressing CU, effective change strategies, lapse contexts, and methods used to 
regain control. Interpretative phenomenological analysis was used to identify themes in their 
responses. 
Results: Participants had a mean age of 23 years (SD = 3.7), started using cannabis at 
age 13.7 (SD = 1.6), began daily use at 17 (SD = 3.1), and had abstained from cannabis for 
7.9 months (SD = 5.4). Awareness of the negative impact of SU across multiple domains and 
the presence of social support for cannabis cessation were seen as vital to sustained success, 
as was utilization of a combination of coping strategies. The ability to address pressure from 
substance using peers was commonly mentioned.  
Conclusions: Maximally effective treatment may need to focus on eliciting a range of 
benefits of cessation and control strategies, and on maximizing both support for change and 
resistance to peer pressure. Further research might focus on comparing perceived effective 
strategies between individuals who obtain sustained cessation versus those who relapse. 
 
Keywords: psychosis; substance use; cannabis; natural recovery 
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7.2 INTRODUCTION 
 Cannabis is the most commonly used illicit substance in people with psychosis, and 
its detrimental effects on this group are well documented (Hjorthøj, et al., 2009; United 
Nations Office on Drugs and Crime, 2011). Clinical trials of psychological treatments for CU 
have not reliably provided strong, well-maintained effects relative to controls (Hjorthøj, et al., 
2009; Madigan, et al., 2013). 
However, some people with psychosis stop or reduce using cannabis, without clinical 
interventions (Childs, et al., 2011; Lobbana, et al., 2010), and a reason for weak or 
inconsistent effects of trials is that control groups also typically improve (Kavanagh & 
Mueser, 2010). An increased understanding of natural recovery may provide ideas for 
strengthening interventions. Our recent review of existing research found that people with 
psychosis had similar reasons for addressing their use as other cannabis users (Rebgetz, 
Kavanagh, et al., 2015a). The main differences in reported reasons related to potential 
symptom exacerbations and amplified functional problems, such as homelessness, that occur 
in co-occurring disorders. However, only seven studies had examined subjective experiences 
of ceasing or reducing cannabis among this population (Rebgetz, Kavanagh, et al., 2015a). 
Qualitative methods may provide additional insights into the issue. The current study 
elicited qualitative responses on ways people with a psychosis recovered from CU, including 
their triggers for addressing it, challenges they encountered, coping strategies they employed, 
and if they relapsed, the context in which that occurred. 
7.3 MATERIALS AND METHODS 
Participants 
Participants were recruited from adult mental health services in the Metro-North Health 
Service District in Brisbane. Ethical approval was obtained from The Prince Charles Hospital 
Human Research Ethics Committee and carried out in accordance to The National Statement 
on Ethical Conduct in Human Research. Inclusion criteria were: (i) current diagnosis of a 
psychotic disorder; (ii) an early stage of psychosis (< 3 psychotic episodes); (iii) history of 
cannabis misuse, (iv) ≥ 1 month abstinence from cannabis in the previous 3 years, and (v) 
ability to read and speak English without translation. Exclusion criteria were a primary 
diagnosis of organic psychosis, psychosis due to a general medical condition, mental 
retardation, developmental disorder or amnestic disorder. 
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Procedure 
Case managers gave potential participants information about the project and referred 
those who expressed interest. The lead author then contacted volunteers to confirm eligibility 
and negotiate a time for the interview, at which time written informed consent was obtained. 
Participants were reimbursed $20 for their costs. 
Data Collection 
The Operational Criteria Checklist (OPCRIT; McGuffin, et al., 1991) was used to 
confirm the presence of current psychotic disorder, based on the medical record. A timeline 
was completed, with the initiation of alcohol and other drug use, commencement of daily CU, 
times they used more or less than usual, times they abstained for ≥ 1 month, together with the 
onset of psychotic experiences, when first diagnosed, and their history of hospitalisations. 
A semi-structured interview assessed reasons for addressing their CU, effective change 
strategies, lapse contexts, and methods used to regain control. Interviews were audiotaped. 
Questions used information from the timeline, and included: (1) “Tell me about the last time 
you stopped using cannabis. What was happening around then? Why did you stop using it 
that time?” (2) “When you weren’t using cannabis, were there times when that was hard?” 
and if they used cannabis again, (3) “What was happening when you went back to using 
cannabis?” 
Data Analysis 
Interviews were transcribed by the first author and analysed using interpretative 
phenomenological analysis (IPA; Smith & Osborn, 2003). The first narrative was used to 
identify preliminary themes, and representative quotations illustrating them were compiled. 
This process was repeated for the remaining narratives. To ensure transparency and 
reliability, all transcripts were read, analysed and coded by at least one other author. Coding 
and interpretations were discussed among all authors until consensus was reached on the key 
themes, allowing inconsistencies to be debated and themes refined (Lobbana, et al., 2010). 
Interconnections between interviews were examined, and a list of master themes constructed. 
Selection of master themes was based on their representativeness and on richness within 
participants’ accounts (Smith & Osborn, 2003). Since all authors had training in CBT and 
MI, potential related biases concerning the interpretation of results were identified and 
monitored (e.g., tendencies to interpret responses as reflecting cognitive or motivational 
interviewing concepts). 
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7.4 RESULTS 
Participant characteristics 
Participants were six males and four females with a mean age of 23 years (SD = 3.7; 
range 19-29). Four were diagnosed with schizophrenia and six with schizophreniform 
disorder. On average, they had 11.1 years of completed education (SD = 0.9), none were 
employed, and only one was in a relationship. Eight had a history of psychiatric admission, 
and their average age at diagnosis of psychosis was 20.5 years (SD = 3.5). On average, they 
started using cannabis at age 13.7 (SD = 1.6), began daily use at 17 (SD = 3.1), and reported 
5.4 years of regular use (SD=2.6, range 2-9). All had used alcohol, three had used opioids and 
two had used hallucinogens. Participants had abstained from cannabis for 7.9 months on 
average (SD = 5.4; range 2-18). Two had previously received minimal treatment for SU (a 
motivational interviewing session or psychoeducation), but no intervention was associated 
with participants’ focal cessation attempt. 
Reasons for cessation 
Six master themes were identified: health, finance/employment, social pressure, mental 
health, dissatisfaction with cannabis, and legal issues. Themes, subthemes and sample 
quotations are in Table 7.1. 
Strategies for maintaining cessation 
The strategies participants utilized to maintain cannabis cessation were ordered into 
five master themes: cognitive, significant other/family, behavioural, finance/employment, and 
lifestyle (Table 7.2). 
Relapse 
Five participants reported a relapse after cannabis cessation. Themes related to: relapse 
triggers (including stressful events), the desire to slow down thoughts or cope with cravings, 
the presence of substance-using peers, and boredom. 
7.5 DISCUSSION 
Reasons for cessation in this sample were highly consistent with those from previous 
research (Rebgetz, Kavanagh, et al., 2015a). Increased appreciation of negative consequences 
of cannabis upon multiple life domains emerged as often being critical. While existing 
approaches attempt to increase insight into negative consequences of use, the current study 
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suggested that either a summative effect on multiple domains or a strong individually-specific 
motivator may be needed to trigger change. Given that people with psychosis often have 
working memory deficits, assistance in assessing the combined impact of multiple factors 
may sometimes be needed (e.g., via pictorial representation). Further investigation of ways 
that recovered users addressed this challenge may offer important suggestions on how 
treatment interventions can more effectively assist people in assessing the impact of their use 
on multiple life areas. 
Awareness of adverse impacts of cannabis on mental health symptoms played a 
particularly important role in both initiating and maintaining a change attempt. Participants 
identified two related but separable insights: awareness that cannabis exacerbated paranoia, 
depression and anxiety, and expectations of symptom improvements upon cessation. Either 
insight alone may be sufficient in triggering cessation if it is highly valued, while both may 
be essential under other circumstances. 
Thinking about incentives (social reinforcement, improved finances, reduced mental 
health symptoms) provided coping strategies as well as triggers for change. Friends also 
assisted by restricting supply, and users altered their social environment by staying away 
from users or asking users not to smoke in front of them. Activities provided distractions, but 
also offered other sources of relaxation and enjoyment, and filled time with rewarding 
behaviours that were inconsistent with SU (e.g., employment, exercise). Some users appeared 
to adopt overarching goals (e.g., stopping all SU, becoming fit and healthy, improving mental 
health) that motivated multiple behavioural changes, which presumably reduced exposure to 
substance-related cues (e.g., quitting tobacco smoking reduces exposure to cigarettes) and 
established mutually reinforcing changes (e.g., exercise becomes easier when people stop 
smoking), as well as competing for time with CU. Therapists may sometimes be concerned 
that multiple concurrent behavioural changes are too difficult for this group; the current 
results suggest that people with psychosis may find multiple changes beneficial if they link to 
a coherent valued goal. In fact, we speculate that such a goal may help to insulate users from 
the effects of fluctuating insight into links between cannabis and worsening symptoms. 
Identified triggers for relapse paralleled ones that are well established in non-psychotic 
populations (Marlatt & Gordon, 1980). However, it is possible that triggers present greater 
challenges for this group. For example, pressure from others who continue using cannabis 
may be particularly difficult, since this group commonly has narrow social networks 
(Jablensky et al., 1999), accentuating the potential impact of further relationship loss, and 
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deficits in verbal communication and negotiation (Langdon, Coltheart, Ward, & Catts, 2002). 
While drug refusal skills are commonly taught and attempts are made to help clients maintain 
and expand their networks, these issues probably form important barriers to sustained change. 
Cognitive deficits are also likely to impair abilities to cope with stressful events and cravings. 
Further insight into strategies some former users successfully employ to deal with stress and 
cravings may provide hints on ways to prepare for them more effectively. 
This qualitative study appears to be the first to distinguish between factors supporting 
the initiation of cannabis cessation, strategies to maintain abstinence, and risk factors for 
relapse, in people with psychosis. The emergence of distinct themes across these phenomena 
suggests that treatments may need to emphasise different aspects at each point. While the 
study had a small sample, this was consistent with a qualitative approach, and recruitment 
continued until no new themes emerged (Baker & Edwards, 2012). Participants were all in 
contact with mental health services, and their responses may have been affected by 
interactions with staff. Our results should be confirmed in community samples with less 
service exposure. While the team’s biases were identified and discussed, this may not have 
averted influences on the derived themes, and our perspectives clearly influenced discussion 
of their implications. Participants’ responses were potentially affected by the order of 
questions and recall biases. These risks may be reduced by repeated assessment over time 
using both qualitative and quantitative approaches. Future research could also benefit from 
comparing responses of people who successfully quit to those who were unsuccessful in their 
quit attempt. 
7.6 CONCLUSION 
Several themes of the current study were consistent with past research, but some raised 
new potential directions for treatment. Increasing awareness of adverse impacts of CU across 
multiple life domains may maximize motivation and avoid overdependence on one aspect. 
Developing overarching goals such as fitness may embed cannabis cessation within less 
stigmatizing contexts and assist in drug refusal. Discovering specific difficulties this group 
has with well-established high-risk situations may guide more effective relapse prevention. 
Further investigation of these hypotheses is indicated. 
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7.7 COMMENTARY (SUMMARY AND IMPLICATIONS) 
This is the first study to explicitly explore the three areas of cessation, maintenance and 
relapse to determine differences at each stage of change. Qualitative interviews were 
conducted with ten participants to identify common themes. Reasons for cessation mirrored 
other studies in this area; with awareness of the negative impact of SU across multiple 
domains and the presence of social support commonly endorsed cessation strategies. A 
variety of maintenance strategies were reported including those related to increased mental 
health symptoms. A number of relapse triggers were identified however further research 
needs to explore this area. As the current study was retrospective in nature recall bias may 
impact the results and a prospective study would address this concern.  
 While treatment for mental health difficulties (i.e., psychosis) was not explicitly 
explored during the study; each participants was currently involved with mental health 
services. Mental health services in which participants were linked focus primarily on 
treatment (case management)t of the individuals mental health; including risk assessment and 
management, mental status examination, mental health act related activities, medication, 
linkage with non-government agencies and supportive counselling. 
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Table 7.1 Reasons for Cannabis Cessation 
Master Theme Subthemes Example quotation 
Health  Improve physical health, quality of life 
Thoughts about death and fear of dying 
“the year up to quitting I was thinking I was dying; I want 
to get fitter” 
“I thought that I could get healthy, I noticed that my 
breathing was much better when I was not using” 
Finance/employment  Improve finances 
Loss of licence and employment 
“weed is really expensive. All my pay would go on it” 
“I lost my licence and I pretty much lost my job to as I 
can’t to work with no licence” 
Social pressure Partner/friends (significant others) wanted me to quit, 
support me to quit 
Motivation by doctor to quit due to health 
concerns/mental health staff 
Interpersonal stress 
“being advised by my friends to stop” 
 
“I spoke with a nurse and after this I stopped using”   
“I was having a kid, so I had to get my life together”             
Mental health Worsening symptoms  “I would smoke a cone and get really bad anxiety” 
Dissatisfaction with 
cannabis use 
Thoughts about not needing it anymore 
Loss of enjoyment in using 
Guilt 
“I don’t need them [drugs] anymore” 
“I stopped enjoying using pot” 
“letting down my family” 
 Legal   “I thought they were going to drug test me so I stopped” 
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Table 7.2  Strategies for Maintaining Cannabis Cessation 
Master Theme Subthemes Example quotation 
Cognitive strategies Thinking about worsening of mental health symptoms 
 
Distraction 
Positive Self-talk 
“how bad it can make you feel sometimes instead of 
something that makes feel happy” 
“just played video games” 
“I believed in myself that I wouldn’t get back into it” 
Significant other/family Social reinforcement, restricting supply “my friends didn’t let me” 
Behavioural strategies Exercise 
Pleasant or relaxing activities 
 
“I was going to the gym” 
“walking the dog, I find relaxing, just walking him around 
the block” 
Finance/employment  Not wanting to waste money 
Employment 
“I hate dishing money to worthless things you know” 
“gaining employment and having more money” 
Lifestyle  Cessation of alcohol and other substances 
Avoidance of high risk situations and other users 
 
Healthy eating 
Drug refusal  
“I found giving up cigarettes helped” 
“lock myself away. Stay away from friends that smoke 
and ask them to not smoke in front of you and put it 
away” 
“diet is important” 
“just saying no, no, no; you just have to say no” 
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Table 7.3  Relapse to CU 
Master Theme Subthemes Example quotation 
Triggers Stressful events 
Slow down thoughts 
 
Cope with cravings 
Presence of substance using peers 
 
Boredom 
“I broke up with my girlfriend who was pregnant” 
“because I was stressed I reckon, it was to help relax… 
give my mind a rest” 
“I was fanning for a cone after stopping for a year” 
“then your friends are having it and it will start off with 
just have one, and then you have two and then you have 
more and then you have more and your addicted again 
 
“I just got bored” 
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Abstract 
 Introduction: There is growing evidence for natural recovery from cannabis use by 
people with psychosis, but mechanisms underpinning it need further exploration. This study 
prospectively explored this issue.  
 Method: Twenty-two people with psychosis and cannabis misuse were recruited: 19 
provided data for at least one follow-up assessment, and 13 of these (68%) reduced or ceased 
using cannabis. A semi-structured interview with the latter group explored reasons for 
initiating the attempt, strategies they employed, and context/s where any relapse occurred. 
Interpretative phenomenological analysis was used to identify themes.  
 Results: Participants who reduced or ceased cannabis use had fewer negative 
symptoms at baseline, and were more likely to only use cannabis. Major reasons for starting 
an attempt were worsening mental health, relationship and lifestyle difficulties. Effective 
strategies fell into psychological, relationship, lifestyle and medication themes. Only three 
participants reported a relapse: triggers involved substance-using peers, relationship 
difficulties, and problems with negative emotions including ones from past trauma. 
 Conclusions: An encouragingly high rate of maintained reductions in cannabis use 
was seen. Increased awareness of the benefits across multiple life domains from addressing 
cannabis use may be critical to the initiation and maintenance of attempts, both to maximise 
motivation, and avoid over-dependence on improvements in any single domain. Negative 
symptoms, multiple substance use, dysphoria and pressure from substance-using peers clearly 
offer additional challenges for control.  
 
Keywords: psychosis; substance use; cannabis use; natural recovery   
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8.2 INTRODUCTION 
Up to 80% of people with psychosis report CU, which has been associated with a range 
of adverse psychological, social, and physical health outcomes (Hjorthøj, et al., 2009; van der 
Meer, et al., 2015). Clinical trials of psychological treatments for CU in people with 
psychosis have not consistently reported better outcomes than control conditions (Hjorthøj, et 
al., 2009; Rebgetz, Kavanagh, et al., 2015a). This indicates that some people with psychosis 
cease or reduce using cannabis with little or no related treatment (Childs, et al., 2011; 
Lobbana, et al., 2010). An increased understanding of such ‘natural recovery’ could be used 
to strengthen current treatments.  
In a recent review, we found people with psychosis had similar reasons for reducing SU 
to those reported in the general population (Rebgetz, Kavanagh, et al., 2015a). Any 
differences in these reasons were related to the presence of the psychotic disorder (e.g. 
symptom exacerbation) and the amplified functional problems (e.g. homelessness) that occur 
when someone with psychosis also misuses a psychoactive substance. However, only eight 
studies have examined the subjective experience of ceasing or reducing cannabis among 
individuals with psychosis (Rebgetz, Hides, Kavanagh, & Choudhary, 2015; Rebgetz, 
Kavanagh, et al., 2015a), and there is little examination of mechanisms underpinning the 
phenomenon.  
Qualitative methods have begun to provide additional insights into the strategies used 
by this population. Our recent study found that cessation was linked to the individual’s 
awareness of the multiple negative consequences of CU or a more specific motivator (e.g., 
loss of employment; Rebgetz, Hides, et al., 2015). Maintenance strategies were associated 
with the awareness of the impact of CU on mental health symptoms, thinking about 
incentives and support from others. Reasons for relapse were found to be similar to non-
psychotic groups including pressure from others, stressful events, coping with cravings and 
boredom (Rebgetz, Hides, et al., 2015).  
The retrospective nature of the qualitative studies that have explored recovery from CU 
increases the risk of recall bias. The current study prospectively explored factors influencing 
the decision to cease and maintain cannabis cessation over a 3-month period among people 
with early psychosis. Change strategies and the relapse context of individuals who ceased and 
then resumed CU were also explored.  
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8.3 MATERIALS AND METHODS 
Participants  
Participants were recruited from adult mental health services in the Metro-North Health 
Service District in Brisbane [All participants were inpatients at the time of recruitment]. They 
were required to (i) have a current diagnosis of a psychotic disorder (e.g., schizophrenia, 
schizophreniform disorder, schizoaffective disorder, psychotic disorder NOS); (ii) be in early 
stages of psychosis (less than three psychotic episodes measured on a Timeline Followback 
or medical record) and (iii) have used cannabis in the previous 4 weeks. Participants were 
required to be able to read and speak English without translation. Exclusion criteria were a 
primary diagnosis of organic psychosis or psychosis due to a general medical condition, 
intellectual disability, or a developmental or amnestic disorder.      
Data Collection  
Demographic and clinical data included gender, age at interview, years of education, 
employment and relationship status, ethnicity, living arrangement at interview, current 
diagnosis, medication, family history of mental illness, psychiatric and cannabis treatment 
history.  
Psychosis and symptoms. The Operational Criteria Checklist (OPCRIT; McGuffin, et 
al., 1991) was used to confirm the presence of a current psychotic disorder, based on the 
medical record. Psychiatric symptoms were monitored using the Brief Psychiatric Rating 
Scale (BPRS; Overall & Gorham, 1962). BPRS positive, negative and depression-anxiety 
subscale scores were derived at baseline only (Ventura et al, 2000). BPRS items that did not 
require interviewer observation were included in telephone interviews during follow-up.  
Cannabis use. Consumption of cannabis and other substances in the preceding 4 weeks 
was retrospectively assessed using a Timeline Followback (TLFB;  Sobell & Sobell, 1992), 
in which recollections of past events were used to cue recall of SU. Participants were also 
given a calendar to mark the days they smoked cannabis over the month between follow-up 
assessments.  
Semi-structured interviews. If participants had ceased or reduced use since the previous 
assessment (indexed by ≥ 50% reduction in quantity), they were asked when this occurred, 
what was happening in their lives, why it occurred, any times it was hard to stay in control 
and how they did so. If they went back to using, they were asked what was happening and 
what led them to going back to using. If relapsing participants subsequently attempted to 
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regain control of their CU, the interview protocol included questions about the methods they 
used to do that. The qualitative interviews lasted approximately 60-70 minutes long. 
Procedure  
Participants were referred to the study by their treating team. The principal service 
provider gave potential participants oral and written information about the research project 
and asked if they would like to participate. The lead author then met with the potential 
participants to obtain informed consent, which included information about the assessment 
process. At baseline, demographic data was obtained, and the OPCRIT, BPRS and TLFB 
were administered. Monthly telephone follow-up assessments were conducted using the 
BPRS and TLFB. Each participant was provided with a calendar to assist with the completion 
of the TLFB. They were asked to record days they used cannabis and other substances as well 
as information on any mental health symptoms they experienced during the month. The 
qualitative interviews were undertaken during this phone call. Participants were reimbursed 
$10 at baseline, $15 at Month 1, $20 at Month 2 and $30 at Month 3. Ethical approval to 
conduct the study was obtained from the Brisbane Metro South and Queensland University of 
Technology Human Research Ethics Committees (HREC/12/QPAH/ 606).  
Design 
Participants were assessed at baseline, and attempts were made to follow them up 
monthly to 3 months. Those who had ceased or reduced their cannabis consumption during 
the previous month (indexed by ≥ 50% reduction in quantity from baseline levels) were asked 
the qualitative questions. Table 8.1 provides an overview of each participant’s cannabis use 
and participation in qualitative interviews over the course of the study.  
Qualitative Analysis 
Interviews were transcribed by the first author, and were then analysed using 
interpretative phenomenological analysis (IPA; Smith & Osborn, 2003). The first interview 
was reorganised and interpreted to identify preliminary themes and patterns, with a list of 
representative quotations illustrating each theme compiled. This procedure was repeated for 
each remaining interview, resulting in the identification of new themes. The identification of 
themes for each research question was completed separately. To ensure transparency and 
reliability, all transcripts were reread and coded by at least one other member of the research 
team. Coding and interpretations of the transcripts were discussed by all authors in detail 
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until consensus was reached on the key themes. This approach allowed inconsistencies to be 
debated, and themes to be refined (Lobbana, et al., 2010). Interconnections between 
interviews were examined, and a list of master themes constructed. Selection of master 
themes was based both on the frequency or ‘‘representativeness’’ of specific themes and on 
the richness of the theme within an individual’s account (Smith and Osborn, 2003). Since all 
authors had training in cognitive behavioural therapy (CBT) and motivational interviewing 
(MI), potential related biases in the interpretation of responses were discussed. 
8.4 RESULTS 
Participant characteristics 
Twenty-two participants consented to take part in the study: 19 of these (86%) provided 
at least 1 month of follow-up data, and 16 (73%) completed all 3 months of assessments. Five 
of those who dropped out of the study were lost to contact by the researcher and the health 
service, and the remaining participant withdrew because of work commitments. There were 
no demographic or clinical differences between those who completed the study and those 
who dropped out of the follow-up assessments.  
All participants were inpatients at the time of the baseline assessment, and were 
community patients at each follow-up point. All were prescribed antipsychotic medication 
while an inpatient, with 16 participants being prescribed paliperidone 100mg. Only two 
participants reported receiving any previous cannabis use treatment and all were receiving 
mental health support. No participants said that they had received substance use treatment 
during the study, and only one participants file mentioned receiving psychoeducation for 
psychosis and cannabis use. 
Comparisons of participants who did and did not reduce their cannabis consumption at 
some point assumed that the three who provided no follow-up data did not change their 
usage. Those who reported reduced CU were more likely to have only used cannabis (χ2(1, N 
= 22) = 7.8, p = .005) and had fewer BPRS negative symptoms (rho = .55, n = 22, p < .01) at 
baseline (see Table 8.2). There were no other significant differences between these groups.  
One-way repeated measures ANOVAs assessed changes in CU and BPRS symptoms 
over each follow-up period. The 16 participants providing data to 3 months had a significant 
reduction in the average number of days cannabis was used in the preceding month (baseline 
M = 17.13, SD = 6.51; 3-month M = 7.56, SD = 7.39; F (3,13) = 6.61, p < .01), and in the 
amount of cannabis used per month  than at baseline(M = 4.75, SD = 1.84; 3-month M = 
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1.88, SD = 1.82; F (3,13) = 8.91, p < .005). Significant reductions on several BPRS 
symptoms were also found: Emotional Withdrawal (from M = 2.00, SD = 0.97, to M = 1.38, 
SD = 0.81; F (3,13) = 3.58, p < .05), Guilt (from M = 2.63, SD = 1.41, to M = 1.69, SD = 
1.25; F (3,13) = 5.12, p < .01), and Unusual Thought Content (from M = 2.75, SD = 0.78, to 
M = 1.88, SD = 1.02; F (3,13) = 3.43, p < .05). 
Reasons for cannabis reduction/cessation 
Three themes were identified: mental health, social relationships/connection and 
lifestyle change. These themes are summarised in Table 8.3.  
The understanding of the negative psychological consequences associated with ongoing 
CU on a range of levels was highlighted by participants. Worsening of mental health was 
identified as a key motivator for ceasing cannabis, particularly relating to negative 
experiences from using cannabis and the worsening of psychiatric symptoms:  
Well I just had this unpleasant experience...... I was just scared and like I don’t want to 
end up back in hospital. - I thought people were out to get me.... Just trying to sort out 
my mental health issues. (P14) 
A realisation that cannabis did not help with emotional difficulties or was inconsistent 
with key values or goals (internal conflict) was also commonly reported: 
I realised that it wasn’t helping me, the hurt was still there when I was sober…(P5) 
I just saw that my life wasn’t going anywhere…(P11) 
Receiving medication or other treatment, or being hospitalised also played a role: 
...Well it was when I came into hospital......Well I have been linked in with a case 
manager. They are helping me sort out my head. I have the psychiatrist to see.... Well 
they have me on this medication also...(P14) 
The second theme related to social relationships. Social contexts and relationships are 
clearly important in the recovery of substance use. Letting others down was mentioned by 
participants:  
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Because it was horrible, I thought I was going to die and not be able to continue to 
support my partner. He is in a wheelchair. I felt I could not leave him, you know what 
would happen to him if I was to die. (P1)  
Trusting others was identified by this participant as important:  
Well it was sort to do with trusting people. I have difficulties trusting people and this 
causes difficulties in my relationship with my partner. Just help with that, you 
know…(P1) 
Having support from others and a change of social network were also seen as 
important:  
My mum came and saw me and I met some nice people. The staff on the ward were 
really kind to me also. I just thought I would try and give it a go…. I just didn’t want it 
to keep messing with my head. I wanted to try and stay clean so I could have a 
relationship with mum, try and make some new friends.... Yes, just trying to be a bit 
more social. (P20)   
Another common reason for cannabis cessation/reduction was related to lifestyle 
change. Participants reported that engaging in education/employment and finances triggered 
changes in their use potentially by providing an alternate to using substances and giving 
meaning in their daily lives:  
I was just having trouble with work. My mind was all over the place. I just didn’t think 
it was helping anymore. (P16) 
It sort of stopped me doing things also like having the motivation to get to work. (P7) 
I say to myself don’t do it you cannot afford it. There are things you need to spend your 
money on like my son. (P11) 
These themes point to the ability to manage psychological difficulties and a strong 
emphasis on the role of external factors in the decision to make a change in ones CU. For 
example Participant 2 reported: 
…I had this admission to hospital where I met you the first time. I thought I was going 
crazy and the voices were telling me to take all my medication.... the voices became 
worse” and “I felt really guilty that I was stuffing up my children’s lives...I just saw the 
impact it was having on my children. I didn’t realise how much it affected them. I have 
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stuffed up their lives and I didn’t know how much...Also about my mum’s health and I 
feel like I have stuffed up her life. 
 Importantly it is likely that a combination of motivators is required for a person to 
make an effective change and the realisation of the severity of the consequences of substance 
use experienced by participants. This was highlighted by a number of participants. For 
example Participant 5 reported:  
I realised that it wasn’t helping me, the hurt was still there when I was sober... Well 
with my parents, it was mainly my Dad. I think they knew I smoked but I didn’t want to 
have to admit it to him and be a disappointment to him... Not really. I guess I wasn’t 
hanging out with the same people and I used to smoke with my ex, so it was different. I 
was trying to study also and I don’t think it was helping me out there. 
Participant 7 said: 
I just didn’t want to feel that way anymore.... Not really it was just getting depressed 
and I don’t reckon the weed was helping me. I think it made me more emotional also... 
Well I thought if I quit smoking weed I might feel better. I guess I also didn’t want to 
let my mum down. My mum also tells me to get to work. Mum doesn’t like me just 
lying around the house. It sort of stopped me doing things also like having the 
motivation to get to work. Well I have had a bit more motivation. I still feel weird but I 
am trying to go to work. 
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Table 8.1 Participation and cannabis use 
 
 Baseline 1 month 2 months 3 months 
Participant 
 
THC use THC use Qualitative Interview THC use Qualitative Interview THC Use Qualitative Interview 
1 Yes No – A √ No – A √ No – A √ 
2 Yes Yes - R - No - A √ No – A √ 
3 Yes No - A √ No - A √ No – A √ 
4 Yes Yes - U - Yes - U - Yes – U - 
5 Yes No- A √ …1 … … … 
6 Yes Yes - U - Yes - U - Yes – U - 
7 Yes No - A √ No - A √ …1 … 
8 Yes …1 … … … … … 
9 Yes Yes - U - Yes - U - Yes – U - 
10 Yes Yes - U - Yes – R √ Yes – R √ 
11 Yes Yes - R √ No - A √ Yes – R √ 
12 Yes Yes - U - Yes - U - Yes – U - 
13 Yes Yes - U - Yes - U - Yes – U - 
14 Yes No - A √ No - A √ …1 … 
15 Yes Yes - U - Yes - U - Yes – U - 
16 Yes Yes - U - Yes - U - No – A √ 
17 Yes Yes - R √ No - A √ Yes – R √ 
18 Yes No - A √ No - A √ No – A √ 
19 Yes …1 … … … … … 
20 Yes No - A √ Yes - R √ Yes – U - 
21 Yes Yes - R √ No - A √ No – A √ 
22 Yes …1 … … … … … 
1. Lost to follow-up 
2. U - unchanged or higher consumption than at baseline 
3. R - reduced from baseline (by 50%) 
4. A – abstinent 
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Table 8.2 Demographic, substance use and clinical characteristics of the patients who ceased/reduced (N=13) and did not cease/reduce (N=9) 
cannabis use   
 
 Reduction/cessation  
 
 Reduction/cessation  
 
 Yes 
(n = 13) 
No 
(n = 9) 
p  Yes 
(n = 13) 
No 
(n = 9) 
p 
Demographics 
  Age, M (SD) 
 
25.8 (4.1) 
 
23.9 (6.0) 
 
0.38 
Diagnosis, N (%) 
Schizophrenia 
 
5 (39%) 
 
4 (44%) 
0.21 
  Gender, male, N (%) 10 (77%) 6 (67%) 0.60 Schizophreniform Disorder 4 (31%) 4 (44%)  
  Employed, N (%) 5 (39%) 1 (11%) 0.11 Substance-Induced - 1 (11%)  
  Living arrangements, Live Alone, N (%) 0 (0)% 1 (11%) 0.12 Schizoaffective Disorder 4 (31%) -  
  Ethnicity, Australian born, non-Aboriginal, N (%) 11 (85%) 8 (89%) 0.68 Symptoms on BPRS  
 Total, M (SD)    
 
44.6 (9.5) 
 
47.8 (17.2) 
 
0.82 
  Years of education, M (SD) 12 (1.6) 10.7 (1.3) 0.90  Negative, M (SD)    7.5 (1.9) 5.7 (1.1) 0.01 
  Relationship, single, N (%) 12 (92%) 6 (67%) 0.31  Positive, M (SD)    10.0 (2.4) 12.0 (4.5) 0.32 
Clinical     Depression-anxiety, M (SD)    9.5 (4.8) 8.1 (3.7) 0.43 
  First hospital admission, N (%) 8 (62%) 6 (67%) 0.81  Manic-excitement, M (SD)    9.9 (3.5) 12.2 (9.2) 0.87 
  Number of previous hospital admission, M (SD) 1.5 (0.8) 1.4 (0.7) 0.79 Substance Use                              
  Prescribed medication, N (%) 13 (100%) 9 (100%) -    Previous treatment, M (SD) 1 (8%) 1 (11%) 0.80 
  Family history of psychosis, N (%) 6 (46%) 2 (22%) 0.25    Days used cannabis, M (SD) 18.3 (6.7) 13.3 (5.3) 0.08 
  Family history of other mental illness, N (%) 5 (39%) 4 (44%) 0.78    Cones per cannabis use day, M (SD) 5.0 (1.7) 3.8 (2.0) 0.01 
       Polysubstance use, N (%) 4 (31%) 9 (100%) 0.00 
        
 136 Chapter 8: Paper 7 
Strategies for maintaining cannabis cessation 
Strategies participants used to maintain cannabis cessation/reduction were ordered into 
four themes: psychological strategies, relationship/connection, social related changes, and 
medication (Table 8.3).  
 A wide range of psychological strategies was employed, with a variety of strategies 
likely needed for effective change. A common cognitive strategy was for participants to 
reflect on past negative experiences and the effect on their mental illness:  
The fear of having an unpleasant experience and the cops coming around again stops 
me from using. I’m worried about having another break down and getting locked up. 
(P14) 
Trying to think about how the pot affects my mental illness. (P2) 
For these two participants’ motivators for cessation included negative experience and 
worsening of mental health symptoms. The motivators for change were clearly linked with 
ongoing effective maintenance strategies.  
Other psychological strategies included emotional change:  
Just tried not to feel bad and think of not wanting to feel bad again. Realising that 
smoking weed probably wouldn’t help and I would feel guilty afterwards anyway 
which would make me feel bad. (P7) 
Self-belief and self-talk were also seen as important:   
Well I just have to get through it. Just telling myself ‘no’. It is easy to go back and use. 
(P11) 
 Behavioural strategies included playing video games, sleeping, breathing, exercising 
and engaging in other distracting activity. Having a plan appeared to be an important factor:  
Just by making sure I had a plan of what I was going to say if I ran into them. Have an 
excuse that I was busy. (P18) 
Relationships played a role in helping participants stay in control, and included the 
ability to trust others, getting support from others and thinking of others:  
Being able to trust them and not feel bad when I need time out..... my partner helps 
me.... I speak with my mum... I think of the kids. I don’t want to stuff them up even 
more.....think about how much I have already messed the kids up. (P2) 
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Changing their social network or lifestyle, and taking medication (e.g., antipsychotics) 
were cited as other ways participants stayed in control. 
For participants to stay in control, the realisation that any short-term relief from 
cannabis was outweighed by more positive outcomes was important. An example was 
provided by Participant 5 who reported: 
Well I just felt like I couldn’t be by myself. I felt that if I smoked it would be easier. 
But I knew that it wasn’t going to make it better, I’d feel the same the next day. 
Anyways I had gotten past the addiction so I just had to keep off it.  
Many maintenance strategies identified in by participants was similar to the initial 
reasons for change. An example is provided by Participant 1 who reported an initial reason 
as:  
I had this negative experience where after having bongs I collapsed to the floor. I was 
really scared and I was never going to use again as a result. 
And maintenance strategies as: 
Thinking about that time when I collapsed on the floor. I never want that shit to happen 
again. It really freaked me and my partner out. 
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Table 8.3  Motivators and effective strategies for reduction or cessation of cannabis use 
 
 
Motivators Strategies Relapse 
Worsening Mental Health Psychological strategies Substance using peers 
Social Relationships/Connections Relationship/Connection Difficulties in relationships 
Lifestyle Change Social Related Changes Coping with difficult emotions 
 
Medication  
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Relapse  
Only 3 of the 11 interviewed participants who ceased CU altogether reported a relapse 
(a return to using cannabis). Their accounts identified the presence of substance using peers, 
difficulties in relationships and coping with difficult emotions related to past trauma, 
depressed or lonely feelings as triggers for this relapse:  
I was just lonely, my family are not around and I don’t have any friends so I just started 
smoking again..... Just as a comforter, rather than thinking about my childhood. Just to shut 
my body down for a bit, stop having to deal with it all. (P20) 
For those participants that relapsed there appeared to be less emphasis on social aspects 
in their reported effective maintenance strategies and relationship difficulties and associated 
negative emotions played a role in relapse. 
8.5 DISCUSSION 
This qualitative prospective study explored natural recovery from CU among people 
with early psychosis over 3 months. Consistent with previous research, worsening mental 
health symptoms were identified as a major reason for reducing/ceasing CU (Rebgetz, Hides, 
et al., 2015; Rebgetz, Kavanagh, et al., 2015a). Relationship issues were identified as another 
major reason for making a change in CU particularly concerns about letting others down. 
While these issues appeared to be powerful motivators for change, a focus on past difficulties 
may undermine self-efficacy and coping. Focusing users’ attention on instances where they 
maintained control of CU and fulfilled their responsibilities may allow these concerns to 
sustain a control attempt without triggering distress and hopelessness.  
Relationships with others were also identified as key motivator for maintaining 
cannabis reduction/cessation. Maisto and colleagues (1999), also found the receipt of 
emotional and practical support was a key therapeutic factor in reasons for change for SUD in 
schizophrenia. Treatments focused on developing and maintaining healthy relationships could 
help to reduce the use of illicit drugs to cope with problematic attachments (Alexander, 
2008).  
An important finding of the current study was the breadth and severity of the adverse 
SU consequences experienced by participants. As we identified in our recent review 
(Rebgetz, Kavanagh, et al., 2015a), the psychotic symptoms, distress, narrowing of social 
networks and activities and poverty that are experienced by people with psychosis, renders 
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this group particularly susceptible to negative effects of SU on relationships, discretionary 
incomes, activities and wellbeing. The negative nature of some of these experiences is likely 
to amplify motivation to reduce CU, to the extent seen among more extreme substance users 
in the general population (which may help to explain the frequency of their attempts to 
control use, even when the amounts consumed are relatively small). Among these impacts 
were financial and employment-related reasons for change, which have also been identified 
in previous research (Rebgetz, Kavanagh, et al., 2015a). Emphasising the negative effects of 
cannabis on multiple life domains may maximise the chance that people with psychosis will 
begin an attempt to control CU and may offer a key to successful control  (Green, 
Yarborough, Polen, Janoff, & Yarborough, 2015). 
While distress about these issues may be motivating, difficulties dealing with distress 
more generally constituted a perceived risk for control, as did the limited range of coping 
mechanisms they appeared to have to cope with it. In common with dysfunctional SU in other 
contexts, maintenance of control required relinquishing any short-term relief from cannabis in 
favour of more positive distal outcomes. Where people with psychosis have experienced 
trauma, maintaining control despite negative emotions may be particularly challenging. Links 
between lifetime cannabis consumption, childhood abuse and psychosis are well documented 
(Houston, Murphy, Adamson, Stringer, & Shevlin, 2008; van Dam et al., 2015). There were 
some indications in the current study that trauma may be important, particularly in relation to 
relapse, but as only three participants with a trauma history reported a relapse, these results 
must be viewed with caution. Examination of relationships between trauma and relapse in a 
larger study may clarify the extent of its role.  
Our results are consistent with previous research on relapse in substance users from 
both the general population and in people with serious mental disorders (Rebgetz, Hides, et 
al., 2015). They also support relapse models of SU that highlight the interaction between 
situational risk factors and individual characteristics (Anderson, Frissell, & Brown, 2007), 
and emphasise the need to develop strategies for emotion regulation as an important 
component of treatments. Schema therapy may also assist, given emerging evidence on its 
application to  SU by people with personality disorders (Kellogg & Tatarsky, 2012). 
 This study explicitly distinguished between strategies that may assist with initiating 
reduction or cessation from those involved in maintaining it. We previously identified a 
number of strategies that could support users at both stages (Rebgetz, Kavanagh, et al., 
2015a). Psychological strategies (remembering negative experience; self-belief; behavioural 
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change; effect on mental illness), social reinforcement related to family and significant 
others, lifestyle change and using medication were the main factors which respondents said 
had helped them stay in control. However, there was a limited range of coping strategies to 
control use, and these strategies tended to be relatively basic (e.g. escaping a high-risk 
situation, rather than being able to deal with the risk). Implications include the importance of 
ensuring that treatments focus on behavioural rather than cognitive strategies, and on ones 
that are both readily trained and likely to be effective.  
 This study appears to be the first to prospectively follow a sample of cannabis users 
with psychosis to qualitatively explore - the initiation of cannabis cessation, strategies to 
maintain abstinence, and risk factors for relapse in CU. While there were many similarities in 
the themes relating to these contexts, the emergence of some key differences in responses 
suggests that treatment approaches may need to emphasise different aspects at each point in 
the recovery journey. The use of psychological approaches that address emotional issues 
including any past trauma may be particularly important for relapse prevention.  
Limitations of this study include relatively small group of purposively sampled 
participants. However, recruitment continued until no new themes emerged, which suggests 
that a larger sample was unlikely to identify additional themes. As all participants were 
inpatients at the time of recruitment and were under the care of outpatient case managers 
from their local mental health services during follow-up, it is possible that their responses 
may have been influenced by their interactions with staff or patients (e.g. reflecting staff 
opinions of key factors and effective strategies), which were not recorded on file. Only one 
file mentioned “psychoeducation for psychosis and SU”. While no such interventions were 
reported as a motivator or maintenance strategy during qualitative interviews, results of the 
current study should be confirmed in a community sample with less service exposure. Biases 
relating to the research team’s knowledge of and theoretical adherence to CBT and MI were 
considered, but that may not have been sufficient to avert an influence from those 
perspectives on the perceived themes. The perceptions of respondents were potentially 
affected by the order of questions and by repeated questioning over time. It is also likely that 
tracking CU may have influenced participants’ decisions in regards to ongoing SU. Future 
research could minimise these risks by using respondent validation and applying experience 
sampling or mixed methods (e.g. with a sufficient sample to compare themes within 
subgroups that have varying mental health symptoms, stress, and motivation).  
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Conclusion 
Increasing people’s awareness of the adverse impact of CU across multiple life 
domains may be critical to cannabis cessation and maintenance of change, both in order to 
maximise motivation, and to avoid over-dependence on one life area. Development of a range 
of coping strategies to manage stress, alleviate boredom and deal with pressure from 
substance-using peers also appears important, if users are to effectively meet these common 
challenges. Focusing on emotion regulation and developing and maintaining healthy 
relationships appear to be areas worthy of particular additional exploration.  
Role of Funding Sources: Leanne Hides is supported by an Australian Research 
Council Future Fellowship. Shane Rebgetz and Anand Choudhary are employees of 
Queensland Health (where the research was conducted). The Authors have no other relevant 
conflicts of interest.  
Contributors: Rebgetz, Hides, and Kavanagh designed the study. Rebgetz and 
Choudhary collected the data. All authors contributed to the data analysis and paper, and 
approved the final manuscript. 
Conflict of Interest: All authors declare that they have no conflicts of interest. 
Acknowledgements: Nil. 
 
 
 
 
 
 
 
 
 
 
 143 
 
8.6 COMMENTARY (SUMMARY AND IMPLICATIONS) 
This study appears to be the first to prospectively explore cannabis cessation, 
maintenance strategies and relapse contexts among individuals with early psychosis. 
Commonly endorsed cannabis cessation was related to mental health, relationships and 
connection and lifestyle factors. Maintenance strategies were similar in that mental health and 
relationship and connection are important in addition to social aspects and medication. 
Relapse contexts were difficult to interpret due to the limited number of participants 
relapsing. Further research is required to replicate these findings on a larger scale.  
 While treatment for mental health difficulties (i.e., psychosis) was not explicitly 
explored during the study; each participants was currently involved with mental health 
services. Mental health services in which participants were linked focus primarily on 
treatment (case management) of the individuals mental health; including risk assessment and 
management, mental status examination, mental health act related activities, medication, 
linkage with non-government agencies and supportive counselling. 
Telephone interviews using the BPRS is not a well-established method and therefore a 
limitation in regards to the psychiatric measurement of the paper; however this process has 
been used in previous studies and the items not rated are not crucial for determination of 
symptoms or relapse (i.e., Hides et al., 2006). 
In retrospect, it would have made the data richer if the reasons and contexts associated 
with those participants who did not change their SU was explored.  
Table 8.4 shows an average substantial change for those who ceased/reduced their use 
between baseline and follow-up time point one which was sustained across the follow-up 
periods. 
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Table 8.4 Cannabis use over time 
Days used cannabis, M (SD)    No Yes 
B 13.3 (5.3) 18.3 (6.7) 
F1 13.3 (5.5) 4.8 (5.7) 
F2 17.2 (7.2) 2.4 (4.5) 
F3 14.0 (5.6) 3.7 (5.4) 
Cones per cannabis use day, M 
(SD) 
  
B 3.8 (2.0) 5.0 (1.7) 
F1 3.8 (2.6) 1.4 (1.8) 
F2 3.8 (1.8) 0.7 (1.2) 
F3 3.3 (1.5) 1.0 (1.4) 
B = baseline 
F1 = Follow-up 1 
F2 = Follow-up 2 
F3 = Follow up 3 
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Chapter 9: General Discussion 
9.1 OVERALL DISCUSSION 
The overall objective of this research was to identify what variables and processes are 
involved in recovery from CU among individuals with psychosis. Current treatments for this 
comorbidity have had limited impact. In consequence, this thesis aimed to progress the small 
research field on natural recovery from CU in individuals with psychosis, in order to identify 
potential ways that the impact of treatments may be strengthened. Current treatment design 
for CU in psychosis has not been guided by a strong body of research on natural recovery. 
Natural recovery may assist in both refining treatments and increasing their impact (Green, et 
al., 2007; Mueser, et al., 2007).  
Paper 1 (Chapter 2) reported a systematic review of the existing literature on natural 
recovery from SU. A systematic review and meta-analyses was then conducted to examine 
the CU outcomes of general population samples of cannabis users in control conditions of 
treatment trials (Paper 2, Chapter 3). A meta-analysis (Paper 3, Chapter 4) of psychotic 
individuals in the control conditions of cannabis treatment trials followed. A series of natural 
recovery studies were conducted in Paper 4 to 7 (Chapter 5 to 8), two of which comprised 
quantitative analyses of existing datasets, and two were new studies that were primarily 
qualitative. 
These papers addressed the overall aims of the research program, namely - What 
triggers the decision to initiate a change and what are the associated reasons for reducing or 
ceasing CU among substance users with psychosis? What maintains cannabis cessation 
among substance users with psychosis? What predicts lapses in control, and what strategies 
are most commonly used to regain control among substance users with psychosis? 
The systematic review of natural recovery in psychosis and SU in Paper 1 highlighted 
the limited research conducted on this specific topic. The seven identified studies found a 
range of motivators for reduction or cessation, including issues related to health, finances, 
family/significant others, legal problems, social functioning and lifestyle, as well as mental 
health. When these factors were compared to changes in CU in the general population (37 
studies), few differences were noted. Exceptions were those of particular relevance to people 
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with psychosis: motivations to control psychotic symptoms, avoid hospitalization, please 
treatment providers, and avoid homelessness. Stable psychotic symptoms and close 
connections with others appeared particularly important for successful control. The small 
number of studies identified in the psychotic population necessitated the inclusion of both 
qualitative and quantitative studies that varied widely in quality and the research methods 
(e.g., assessments) used. The review concluded that further research on natural recovery from 
CU in psychosis is required, which adopts more robust methodology including a clear 
definition of abstinence or reduction of use, use of the same psychiatric and SU assessments 
and using the same follow-up duration. The focus on intervention related to mental illness 
(psychosis), highlights the need of integrative treatment approaches which has consistently 
been reported in the literature (Mueser & Gingerich, 2013). The best timing and primary 
focus of such interventions remains unclear, with these results suggesting a focus on the 
mental health intervention first may be important. 
When the degree that CU reduced in control conditions of RCTs in general population 
samples was examined in a meta-analysis in Paper 2, consumption frequency was found to 
reduce by an average of 4.6 days over 2-4 months across eight studies, with a mean reduction 
across the studies of 0.4 SD. Paper 3 undertook a similar review in trials on CU by people 
with psychosis. A mean reduction of 0.3-0.4 SD in the frequency of SU over 6-24 months 
was found in the control groups of eight trials—a reduction that compared favourably with 
the results of cannabis users from the general population. Together, these reviews provided a 
benchmark effect size for assessment of interventions, determining the clinical significance, 
and suggested that at least partial natural recovery from CU appears possible, even in samples 
with psychosis.   
Mean improvements in control groups within people with psychosis were around half 
these in the general population, however effect sizes at 3-6 months were only 25 percent 
lower. Comparisons were subject to different durations of follow-up, and the fact that 
baseline consumption in the psychosis sample was just over half that of the general 
population samples. The overall picture was of a surprisingly high level of reduction in the 
psychosis sample.  
Paper 4 examined baseline predictors of SU cessation or reduction in 432 patients 
receiving treatment for FEP. The presence of only CUD (rather than polysubstance use) and 
higher levels of premorbid social and occupational functioning predicted SU reduction or 
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cessation at 18-months follow-up. However, the study relied on a retrospective file audit, and 
combined substances into a single SU variable in its follow-up assessments. 
Paper 5 was able to address these limitations in a prospective investigation of predictors 
of cannabis cessation among 67 inpatients with CU and early psychosis. Baseline predictors 
of cannabis cessation across 6 months were living in private accommodation and receiving an 
income.  
The results in Papers 4 and 5 are different and given the studies explored the same 
topic, we would hypothesized the studies would have provided similar results. In contrast, the 
results could also be seen as consistent, since private accommodation and receipt of an 
income suggest higher current functioning, which would be predicted by better premorbid 
functioning. However, private accommodation may also offer specific benefits in reducing 
exposure to SU or supply by others and may indicate better quality and less depressing 
context. Employment gives powerful incentives for cessation,  provides a daily activity that is 
inconsistent with heavy use, and an income offers opportunities for alternative pleasurable 
activities. These findings support the integration of vocational and functional recovery in 
psychosocial treatments for psychosis (Mueser, et al., 2015).  
Alternate explanations as to the importance of income and private accommodation may 
include that these factors assist individuals to be socially connected with others. Having 
contact with others at a place of employment and in accommodation may increase one’s self-
concept and protect against psychotic processes and negate the need to use substances as a 
coping mechanism. It is likely that private accommodation may also offer safety in people 
who are often vulnerable and are preoccupied by external threats. Income and 
accommodation may be overlooked in functional assessments. A needs approach may 
provide valuable insights for current treatments (Young, Klosko, & Weishaar, 2003).  
Kellogg and Tatarsky (2012) have highlighted the importance of therapeutic alliance 
and identity in the treatment of SU. In regards to alliance a strong therapeutic relationship can 
be healing as it provides a place of safety, allows the integration of self-regulaton or self-
management skills the therapist models and teaches and allows a space to resolve 
interpersonal difficulties which is often associated with pain that underlies SU (Kellogg & 
Tatarsky, 2012). Changes due to emotional connections with others may start within the 
therapy relationship. Role identity may assist in motivating people to change their SU. Role 
identity is linked with social contexts and transforms within this domain, which is a 
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dialectical process (Kellogg & Tatarsky, 2012). Individuals have a number of identities of 
which are hierarchical depending on importance in their current lives. Kellogg suggests that 
people who use substances develop a addict identity (Kellogg & Tatarsky, 2012) which then 
dominates the hierarchy and reduces emphasis on other identities (i.e., worker, mother). 
Making a change (with regards to SU) occurs in the process of role conflict such as those 
identified in this project (i.e., related to health, finances, family/significant others, legal 
problems, social functioning and lifestyle).       
Papers 4 and 5 did not identify the challenges that participants encountered, or the 
strategies they employed to deal with them. Accordingly, Paper 6 examined these questions 
in a retrospective qualitative study of ten individuals with CU and early episodes of psychosis 
whom had ceased or reduced CU for at least a month. Consistent with the previous papers in 
this research program, cessation or reduction was associated with the motivational themes of 
health, finance/employment, social pressure, mental health, dissatisfaction with cannabis, and 
legal issues. In addition, maintenance and relapse factors were explored. Strategies fell into 
cognitive, significant other/family, behavioural, finance/employment, and lifestyle themes. 
Contexts for relapse included stressful events, desire to slow down thoughts or cope with 
cravings, the presence of substance-using peers, and boredom. Limitations to Paper 6 
included the retrospective nature of the study. 
Paper 7 therefore involved a prospective qualitative study of 22 cannabis-using 
individuals with early psychosis. Thirteen participants ceased or reduced their use over a 3-
month follow-up, and eleven provided qualitative responses. As in the previous study, 
motivators for cessation or reduction included themes of mental health, 
relationships/connection and lifestyle change. Strategies for maintaining reduction/cessation 
were psychological, relationship/connection, social changes and medication. Only three 
participants relapsed: while substance-using peers were again mentioned, other triggers 
involved difficulties in relationships, trauma and depressed or lonely feelings.   
9.2 DISCUSSION OF PAPERS IN RELATION TO PROJECT AIMS 
9.2.1 What triggers the decision to initiate a change and what are the associated reasons 
for reducing/ceasing CU among substance users with psychosis? 
This thesis highlighted a number of factors that contribute to the cessation or reduction 
of CU among individuals with psychosis, including close connections with people and a 
stable mental state and (Paper 1), having only one substance to address (rather than poly-
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SUDs), better global functioning and better premorbid social and occupational functioning 
(Paper 4), having private accommodation and receiving an income (Paper 5). Key motivators 
or triggers for addressing CU include health, finances and employment, social pressure, 
mental health problems, dissatisfaction with cannabis, legal issues, relationships and lifestyle 
(Papers 6 and 7). Effective strategies included psychological ones, relationship/connection, 
social changes and medication. 
Previous papers (e.g., Maisto, et al., 1999) exploring strategies used to cease cannabis 
in people with psychosis have highlighted the importance of underlying emotions and 
interpersonal connectedness. However, research focusing on this specific issue is limited, and 
current treatments focusing on the cessation or reduction of CU among individuals with 
psychosis appear to pay insufficient attention to these factors. CU is commonly reported to be 
a coping mechanism for dealing with difficult emotional states and assisting people with 
psychosis to heal their emotional difficulties may reduce their need to rely on cannabis to 
cope. It is possible that treatment efficacy may be improved by incorporating these themes. 
Understanding clients’ attachment styles (a measure of ability to form close emotional 
relationships) may also be an important related factor. However, this may not have to extend 
to a special focus on therapeutic alliance: Berry and colleagues (2015) recently found that 
therapist-client alliance was not related to clinical or SU outcomes in individuals participating 
in an RCT of brief MI/CBT compared with longer-term MI/CBT and standard care alone.  
Natural recovery studies exploring motivators for SU cessation/reduction in people 
without psychosis endorsed similar reasons to these. Toneatto and colleagues (1999) also 
noted social pressure or an ultimatum from significant others, observations of effects on 
others, financial or health problems, lifestyle concerns, fear of continued use, or just being 
tired of using in a sample of 50 abstinent (≥ year) untreated former cocaine users. However, 
they also found that cognitive evaluation (weight up the pros and cons) was a common reason 
for cessation, and this factor was not as prominent in the studies in this thesis. It is standard 
MI practice to assist individuals with a decisional balance. The lack of data supporting this 
specific approach in the studies within this thesis may help to account for weak treatment 
outcomes. It is possible that applications of decisional balance sometimes tax the cognitive 
capacity of people with psychosis—e.g. by asking them to sustain too many items in 
attention—and that additional work on adapting such treatments to psychosis is needed. 
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9.2.2 What maintains cannabis cessation among substance users with psychosis? 
The current research was the first to specifically explore factors that maintain cannabis 
cessation in people with psychosis. Previous research on natural recovery from SU in the 
general population reported similar factors to those in Papers 6 and 7, including improvement 
in self-concept, change of friends, change in social life, avoidance of social situations in 
which use may occur, support from significant others, change in drug use, change of address, 
and employment change (Toneatto, et al., 1999). 
For those individuals who were able to achieve cessation/reduction, maintenance 
strategies were generally similar in domain to the reasons that motivated reduction or 
cessation, falling into cognitive, significant other/family, behavioural, finance/employment, 
lifestyle (Paper 6), psychological, relationship/connection, social change, and medication 
domains (Paper 7). Slight differences between motivators for cessation/reduction and 
maintenance strategies across the research project were identified. These factors included a 
larger emphasis on behavioural maintenance strategies and the use of planning and goal 
setting in one’s life. The need for these strategies to be individualised is clearly important. 
The focus on behavioural pattern breaking is common in the later stages of schema therapy 
along with using the therapeutic relationship to address future needs (Young, et al., 2003). 
This process leads to a replacement of existing maladaptive patterns with healthier adaptive 
behaviours. The goal is to generalise insights and knowledge into behavioural change 
(Rafaeli, Bernstein, & Young, 2011).   
9.2.3 What predicts lapses in control, and what strategies are most commonly used to 
regain control among substance users with psychosis? 
Only a small number of studied participants went back to using cannabis, but the 
context in which relapse occurred were highly consistent with theories and research on 
relapse from SU in the general population (Anderson, Frissell, & Brown, 2007; Marlatt & 
Gordon, 1980). Those studies have identified negative emotional states (including ones from 
interpersonal conflict) and social pressure as common triggers for relapse, which were also 
identified in Papers 6 and 7 (Brown, et al., 1989; Ramo & Brown, 2008). Research with 
adolescents and young adults which identified positive emotional states as a potential risk for 
relapse was not supported by our studies in psychotic populations. Instead, the current results 
paralleled those found in previous research on co-occurring SU and SMI, including 
exacerbations of mental health issues, and reduction of meaningful activities or social 
supports for recovery (Drake, et al., 2005).    
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9.3 CLINICAL IMPLICATIONS OF FINDINGS 
9.3.1 Motivators for reduction/cessation 
Consistent with a sound application of motivational interviewing, a focus on potential 
improvements across multiple life domains following cessation or reduction in CU appears to 
be a crucial factor in effective change, perhaps because it avoids reliance on a single domain 
(which may or may not actually change). However, the identification of one or more issues of 
particular value to the individual is also likely to be critical, especially for those whose 
cognitive impairment limits their ability to retain multiple factors in memory. Maximising 
early treatment impacts on factors that have broad-ranging effects on quality of life and 
relapse risk (e.g. drug-free accommodation, employment) is likely to be especially important, 
which is consistent with best current practice (Kavanagh & Mueser, 2010; Mueser & 
Gingerich, 2013; Mueser, et al., 2015). 
Key differences highlighted in the reviews on people with and without psychosis were 
related to mental health symptoms and emotional wellbeing, and to an increased emphasis on 
connections with others (close emotional relationships). These themes were also identified in 
Papers 4, 6 and 7. Strategies to address these issues need to be implemented in integrated 
treatments for SU (Kellogg & Tatarsky, 2012; Mueser, et al., 2015). An amplified need for 
connections with others among individuals with psychosis was highlighted in the results of 
the second Australian National Survey of Psychosis, which found that experiencing 
loneliness (80.1%) and having a need for more friends (48.1%) were particularly common. 
Difficulties around connectedness with others may be related to poor social skills or 
difficulties dealing with trusting relationships and emotions. Indeed, Maisto and colleagues 
(1999) concluded that emotional and practical support received over the course of therapy 
assisted SU recovery. Psychological approaches to addressing these issues may need to adapt 
emotional processing techniques along with focusing on the therapeutic relationship (i.e., 
schema therapy, emotion focused therapy) to overcome such difficulties (Berry, et al., 2015). 
These approaches tend to go beyond those found in standard CBT, which is utilised in 
research trials of SU and psychosis.  
Social networks of people with psychosis rapidly diminish over the early years of their 
illness, and often result in their only contacts being with their family (with severe cases also 
including a loss of family) and others with severe mental disorder. There are many reasons 
for this including the fact that friends become increasing distant in their life trajectory (due to 
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education, employment, marriage and family), interests become increasingly polar, distrust of 
others and social withdrawal increase. There are several implications for cannabis users. The 
narrowing of these networks to fellow users happens at much lower levels of use than for the 
general population, resulting in fewer people to model and reinforce non-use. The 
relationships they do have—e.g. with their drug dealer and fellow users—become more 
valuable—which reinforces continued use. Their relationships are more chaotic, because of 
the symptoms and behaviour of the people they are with (as well as their own symptoms) 
which maintains ongoing use as a coping mode. Psychological interventions targeting these 
social issues appear to have had a limited impact to date and may need to be revised. Such an 
approach is found in schema therapy where schema modes may offer a conceptual 
understanding of these factors due to modes incorporating cognitive, behavioural, emotional 
and physiological responses. Involving the family in these treatment approaches may offer 
further therapeutic gains (Lobban & Barrowclough, 2016; Smeerdiijk, et al., 2014).  
Measuring premorbid functioning may assist in identifying those individuals who 
require more focus on the treatment of their mental health concerns in order to achieve better 
CU outcomes. Dual insight into adverse impacts of cannabis on mental health symptoms 
should be addressed, as only having one type of insight (i.e., cannabis exacerbates mental 
health symptoms or expectations of improvement in mental health symptoms upon cessation) 
is likely not enough for change to occur. Addressing functional deficits, as well as preventing 
the development of poly-SUDs, needs to be integrated into treatment design. Such 
approaches as early identification and intervention and harm minimisation approaches to 
focus on only one substance may assist.  
Current interventions which focus on a range of MI and CBT strategies to address 
cessation/reduction are an important aspect of recovery for this population. A number of 
strategies including exploration of the benefits of cessation/reduction, incentives for change, 
drug-refusal skills, improving relaxation and enjoyment, and reframing unhelpful thinking 
patterns have proven effective (Baker, et al., 2006; Mueser, et al., 2015). As mentioned 
above, the timing of these interventions is not well understood, the need for treatment to be 
integrated is established. However it is likely these strategies will often need to be addressed 
once psychosocial, mental health and emotional issues have been targeted. Multiple changes 
are likely to be required before treatment benefits are obtained, and the multiple changes are 
linked to a common goal.  
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9.3.2 Maintenance factors for continued reduction/cessation 
An understanding of the factors which contribute to cessation or reduction of CU could 
enhance maintenance treatment. As the strategies individuals endorsed to achieve 
cessation/reduction maintenance in our study, were generally similar to those which 
motivated reduction/cessation focusing on these motivators is key. Incorporating 
psychosocial (i.e., employment), family interventions and the use of MI and CBT 
interventions in the maintenance treatment are warranted. It is clear from our findings that 
these interventions needs to be individualised, targeting the motivators for change. 
Additionally, treating mental health and emotional difficulties is needed to improve current 
research trials (Hjorthøj, et al., 2013; Mueser, et al., 2015).   
9.3.3 Relapse contexts 
As the relapse triggers we identified among CU with psychosis, mirror those identified 
in the general population, current interventions for relapse are likely to assist in individuals 
with psychosis. Highlighting the interaction between situational risk factors and individual 
risk factors in relapse prevention should be a primary focus. Addressing related cognitive 
deficits in individuals with psychosis may be required to tailor relapse strategies for this 
group. One could hypothesise that individualised treatment plans incorporating motivators for 
initial cannabis cessation and maintaining change could be enhanced to reduce relapse risk, 
however limited research on this topic has been conducted to date, particularly in relation to 
cannabis and psychosis. Ensuring relatives are involved in relapse planning and able to 
provide ongoing support is likely to be a useful.  
9.3.4 Theoretical implications 
Our current results give added weight to the use of current theories and related 
interventions in the treatment of CU and psychosis. CBT, MI, family intervention and 
supported employment and education in an integrative approach are integral in current 
psychosocial theory and intervention. Recent literature on psychosocial theory and 
intervention for psychosis and SU highlights the integrative role of CBT, MI, family 
intervention and employment/educational support (Mueser, et al., 2015). An integrative 
approach is clearly needed given the range of psychosocial components reported in the 
literature and this research program.  
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Close connections with people and a stable mental state were associated with SU 
reduction/cessation in our research (Paper 1); both factors are likely to protect against an 
increase in psychological distress and the subsequent need to utilise maladaptive coping 
behaviours (e.g., SU). Other variables found to be associated with SU reduction included 
having only one substance to address (rather than poly-SUDs), better global functioning and 
better premorbid social and occupational functioning (Paper 4). It may be that an individual’s 
coping abilities contribute to their more effective management of psychological distress 
(rather than needing to adopt maladaptive coping behaviours, such as SU). Having private 
accommodation and receiving an income (Paper 5) potentially increases one’s sense of safety 
and self-esteem in which they can effectively manage psychological distress without the need 
to use substances. Addressing health, finances and employment, social pressure, mental 
health problems, dissatisfaction with cannabis, legal issues, relationships and lifestyle (Papers 
6 and 7) have been found to aide SU cessation/reduction; this may be due to these reducing 
the chances of psychological distress and therefore reducing the need to manage this distress 
through SU. Building on the work of Kellogg and Tatarsky (2012) the above reasons to make 
a change with regards to SU may be linked with identity theory. Identity theory is a model of 
multiplicity where individuals are understood to have several identities. Role conflict, as seen 
in the results of paper 6 and 7, may lead an individual to make changes in their SU as the SU 
identity does not fit with other identities (identity of a worker). Kellogg and Tatarsky (2012) 
suggest that identity transformations occur within a social context, which may account for 
results of paper 5.  
Little further insight to improve treatments was provided by our results on reasons for 
change, effective strategies and relapse triggers. Cognitive deficits, accommodation, income, 
and multiple drug use may be more important than positive symptoms of psychosis. Targets 
with multiple impacts maybe necessary (i.e., quality housing away from other substance 
users). People with poorer prognosis/lack of unassisted recovery may have better prospects of 
differential treatment effects. As those with better cognitive functioning, reduced 
polysubstance use, increased personal resources and better living contexts are more likely to 
self-initiate a reduction/cessation in SU; treatment should focus on those that are less likely to 
naturally recovery from SU.    
In regards to our results on substance relapse, the main findings linked with negative 
emotional states (including ones from interpersonal conflict), social pressure and trauma. 
Exploring trauma in people with SMI, Mueser and colleagues (2008) reported that trauma 
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(Posttraumatic Stress Disorder; PTSD) ranges from 29% to 49% in this population. Given 
that trauma maybe a risk factor for psychosis and SU, and on the background of our results 
that suggest it plays a role in relapse, this is an important area of exploration. The study by 
Mueser and colleagues (2008) compared CBT with treatment as usual (TAU) in assisting 
people with PTSD and SMI. The results suggest that CBT was effective in reducing PTSD 
symptoms and negative trauma related cognitions.  
In conclusion, there is evidence for the efficacy of various treatment components, there 
appears significant advantages to an integrative model that allows therapists to draw 
judiciously on the range of interventions available to them.  
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9.4 STRENGTHS AND LIMITATIONS OF THIS PROJECT 
The strengths of the research papers are reported in each of the relevant chapters. This 
PhD systematically explored the concept of natural recovery from CU in psychosis. Existing 
research was synthesised and meta-analyses were performed to identify benchmarks for 
recovery from CU in psychosis for future interventions to be measured against. Baseline 
predictors of cannabis cessation were identified over 6 and 18 months and qualitative studies 
exploring natural recovery from cannabis were conducted retrospectively and then 
prospectively. Throughout this program of research initial motivators for making a change in 
cannabis use, as well as maintenance strategies and relapse contexts were explored. While the 
phases had similarities, important differences were found, suggesting that specific 
individualised interventions at each stage of recovery may be required. 
Limitations relating to each study were also outlined in the relevant chapters. Perhaps 
the most important limitation was the lack of a large mixed methods study, due to the limited 
timeframe provided by a doctoral degree. Such a study would have provided greater 
confidence in the generalizability of the results and may have provided greater specificity in 
the recommendations for future treatment. The qualitative themes may also have been subject 
to personal bias, interviews were conducted until thematic saturation was reached, and were 
reviewed by multiple investigators, restricting the extent that such bias may have affected the 
results. It was clear that a large number of participants did not cease/reduce their use and an 
understanding of these barriers may be important. Additionally, qualitative assessment with 
significant others would potentially offer greater insights into motivators, maintenance 
strategies and relapse contexts.  
Other limitations included only having a combined SU variable (Paper 4), not exploring 
specific change strategies (Paper 4 and 5), inclusion of samples with differing psychiatric 
diagnoses, and a lack of definition of cessation/reduction (with regards to frequency and 
timeframes) in Papers 4-7. There were a number of methodological differences between the 
studies that may have affected the overall results of the research program: for example, using 
different definitions of SU and of reduction or cessation of use, not specifically 
operationalising reduction as opposed to cessation, the use of different follow-up durations, 
and including different durations of change to meet criteria for a reduction or cessation (e.g., 
Paper 4 vs. 5). These discrepancies rendered it difficult to make comparisons between the 
studies. These issues were refined through the course of the research project to ensure 
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consistency in future studies: for example, specifically exploring regular cannabis users, 
using a one-month time period and using a reduction of 50% of baseline use to achieve 
reduction (Paper 7).  
It is also important to note that Papers 4, 6 and 7 relied on self-reports of SU without 
verification using urine drug screening. That said, Paper 5 used cannabis immunoassay and 
gas chromatography/mass spectrometry, and found a high level of agreement between the 
assays and self-reported CU (Cohen’s kappa = 0.90). This result suggests that the self-reports 
were mostly reliable and supports other research exploring the correlation between self-
reported CU and plasma samples in individuals with psychosis (Hjorthøj, Fohlmann, Larsen, 
Arendt, & Nordentoft, 2012).  
Particularly in study 7 eliciting verbal responses was difficult and limited information 
was obtained despite the use of open ended questions and re-phrasing of the questions in 
numerous ways. The use of focus groups may assist in the production of greater responses. 
Additional questions relating to topics such as hopes/dreams and how current difficulties fit 
with these concepts may assist in richer data.  
While a definition of natural recovery has been used in the SU literature for some time, 
there is a notion that underlies this definition which may account for part of the results and 
this was not clearly articulate in the above chapters. The assumption is that SU is an episodic 
illness and those people who entered each study are likely to have been at a difficult period in 
their SU and as a result “naturally” cycled towards recovery. Therefore the spontaneous 
reductions found in the series of studies in this thesis may appear as a normal part of this 
episodic course of the disorder. Consequently, a subgroup of people do reach complete 
abstinence and no longer experience an episodic course. Understanding prevalence rates of 
those who recovery and those who continue to experience an episodic course may assist in 
targeting specific interventions and specific points in an individual’s recovery. Across the 
studies in this research program participants were selected at differing time points in their SU 
journey. With Study 5, of 67 participants that were using cannabis at baseline 19 participants 
(28%) did not use cannabis at all over the 6-month follow-up period. In fact, another 26 
participants (39%) reduced or ceased their use over the 6-month follow-up period. Future 
research should aim to better understand at what time point participants are at in their SU 
cycle and the prevalence of those who cease and reduce their use. 
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9.5 FUTURE DIRECTIONS FOR THIS RESEARCH 
This thesis aimed to advance current understanding of the natural recovery from CU 
among individuals with psychosis. The methodological issues and refinements described in 
the thesis may guide future research in this area. Future research is required to address 
methodological issues and expand and replicate the results of the studies included in this 
research project. A logical step would be to confirm qualitative findings using quantitative 
designs with larger samples, and extending the work in Paper 7, by conducting a large mixed 
methods study that focuses on natural recovery from CU by individuals with psychosis - 
examining motivators for cessation, maintenance factors and relapse contexts. Additional 
interviews with collateral informants may enhance the findings.  
Additional variants to include in future studies are longitudinal studies, as these would 
allow a greater understanding of recovery over time. Adding a randomised matched control 
group for comparison in prospective studies on natural recovery and CU would allow a direct 
comparison of motivators, strategies and contexts for individuals with psychosis compared 
with the general population, and may further highlight subtle differences between groups, 
which could then inform interventions. The weight of impact and frequency of strategies and 
contexts in natural recovery may need to be addressed, as little differences between groups 
with and without psychosis may continue to be found. There is the possibility that the reasons 
are differentially weighted, or have different frequencies of use between groups, and this 
should be explored. Examining naturalistic change over longer time periods consistent with 
other SU research is also required. This would allow a greater understanding of the course of 
CU in people with psychosis. Natural recovery studies may need to more thoroughly examine 
other characteristics of people who naturally recover from CU. For example, factors such as 
being in a relationship or having fewer diagnoses may be important. Greater clarity could be 
obtained by studies that include an improved characterisation of participants in terms of 
symptoms, diagnostic history and degree of SU problems. It may also be important to 
distinguish between reasons for controlling different substances or substance combinations 
(e.g., cannabis and alcohol or cannabis and amphetamines) given the high prevalence of poly 
SU. Paper 7 provides clear guidance on the measurement of such variables, which should be 
followed in future research to allow direct comparisons. Directly exploring the results of the 
current research may assist in understanding the exact reason for change as a number of the 
results are open to multiple interpretations (i.e., living in private accommodation). 
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Across each paper in this research project, participants were involved in a number of 
concurrent treatments, including antipsychotic medication and case management. To improve 
the naturalistic context of the research and provide more ‘pure’ data on natural recovery, 
future studies should attempt to explore the topic with less intensively treated samples. Wider 
collection of participants who are not linked in with mental health services, using newspaper 
or internet advertisements may provide such an avenue. 
Based on the findings of this research project, we have recommended a number of 
suggestions for the refinement of current treatment approaches for ceasing or reducing CU 
among people with psychosis. Additionally we have advocated for an integrative approach, 
namely schema therapy, in addressing SU (and psychosis). Once such treatments have been 
developed and implemented, assessing the viability and outcome is required (e.g., through 
pilot studies, RCTs). An area which requires in-depth assessment and review is that of 
emotional connection and healing. Such research could use a schema therapy approach and 
initially assess underlying life patterns using the Young Schema Questionnaire (Young, 
2003).  
Results from Paper 3 should be used to estimate likely differential effects of future 
treatment interventions and required sample sizes for treatment trials. By using the 
benchmark of a mean reduction of 0.4 SD, interventions would require improvements beyond 
this to be worthy of ongoing exploration. Finally, a second systematic literature review 
should be conducted; it is recommended that this review includes research published since 
our review in August 2014 – including our published research that is presented in Papers 6 
and 7. A second review would allow an updated synthesis of the literature on natural recovery 
from CU in people with psychosis. Summarising and exploring limitations to these studies 
may identify directions for future research and assist in developing treatments that show more 
consistent and sustained benefits over control conditions. Further comparisons could also be 
made with result from systematic reviews in the general population. Knowledge gained from 
such research could lead to the development of conceptual models of recovery for a CU and 
psychosis population. 
9.6 FINAL COMMENT 
There has been a dearth of research on effective interventions for CU in psychosis, 
despite the adverse consequences of CU in this population. This research program 
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endeavoured to improve CU treatment by conducting a series of studies on natural recovery 
from CU among individuals with psychosis. A range of factors that can assist in the 
cessation/reduction, maintenance and relapse of CU were identified. Future research is 
required to replicate these findings in larger sample of cannabis users with psychosis over 
time, and incorporate these results into the development of new integrated treatments for CU 
in psychosis.  
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Days of cannabis or other substance use in the past 30 days, in control groups of substance use treatment trials in psychotic samples at baseline and follow up  
 Substance Baseline 6 months 10-12 months 24 months 
  N M SD N M SD N M SD N M SD 
Drake et al., 19981  S  40 12.5  8.7  40  7.6  8.2  40  7.9  9.1  40  6.3  8.1 
Edwards et al., 20062 C  24 7.8  8.5  24  5.6  9.2       
Essock et al., 20061 S  99 8.1  9.5  99  6.8  9.4  99  5.8  8.4  99  6.8  8.8 
Morse et al., 20063 S/C  49 3.2  3.2  49  2.1  2.5  49  2.5  2.7  49  2.1  2.6 
Barrowclough et al., 20104 S/C 163 21.9  8.2 148 18.1 11.5 137 17.6 11.2 117 15.4 11.9 
Morrens et al., 2011 S/C  35 5.5  2.1  10  4.3 2 .9   7  4.8  2.6    
Smeerdijk et al., 20123 C  27 17.6 10.7     20 13.4 11.0    
Madigan et al., 2013  C  29 10.1  3.6     14 10.1  4.0    
Weighted means              
       Studies to 6 months   13.2   10.6        
       Studies to 10-12 months   13.5      10.6     
       Studies to 24 months   14.3         9.3  
Conversion formulae from reported means (M) to give days of use in the past 30 days:  (1) Days used in past 6 months: M/6; (2) % days used in past 4 weeks: M x 30; (3) Days 
used in past 90: M/3; (4) Proportion of days abstinent from main substance in past 90: (1-M)*30. 
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Appendix B 
Demographic Information      Participant #:  ___________ 
 
Date of Interview:   ___________________  Gender (circle):  Male Female  
 
Age:           _____  years 
 
Education:   What grade did you finish at school?     _____ years 
 
Did you finish any studies after school?     Trade   _____  years PT 
 
            Diploma/certificate _____  years FT/PT  
 
            University degree/s_____ years FT/PT 
 
            Other :  ___________________________________________________ _____ years FT/PT 
 
Total                years FTE  
 
Employment (can check > 1):   Unemployed/benefits 
      Student 
Employed PT/FT as   ______________________ 
 
Current relationship:    Never married 
      Separated/divorced/widowed 
      Partnered/married 
 
How would you describe your background?   Australian Born, Non-Aboriginal 
      Australian Born, Aboriginal or TSI 
      Born in _________________________________ 
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Who do you live with?    No one—live alone 
      With partner  
Share accommodation 
      Hostel/boarding house   
      With parents 
   
Current Diagnosis:      _____________________________________  
 
Have you ever been in hospital for a mental health problem? 
 
No  Yes –How many times? _____________  
 
What medication/s are you on now?  ___________________________________________________ 
 
 _____________________________    ____________________ _______________________________ 
 
Has anyone else in your family had mental health difficulties? (Including aunts, uncles, cousins...?) 
 
No  Yes --Who?  _______________________ What was the problem? _______________ 
 
Anyone else? ______________________ What was the problem?  ______________ 
 
Have you ever had treatment for cannabis use?    No  Yes --When? ______________  
 
What was the treatment?  
_________________________________________________________________ 
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Timeline Questions: 
To help us learn about your drug and alcohol use, we would like you to help us fill out this timeline.  
-  We understand you won’t remember everything. That’s OKAY.
 
Can you tell me when you started: 
- Drinking alcohol 
- Smoking Cannabis 
- Using other drugs (including amphetamines, hallucinogens, inhalants, prescription 
medication) 
Can you tell me when you started using cannabis every day?   
(If never, get time for “most days”) 
Can you tell me about any times you had more cannabis than usual? 
- Were there any other times you had more cannabis than usual? 
- Was there any change in your drinking or other drug use then? 
Can you tell me about any times you had less cannabis than usual? 
- Were there any other times you had less cannabis than usual? 
- Was there any change in your drinking or other drug use then? 
 
Can you tell me about any times you stopped using cannabis for a month or more? 
- Were there any other times you stopped using cannabis for a month or more? 
- Was there any change in your drinking or other drug use then? 
 
Can you tell me when you were first diagnosed with a mental illness? 
 
Can you tell me when you were in hospital for a mental illness? 
- Was there any change in your drinking or other drug use then? 
- Were there any other times you were in hospital for a mental illness? 
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Qualitative Questions: 
 
If there is a previous attempt to stop/reduce use (ask the following) 
 
1.       Tell me about the last time you stopped using cannabis.  
(if none: …when you cut down cannabis use).  
What was happening around then?   
(If it was just a lack of supply, look for another time). 
(Was anything else happening then?) 
Why did you stop using it that time? 
  (Were there any other reasons you stopped using it then?) 
  
2.       When you weren’t using cannabis (point to timeline), were there times when that was hard? 
a.      Tell me more about that... 
b.      How did you stay in control? 
c.       Any other times you found it hard to stop using? (repeat questions). 
  
3.       (If went back to using):  
What was happening when you went back to using cannabis? 
(Was anything else happening then?) 
Why did you go back to using it? 
  (Were there any other reasons you went back to using it?) 
a.       Tell me more about that... 
(If there was a previous time the person stopped using cannabis, ask the same questions about that one) 
Tell me about the previous time you stopped using cannabis.  
(if none: …when you cut down cannabis use).  
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Appendix C 
Demographic Information      Participant #:  ___________ 
 
Date of Interview:   ___________________  Gender (circle):  Male Female  
 
Age:           _____  years 
 
Education:   What grade did you finish at school?     _____ years 
 
Did you finish any studies after school?     Trade   _____  years PT 
 
            Diploma/certificate _____  years FT/PT  
 
            University degree/s_____ years FT/PT 
 
            Other :  ___________________________________________________ _____ years FT/PT 
 
Total                years FTE  
 
Employment (can check > 1):   Unemployed/benefits 
      Student 
Employed PT/FT as   ______________________ 
 
Current relationship:    Never married 
      Separated/divorced/widowed 
      Partnered/married 
 
How would you describe your background?   Australian Born, Non-Aboriginal 
      Australian Born, Aboriginal or TSI 
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      Born in _________________________________ 
 
Who do you live with?    No one—live alone 
      With partner  
Share accommodation 
      Hostel/boarding house   
      With parents 
   
Current Diagnosis:      _____________________________________  
 
Have you ever been in hospital for a mental health problem? 
 
No  Yes –How many times? _____________  
 
What medication/s are you on now?  ___________________________________________________ 
 
 _____________________________    ____________________ _______________________________ 
 
Has anyone else in your family had mental health difficulties? (Including aunts, uncles, cousins...?) 
 
No  Yes --Who?  _______________________ What was the problem? _______________ 
 
Anyone else? ______________________ What was the problem?  ______________ 
 
Have you ever had treatment for cannabis use?    No  Yes --When? ______________  
 
What was the treatment?  _________________________________________________________________ 
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Qualitative Questions: 
 
If there is a reduction/cessation in cannabis (ask the following) 
 
1.       Tell me about when you stopped/cut down using cannabis.  
What was happening around then?   
 (Was anything else happening then?) 
Why did you stop/cut down using it that time? 
  (Were there any other reasons you stopped/cut down using it then?) 
  Did you use any other alcohol or drugs more during this time? 
  
2.       When you weren’t using as much cannabis, were there times when this was hard? 
a.      Tell me more about that... 
b.      How did you stay in control? 
c.       Any other times you found it hard? (repeat questions). 
  
3.       (If went back to using or increased use):  
What was happening when you went back to using/ increased your cannabis? 
(Was anything else happening then?) 
Why did you go back to using/increase it? 
  (Were there any other reasons you went back to using/increase it?) 
a.       Tell me more about that... 
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Brief Psychiatric Rating Scale (BPRS) 
Expanded Version (4.0) 
 
Introduction 
This section reproduces an interview schedule, symptom definitions, and specific anchor 
points for rating symptoms on the BPRS. Clinicians intending to use the BPRS should 
also consult the detailed guidelines for administration contained in the reference below. 
 
Scale Items and Anchor Points 
Rate items 1-14 on the basis of individual's self-report. Note items 7, 12 and 13 are also 
rated on the basis of observed behaviour. Items 15-24 are rated on the basis of 
observed behaviour and speech. 
 
1. Somatic Concern 
Degree of concern over present bodily health. Rate the degree to which physical health 
is perceived as a problem by the individual, whether complaints have realistic bases or 
not. Somatic delusions should be rated in the severe range with or without somatic 
concern. Note: be sure to assess the degree of impairment due to somatic concerns only 
and not other symptoms, e.g., depression. In addition, if the individual rates 6 or 7 due to 
somatic delusions, then you must rate Unusual Thought Content at least 4 or above. 
 
2 Very mild Occasional somatic concerns that tend to be kept to self. 
3 Mild Occasional somatic concerns that tend to be voiced to others (e.g., family, 
doctor). 
4 Moderate Frequent expressions of somatic concern or exaggerations of existing ills 
OR some preoccupation, but no impairment in functioning. Not delusional. 
5 Moderately severe Frequent expressions of somatic concern or exaggerations of 
existing ills OR some preoccupation and moderate impairment of functioning. Not 
delusional. 
6 Severe Preoccupation with somatic complaints with much impairment in functioning 
OR somatic delusions without acting on them or disclosing to others. 
7 Extremely severe Preoccupation with somatic complaints with severe impairment in 
functioning OR somatic delusions that tend to be acted on or disclosed to others. 
 
"Have you been concerned about your physical health?" "Have you had any physical 
illness or seen a medical doctor lately? (What does your doctor say is wrong? How 
serious is it?)" 
"Has anything changed regarding your appearance?" 
"Has it interfered with your ability to perform your usual activities and/or work?" 
"Did you ever feel that parts of your body had changed or stopped working?" 
[If individual reports any somatic concerns/delusions, ask the following]: 
"How often are you concerned about [use individual's description]?" 
"Have you expressed any of these concerns to others?" 
 
2. Anxiety 
Reported apprehension, tension, fear, panic or worry. Rate only the individual's 
statements - not observed anxiety which is rated under Tension. 
 
2 Very mild Reports some discomfort due to worry OR infrequent worries that occur 
more than usual for most normal individuals. 
3 Mild Worried frequently but can readily turn attention to other things. 
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4 Moderate Worried most of the time and cannot turn attention to other things easily but 
no impairment in functioning OR occasional anxiety with autonomic accompaniment but 
no impairment in functioning. 
5 Moderately Severe Frequent, but not daily, periods of anxiety with autonomic 
accompaniment OR some areas of functioning are disrupted by anxiety or worry. 
6 Severe Anxiety with autonomic accompaniment daily but not persisting throughout the 
day OR many areas of functioning are disrupted by anxiety or constant worry. 
7 Extremely Severe Anxiety with autonomic accompaniment persisting throughout the 
day OR most areas of functioning are disrupted by anxiety or constant worry. 
 
"Have you been worried a lot during [mention time frame]? Have you been nervous or 
apprehensive? (What do you worry about?)" 
"Are you concerned about anything? How about finances or the future?" 
"When you are feeling nervous, do your palms sweat or does your heart beat fast (or 
shortness of breath, trembling, choking)?" 
[If individual reports anxiety or autonomic accompaniment, ask the following]: 
"How much of the time have you been [use individual's description]?" 
"Has it interfered with your ability to perform your usual activities/work?" 
 
3. Depression 
Include sadness, unhappiness, anhedonia and preoccupation with depressing topics 
(can't attend to TV or conversations due to depression), hopeless, loss of self-esteem 
(dissatisfied or disgusted with self or feelings of worthlessness). Do not include 
vegetative symptoms, e.g., motor retardation, early waking or the amotivation that 
accompanies the deficit syndrome. 
 
2 Very mild Occasionally feels sad, unhappy or depressed. 
3 Mild Frequently feels sad or unhappy but can readily turn attention to other things. 
4 Moderate Frequent periods of feeling very sad, unhappy, moderately depressed, but 
able to function with extra effort. 
5 Moderately Severe Frequent, but not daily, periods of deep depression OR some 
areas of functioning are disrupted by depression. 
6 Severe Deeply depressed daily but not persisting throughout the day OR many areas 
of functioning are disrupted by depression. 
7 Extremely Severe Deeply depressed daily OR most areas of functioning are disrupted 
by depression. 
 
"How has your mood been recently? Have you felt depressed (sad, down, unhappy, as if 
you didn't care)?" 
"Are you able to switch your attention to more pleasant topics when you want to?" 
"Do you find that you have lost interest in or get less pleasure from things you used to 
enjoy, like family, friends, hobbies, watching TV, eating?" 
[If individual reports feelings of depression, ask the following]: 
"How long do these feelings last?" "Has it interfered with your ability to perform your 
usual activities?" 
 
4. Suicidality 
Expressed desire, intent, or actions to harm or kill self. 
 
2 Very mild Occasional feelings of being tired of living. No overt suicidal thoughts. 
3 Mild Occasional suicidal thoughts without intent or specific plan OR he/she feels they 
would be better off dead. 
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4 Moderate Suicidal thoughts frequent without intent or plan. 
5 Moderately Severe Many fantasies of suicide by various methods. May seriously 
consider making an attempt with specific time and plan OR impulsive suicide attempt 
using non-lethal method or in full view of potential saviours. 
6 Severe Clearly wants to kill self. Searches for appropriate means and time, OR 
potentially serious suicide attempt with individual knowledge of possible rescue. 
7 Extremely Severe Specific suicidal plan and intent (e.g., "as soon as ________ I will 
do it by doing X"), OR suicide attempt characterised by plan individual thought was lethal 
or attempt in secluded environment. 
 
"Have you felt that life wasn't worth living? Have you thought about harming or killing 
yourself? Have you felt tired of living or as though you would be better off dead? Have 
you ever felt like ending it all?" 
[If individual reports suicidal ideation, ask the following]: 
"How often have you thought about [use individual's description]?" 
"Did you (Do you) have a specific plan?" 
 
5. Guilt 
Overconcern or remorse for past behaviour. Rate only individual's statements, do not 
infer guilt feelings from depression, anxiety, or neurotic defences. Note: if the individual 
rates 6 or 7 due to delusions of guilt, then you must rate Unusual Thought Content at 
least 4 or above, depending on level of preoccupation and impairment. 
 
2 Very mild Concerned about having failed someone, or at something, but not 
preoccupied. Can shift thoughts to other matters easily. 
3 Mild Concerned about having failed someone, or at something, with some 
preoccupation. Tends to voice guilt to others. 
4 Moderate Disproportionate preoccupation with guilt, having done wrong, injured others 
by doing or failing to do something, but can readily turn attention to other things. 
5 Moderately Severe Preoccupation with guilt, having failed someone or at something, 
can turn attention to other things, but only with great effort. Not delusional. 
6 Severe Delusional guilt OR unreasonable self-reproach very out of proportion to 
circumstances. Moderate preoccupation present. 
7 Extremely Severe Delusional guilt OR unreasonable self-reproach grossly out of 
proportion to circumstances. Individual is very preoccupied with guilt and is likely to 
disclose to others or act on delusions. 
 
"Is there anything you feel guilty about? Have you been thinking about past problems?" 
"Do you tend to blame yourself for things that have happened?" 
"Have you done anything you're still ashamed of?" 
[If individual reports guilt/remorse/delusions, ask the following]: 
"How often have you been thinking about [use individual's description]?" 
"Have you disclosed your feelings of guilt to others?" 
 
6. Hostility 
Animosity, contempt, belligerence, threats, arguments, tantrums, property destruction, 
fights, and any other expression of hostile attitudes or actions. Do not infer hostility from 
neurotic defences, anxiety or somatic complaints. Do not include incidents of appropriate 
anger or obvious self-defence. 
 
2 Very mild Irritable or grumpy, but not overtly expressed. 
3 Mild Argumentative or sarcastic. 
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4 Moderate Overtly angry on several occasions OR yelled at others excessively. 
5 Moderately Severe Has threatened, slammed about or thrown things. 
6 Severe Has assaulted others but with no harm likely, e.g., slapped or pushed, OR 
destroyed property, e.g., knocked over furniture, broken windows. 
7 Extremely Severe Has attacked others with definite possibility of harming them or with 
actual harm, e.g., assault with hammer or weapon. 
 
"How have you been getting along with people (family, co-workers, etc.)?" 
"Have you been irritable or grumpy lately? (How do you show it? Do you keep it to 
yourself?" 
"Were you ever so irritable that you would shout at people or start fights or arguments? 
(Have you found yourself yelling at people you didn't know?)" 
"Have you hit anyone recently?" 
 
7. Elevated Mood 
A pervasive, sustained and exaggerated feeling of well-being, cheerfulness, euphoria 
(implying a pathological mood), optimism that is out of proportion to the circumstances. 
Do not infer elation from increased activity or from grandiose statements alone. 
 
2 Very mild Seems to be very happy, cheerful without much reason. 
3 Mild Some unaccountable feelings of well-being that persist. 
4 Moderate Reports excessive or unrealistic feelings of well-being, cheerfulness, 
confidence or optimism inappropriate to circumstances, some of the time. May frequently 
joke, smile, be giddy, or overly enthusiastic OR few instances of marked elevated mood 
with euphoria. 
5 Moderately Severe Reports excessive or unrealistic feelings of well-being, confidence 
or optimism inappropriate to circumstances, much of the time. May describe feeling `on 
top of the world', `like everything is falling into place', or `better than ever before', OR 
several instances of marked elevated mood with euphoria. 
6 Severe Reports many instances of marked elevated mood with euphoria OR mood 
definitely elevated almost constantly throughout interview and inappropriate to content. 
7 Extremely Severe Individual reports being elated or appears almost intoxicated, 
laughing, joking, giggling, constantly euphoric, feeling invulnerable, all inappropriate to 
immediate circumstances. 
 
"Have you felt so good or high that other people thought that you were not your normal 
self?" "Have you been feeling cheerful and `on top of the world' without any reason?" 
[If individual reports elevated mood/euphoria, ask the following]: 
"Did it seem like more than just feeling good?" 
"How long did that last?" 
 
8. Grandiosity 
Exaggerated self-opinion, self-enhancing conviction of special abilities or powers or 
identity as someone rich or famous. Rate only individual's statements about himself, not 
his/her demeanour. Note: if the individual rates 6 or 7 due to grandiose delusions, you 
must rate Unusual Thought Content at least 4 or above. 
 
2 Very mild Feels great and denies obvious problems, but not unrealistic. 
3 Mild Exaggerated self-opinion beyond abilities and training. 
4 Moderate Inappropriate boastfulness, e.g., claims to be brilliant, insightful or gifted 
beyond realistic proportions, but rarely self-discloses or acts on these inflated 
selfconcepts. 
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Does not claim that grandiose accomplishments have actually occurred. 
5 Moderately Severe Same as 4 but often self-discloses and acts on these grandiose 
ideas. May have doubts about the reality of the grandiose ideas. Not delusional. 
6 Severe Delusional - claims to have special powers like ESP, to have millions of 
dollars, invented new machines, worked at jobs when it is known that he/she was never 
employed in these capacities, be Jesus Christ, or the Prime Minister. Individual may not 
be very preoccupied. 
7 Extremely Severe Delusional - same as 6 but individual seems very preoccupied and 
tends to disclose or act on grandiose delusions. 
 
"Is there anything special about you? Do you have any special abilities or powers? Have 
you thought that you might be somebody rich or famous?" 
[If the individual reports any grandiose ideas/delusions, ask the following]: 
"How often have you been thinking about [use individuals description]? Have you told 
anyone about what you have been thinking? Have you acted on any of these ideas?" 
 
9. Suspiciousness 
Expressed or apparent belief that other persons have acted maliciously or with 
discriminatory intent. Include persecution by supernatural or other non-human agencies 
(e.g., the devil). Note: ratings of 3 or above should also be rated under Unusual Thought 
Content. 
 
2 Very mild Seems on guard. Reluctant to respond to some `personal' questions. 
Reports being overly self-conscious in public. 
3 Mild Describes incidents in which others have harmed or wanted to harm him/her that 
sound plausible. Individual feels as if others are watching, laughing or criticising him/her 
in public, but this occurs only occasionally or rarely. Little or no preoccupation. 
4 Moderate Says other persons are talking about him/her maliciously, have negative 
intentions or may harm him/her. Beyond the likelihood of plausibility, but not delusional. 
Incidents of suspected persecution occur occasionally (less than once per week) with 
some preoccupation. 
5 Moderately Severe Same as 4, but incidents occur frequently, such as more than 
once per week. Individual is moderately preoccupied with ideas of persecution OR 
individual reports persecutory delusions expressed with much doubt (e.g., partial 
delusion). 
6 Severe Delusional - speaks of Mafia plots, the FBI or others poisoning his/her food, 
persecution by supernatural forces. 
7 Extremely Severe Same as 6, but the beliefs are bizarre or more preoccupying. 
Individual tends to disclose or act on persecutory delusions. 
 
"Do you ever feel uncomfortable in public? Does it seem as though others are watching 
you? Are you concerned about anyone's intentions toward you? Is anyone going out of 
their way to give you a hard time, or trying to hurt you? Do you feel in any danger?" 
[If individual reports any persecutory ideas/delusions, ask the following]: 
"How often have you been concerned that [use individual's description]? Have you told 
anyone about these experiences?" 
 
10. Hallucinations 
Reports of perceptual experiences in the absence of relevant external stimuli. When 
rating degree to which functioning is disrupted by hallucinations, include preoccupation 
with the content and experience of the hallucinations, as well as functioning disrupted by 
acting out on the hallucinatory content (e.g., engaging in deviant behaviour due to 
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command hallucinations). Include thoughts aloud (`gedenkenlautwerden') or 
pseudohallucinations (e.g., hears a voice inside head) if a voice quality is present. 
 
2 Very mild While resting or going to sleep, sees visions, smells odours or hears voices, 
sounds, or whispers in the absence of external stimulation, but no impairment in 
functioning. 
3 Mild While in a clear state of consciousness, hears a voice calling the individual's 
name, experiences non-verbal auditory hallucinations (e.g., sounds or whispers), 
formless visual hallucinations or has sensory experiences in the presence of a 
modalityrelevant stimulus (e.g., visual illusions) infrequently (e.g., 1-2 times per week) 
and with no functional impairment. 
4 Moderate Occasional verbal, visual, gustatory, olfactory or tactile hallucinations with 
no functional impairment OR non-verbal auditory hallucinations/visual illusions more 
than infrequently or with impairment. 
5 Moderately Severe Experiences daily hallucinations OR some areas of functioning 
are disrupted by hallucinations. 
6 Severe Experiences verbal or visual hallucinations several times a day OR many 
areas of functioning are disrupted by these hallucinations. 
7 Extremely Severe Persistent verbal or visual hallucinations throughout the day OR 
most areas of functioning are disrupted by these hallucinations. 
 
"Do you ever seem to hear your name being called?" 
"Have you heard any sounds or people talking to you or about you when there has been 
nobody around? 
[If hears voices]: 
"What does the voice/voices say? Did it have a voice quality?" 
"Do you ever have visions or see things that others do not see? What about smell 
odours that others do not smell?" 
[If the individual reports hallucinations, ask the following]: 
"Have these experiences interfered with your ability to perform your usual 
activities/work? How do you explain them? How often do they occur?" 
 
11. Unusual thought content 
Unusual, odd, strange, or bizarre thought content. Rate the degree of unusualness, not 
the degree of disorganisation of speech. Delusions are patently absurd, clearly false or 
bizarre ideas that are expressed with full conviction. Consider the individual to have full 
conviction if he/she has acted as though the delusional belief was true. Ideas of 
reference/persecution can be differentiated from delusions in that ideas are expressed 
with much doubt and contain more elements of reality. Include thought insertion, 
withdrawal and broadcast. Include grandiose, somatic and persecutory delusions even if 
rated elsewhere. Note: if Somatic Concern, Guilt, Suspiciousness or Grandiosity are 
rated 6 or 7 due to delusions, then Unusual Thought Content must be rated 4 or above. 
 
2 Very mild Ideas of reference (people may stare or may laugh at him), ideas of 
persecution (people may mistreat him). Unusual beliefs in psychic powers, spirits, UFOs, 
or unrealistic beliefs in one's own abilities. Not strongly held. Some doubt. 
3 Mild Same as 2, but degree of reality distortion is more severe as indicated by highly 
unusual ideas or greater conviction. Content may be typical of delusions (even bizarre), 
but without full conviction. The delusion does not seem to have fully formed, but is 
considered as one possible explanation for an unusual experience. 
4 Moderate Delusion present but no preoccupation or functional impairment. May be an 
encapsulated delusion or a firmly endorsed absurd belief about past delusional 
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circumstances. 
5 Moderately Severe Full delusion(s) present with some preoccupation OR some areas 
of functioning disrupted by delusional thinking. 
6 Severe Full delusion(s) present with much preoccupation OR many areas of 
functioning are disrupted by delusional thinking. 
7 Extremely Severe Full delusion(s) present with almost total preoccupation OR most 
areas of functioning disrupted by delusional thinking. 
 
"Have you been receiving any special messages from people or from the way things are 
arranged around you? Have you seen any references to yourself on TV or in the 
newspapers?" 
"Can anyone read your mind?" 
"Do you have a special relationship with God?" 
"Is anything like electricity, X-rays, or radio waves affecting you?" 
"Are thoughts put into your head that are not your own?" 
"Have you felt that you were under the control of another person or force?" 
[If individual reports any odd ideas/delusions, ask the following]: 
"How often do you think about [use individual's description]?" 
"Have you told anyone about these experiences? How do you explain the things that 
have been happening [specify]?" 
Rate items 12-13 on the basis of individual's self-report and observed behaviour. 
 
12. Bizarre behaviour 
Reports of behaviours which are odd, unusual, or psychotically criminal. Not limited to 
interview period. Include inappropriate sexual behaviour and inappropriate affect. 
 
2 Very mild Slightly odd or eccentric public behaviour, e.g., occasionally giggles to self, 
fails to make appropriate eye contact, that does not seem to attract the attention of 
others OR unusual behaviour conducted in private, e.g., innocuous rituals, that would 
not attract the attention of others. 
3 Mild Noticeably peculiar public behaviour, e.g., inappropriately loud talking, makes 
inappropriate eye contact, OR private behaviour that occasionally, but not always, 
attracts the attention of others, e.g., hoards food, conducts unusual rituals, wears gloves 
indoors. 
4 Moderate Clearly bizarre behaviour that attracts or would attract (if done privately) the 
attention or concern of others, but with no corrective intervention necessary. Behaviour 
occurs occasionally, e.g., fixated staring into space for several minutes, talks back to 
voices once, inappropriate giggling/laughter on 1-2 occasions, talking loudly to self. 
5 Moderately Severe Clearly bizarre behaviour that attracts or would attract (if done 
privately) the attention of others or the authorities, e.g., fixated staring in a socially 
disruptive way, frequent inappropriate giggling/laughter, occasionally responds to voices, 
or eats non-foods. 
6 Severe Bizarre behaviour that attracts attention of others and intervention by 
authorities, e.g., directing traffic, public nudity, staring into space for long periods, 
carrying on a conversation with hallucinations, frequent inappropriate giggling/laughter. 
7 Extremely Severe Serious crimes committed in a bizarre way that attract the attention 
of others and the control of authorities, e.g., sets fires and stares at flames OR almost 
constant bizarre behaviour, e.g., inappropriate giggling/laughter, responds only to 
hallucinations and cannot be engaged in interaction. 
 
"Have you done anything that has attracted the attention of others?" 
"Have you done anything that could have gotten you into trouble with the police?" 
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"Have you done anything that seemed unusual or disturbing to others?" 
 
13. Self-neglect 
Hygiene, appearance, or eating behaviour below usual expectations, below socially 
acceptable standards or life threatening. 
 
2 Very mild Hygiene/appearance slightly below usual community standards, e.g., shirt 
out of pants, buttons unbuttoned, shoe laces untied, but no social or medical 
consequences. 
3 Mild Hygiene/appearance occasionally below usual community standards, e.g., 
irregular bathing, clothing is stained, hair uncombed, occasionally skips an important 
meal. No social or medical consequences. 
4 Moderate Hygiene/appearance is noticeably below usual community standards, e.g., 
fails to bathe or change clothes, clothing very soiled, hair unkempt, needs prompting, 
noticeable by others OR irregular eating and drinking with minimal medical concerns and 
consequences. 
5 Moderately Severe Several areas of hygiene/appearance are below usual community 
standards OR poor grooming draws criticism by others and requires regular prompting. 
Eating or hydration are irregular and poor, causing some medical problems. 
6 Severe Many areas of hygiene/appearance are below usual community standards, 
does not always bathe or change clothes even if prompted. Poor grooming has caused 
social ostracism at school/residence/work, or required intervention. Eating erratic and 
poor, may require medical intervention. 
7 Extremely Severe Most areas of hygiene/appearance/nutrition are extremely poor and 
easily noticed as below usual community standards OR hygiene/appearance/nutrition 
require urgent and immediate medical intervention. 
 
"How has your grooming been lately? How often do you change your clothes? How often 
do you take showers? Has anyone (parents/staff) complained about your grooming or 
dress? Do you eat regular meals?" 
 
14. Disorientation 
Does not comprehend situations or communications, such as questions asked during the 
entire BPRS interview. Confusion regarding person, place, or time. Do not rate if 
incorrect responses are due to delusions. 
 
2 Very mild Seems muddled or mildly confused 1-2 times during interview. Oriented to 
person, place and time. 
3 Mild Occasionally muddled or mildly confused 3-4 times during interview. Minor 
inaccuracies in person, place, or time, e.g., date off by more than 2 days, or gives wrong 
division of hospital or community centre. 
4 Moderate Frequently confused during interview. Minor inaccuracies in person, place, 
or time are noted, as in 3 above. In addition, may have difficulty remembering general 
information, e.g., name of Prime Minister. 
5 Moderately Severe Markedly confused during interview, or to person, place, or time. 
Significant inaccuracies are noted, e.g., date off by more than one week, or cannot give 
correct name of hospital. Has difficulty remembering personal information, e.g., where 
he/she was born or recognising familiar people. 
6 Severe Disoriented as to person, place, or time, e.g., cannot give correct month and 
year. Disoriented in 2 out of 3 spheres. 
7 Extremely Severe Grossly disoriented as to person, place, or time, e.g., cannot give 
name or age. Disoriented in all three spheres. 
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"May I ask you some standard questions we ask everybody?" 
"How old are you? What is the date [allow 2 days]" 
"What is this place called? What year were you born? Who is the Prime Minister?" 
Rate items 15-24 on the basis of observed behaviour and speech. 
 
15 Conceptual disorganisation 
Degree to which speech is confused, disconnected, vague or disorganised. Rate 
tangentiality, circumstantiality, sudden topic shifts, incoherence, derailment, blocking, 
neologisms, and other speech disorders. Do not rate content of speech. 
 
2 Very mild Peculiar use of words or rambling but speech is comprehensible. 
3 Mild Speech a bit hard to understand or make sense of due to tangentiality, 
circumstantiality, or sudden topic shifts. 
4 Moderate Speech difficult to understand due to tangentiality, circumstantiality, 
idiosyncratic speech, or topic shifts on many occasions OR 1-2 instances of incoherent 
phrases. 
5 Moderately Severe Speech difficult to understand due to circumstantiality, 
tangentiality, neologisms, blocking or topic shifts most of the time, OR 3-5 instances of 
incoherent phrases. 
6 Severe Speech is incomprehensible due to severe impairment most of the time. Many 
BPRS items cannot be rated by self-report alone. 
7 Extremely Severe Speech is incomprehensible throughout interview. 
 
16. Blunted affect 
Restricted range in emotional expressiveness of face, voice, and gestures. Marked 
indifference or flatness even when discussing distressing topics. In the case of euphoric 
or dysphoric individuals, rate Blunted Affect if a flat quality is also clearly present. 
 
2 Very mild Emotional range is slightly subdued or reserved but displays appropriate 
facial expressions and tone of voice that are within normal limits. 
3 Mild Emotional range overall is diminished, subdued or reserved, without many 
spontaneous and appropriate emotional responses. Voice tone is slightly monotonous. 
4 Moderate Emotional range is noticeably diminished, individual doesn't show emotion, 
smile or react to distressing topics except infrequently. Voice tone is monotonous or 
there is noticeable decrease in spontaneous movements. Displays of emotion or 
gestures are usually followed by a return to flattened affect. 
5 Moderately Severe Emotional range very diminished, individual doesn't show 
emotion, smile, or react to distressing topics except minimally, few gestures, facial 
expression does not change very often. Voice tone is monotonous much of the time. 
6 Severe Very little emotional range or expression. Mechanical in speech and gestures 
most of the time. Unchanging facial expression. Voice tone is monotonous most of the 
time. 
7 Extremely Severe Virtually no emotional range or expressiveness, stiff movements. 
Voice tone is monotonous all of the time. 
Use the following probes at end of interview to assess emotional responsivity: 
 
"Have you heard any good jokes lately? Would you like to hear a joke?" 
 
17. Emotional withdrawal 
Deficiency in individual's ability to relate emotionally during interview situation. Use your 
own feeling as to the presence of an `invisible barrier' between individual and 
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interviewer. Include withdrawal apparently due to psychotic processes. 
 
2 Very mild Lack of emotional involvement shown by occasional failure to make 
reciprocal comments, appearing preoccupied, or smiling in a stilted manner, but 
spontaneously engages the interviewer most of the time. 
3 Mild Lack of emotional involvement shown by noticeable failure to make reciprocal 
comments, appearing preoccupied, or lacking in warmth, but responds to interviewer 
when approached. 
4 Moderate Emotional contact not present much of the interview because individual 
does not elaborate responses, fails to make eye contact, doesn't seem to care if 
interviewer is listening, or may be preoccupied with psychotic material. 
5 Moderately Severe Same as 4 but emotional contact not present most of the 
interview. 
6 Severe Actively avoids emotional participation. Frequently unresponsive or responds 
with yes/no answers (not solely due to persecutory delusions). Responds with only 
minimal affect. 
7 Extremely Severe Consistently avoids emotional participation. Unresponsive or 
responds with yes/no answers (not solely due to persecutory delusions). May leave 
during interview or just not respond at all. 
 
18. Motor retardation 
Reduction in energy level evidenced by slowed movements and speech, reduced body 
tone, decreased number of spontaneous body movements. Rate on the basis of 
observed behaviour of the individual only. Do not rate on the basis of individual's 
subjective impression of his own energy level. Rate regardless of medication effects. 
 
2 Very mild Slightly slowed or reduced movements or speech compared to most people. 
3 Mild Noticeably slowed or reduced movements or speech compared to most people. 
4 Moderate Large reduction or slowness in movements or speech. 
5 Moderately Severe Seldom moves or speaks spontaneously OR very mechanical or 
stiff movements 
6 Severe Does not move or speak unless prodded or urged. 
7 Extremely Severe Frozen, catatonic. 
 
19. Tension 
Observable physical and motor manifestations of tension, `nervousness' and agitation. 
Self-reported experiences of tension should be rated under the item on anxiety. Do not 
rate if restlessness is solely akathisia, but do rate if akathisia is exacerbated by tension. 
 
2 Very mild More fidgety than most but within normal range. A few transient signs of 
tension, e.g., picking at fingernails, foot wagging, scratching scalp several times or finger 
tapping. 
3 Mild Same as 2, but with more frequent or exaggerated signs of tension. 
4 Moderate Many and frequent signs of motor tension with one or more signs 
sometimes occurring simultaneously, e.g., wagging one's foot while wringing hands 
together. There are times when no signs of tension are present. 
5 Moderately Severe Many and frequent signs of motor tension with one or more signs 
often occurring sim ultaneously. There are still rare times when no signs of tension are 
present. 
6 Severe Same as 5, but signs of tension are continuous. 
7 Extremely Severe Multiple motor manifestations of tension are continuously present, 
e.g., continuous pacing and hand wringing. 
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20. Unco-operativeness 
Resistance and lack of willingness to co-operate with the interview. The 
uncooperativeness might result from suspiciousness. Rate only unco-operativeness in 
relation to the interview, not behaviours involving peers and relatives. 
 
2 Very mild Shows non-verbal signs of reluctance, but does not complain or argue. 
3 Mild Gripes or tries to avoid complying, but goes ahead without argument. 
4 Moderate Verbally resists but eventually complies after questions are rephrased or 
repeated. 
5 Moderately Severe Same as 4, but some information necessary for accurate ratings 
is withheld. 
6 Severe Refuses to co-operate with interview, but remains in interview situation. 
7 Extremely Severe Same as 6, with active efforts to escape the interview 
 
21. Excitement 
Heightened emotional tone or increased emotional reactivity to interviewer or topics 
being discussed, as evidenced by increased intensity of facial expressions, voice tone, 
expressive gestures or increase in speech quantity and speed. 
 
2 Very mild Subtle and fleeting or questionable increase in emotional intensity. For 
example, at times seems keyed-up or overly alert. 
3 Mild Subtle but persistent increase in emotional intensity. For example, lively use of 
gestures and variation in voice tone. 
4 Moderate Definite but occasional increase in emotional intensity. For example, reacts 
to interviewer or topics that are discussed with noticeable emotional intensity. Some 
pressured speech. 
5 Moderately Severe Definite and persistent increase in emotional intensity. For 
example, reacts to many stimuli, whether relevant or not, with considerable emotional 
intensity. Frequent pressured speech. 
6 Severe Marked increase in emotional intensity. For example, reacts to most stimuli 
with inappropriate emotional intensity. Has difficulty settling down or staying on task. 
Often restless, impulsive, or speech is often pressured. 
7 Extremely Severe Marked and persistent increase in emotional intensity. Reacts to all 
stimuli with inappropriate intensity, impulsiveness. Cannot settle down or stay on task. 
Very restless and impulsive most of the time. Constant pressured speech. 
 
22. Distractibility 
Degree to which observed sequences of speech and actions are interrupted by stimuli 
unrelated to the interview. Distractibility is rated when the individual shows a change in 
the focus of attention as characterised by a pause in speech or a marked shift in gaze. 
Individual's attention may be drawn to noise in adjoining room, books on a shelf, 
interviewer's clothing, etc. Do not rate circumstantiality, tangentiality or flight of ideas. 
Also, do not rate rumination with delusional material. Rate even if the distracting stimulus 
cannot be identified. 
 
2 Very mild Generally can focus on interviewer's questions with only 1 distraction or 
inappropriate shift of attention of brief duration. 
3 Mild Individual shifts focus of attention to matters unrelated to the interview 2-3 times. 
4 Moderate Often responsive to irrelevant stimuli in the room, e.g., averts gaze from the 
interviewer. 
5 Moderately Severe Same as above, but now distractibility clearly interferes with the 
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flow of the interview. 
6 Severe Extremely difficult to conduct interview or pursue a topic due to preoccupation 
with irrelevant stimuli. 
7 Extremely Severe Impossible to conduct interview due to preoccupation with 
irrelevant stimuli. 
 
23. Motor hyperactivity 
Increase in energy level evidenced in more frequent movement and/or rapid speech. Do 
not rate if restlessness is due to akathisia. 
 
2 Very mild Some restlessness, difficulty sitting still, lively facial expressions, or 
somewhat talkative 
3 Mild Occasionally very restless, definite increase in motor activity, lively gestures, 1-3 
brief instances of pressured speech. 
4 Moderate Very restless, fidgety, excessive facial expressions, or non-productive and 
repetitious motor movements. Much pressured speech, up to one-third of the interview. 
5 Moderately Severe Frequently restless, fidgety. Many instances of excessive 
nonproductive 
and repetitious motor movements. On the move most of the time. Frequent 
pressured speech, difficult to interrupt. Rises on 1-2 occasions to pace. 
6 Severe Excessive motor activity, restlessness, fidgety, loud tapping, noisy, etc., 
throughout most of the interview. Speech can only be interrupted with much effort. Rises 
on 3-4 occasions to pace. 
7 Extremely Severe Constant excessive motor activity throughout entire interview, e.g., 
constant pacing, constant pressured speech with no pauses, individual can only be 
interrupted briefly and only small amounts of relevant information can be obtained 
 
24. Mannerisms and posturing 
Unusual and bizarre behaviour, stylised movements or acts, or any postures which are 
clearly uncomfortable or inappropriate. Exclude obvious manifestations of medication 
side effects. Do not include nervous mannerisms that are not odd or unusual. 
 
2 Very mild Eccentric or odd mannerisms or activity that ordinary persons would have 
difficulty explaining, e.g., grimacing, picking. Observed once for a brief period. 
3 Mild Same as 2, but occurring on two occasions of brief duration. 
4 Moderate Mannerisms or posturing, e.g., stylised movements or acts, rocking, 
nodding, rubbing, or grimacing, observed on several occasions for brief periods or 
infrequently but very odd. For example, uncomfortable posture maintained for 5 seconds 
more than twice. 
5 Moderately Severe Same as 4, but occurring often, or several examples of very odd 
mannerisms or posturing that are idiosyncratic to the individual. 
6 Severe Frequent stereotyped behaviour, assumes and maintains uncomfortable or 
inappropriate postures, intense rocking, smearing, strange rituals or foetal posturing. 
Individual can interact with people and the environment for brief periods despite these 
behaviours. 
7 Extremely Severe Same as 6, but individual cannot interact with people or the 
environment due to these behaviours. 
 
 
 
